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3PREFACE 
Approaches to the food safety assessment of foods derived from genetically modified (GM) crops 
have been developed over the last two decades by intergovernmental organisations, including the 
Organisation for Economic Cooperation and Development, as well as the United Nations' World 
Health Organisation (WHO) and Food and Agriculture Organisation (FAO).  The European 
Commission has made substantial contributions to research and expert deliberations in this area: 
over the last twenty years, it has supported 81 projects on the assessment of environmental and 
food safety of genetically modified organisms (GMOs) and derived foods; contributing 
approximately 70 million Euro (see Review of Results of EC-sponsored Research on Safety of 
Genetically Modified Organisms, 2001, http://europa.eu.int/comm/research/quality-of-life/gmo). 
Despite these intensive research efforts assessing the safety of GM crops, European consumers 
remain apprehensive.  Consumer and environmental organisations have voiced concerns about the 
safety of these crops with respect to long-term effects on the environment and human health, as 
well as consumers' freedom of choice between GM containing and ‘GM-free’ foods.  The media 
coverage of this debate demonstrates that a rigorous science-based risk assessment may not 
suffice to introduce a new food production technology into society, but that societal aspects 
should also be taken into account.  The public debate on GMOs is part of a more general 
discussion on the safety of foods produced in Europe, fuelled by the BSE and dioxin crises, which 
have resulted in low public trust in food safety assessment and management practices in Europe. 
The overarching objective of the Thematic Network ENTRANSFOOD was to address scientific 
and societal issues related to the adoption of GM food crops.  The Network consisted of five 
research projects and five Working Groups, which focussed on the development of methods and 
strategies for safety testing, detection, and traceability of GM food crops, as well as societal 
aspects of the introduction of GM foods and started its activities in February 2000 
(www.entransfood.com).
ENTRANSFOOD provided a platform for participants from a wide range of different 
perspectives and disciplines to interact and to explore the interdependence of scientific, 
regulatory, and societal aspects of introducing GM food crops.  Project participants and sponsors 
consider ENTRANSFOOD a trial model to inform future deliberations on how to structure 
multidisciplinary research projects on questions relating to risk.  Integration of scientific, 
regulatory, and societal aspects allowed addressing food safety in an interdisciplinary manner; in 
the wake of the BSE crisis this is now considered essential for the introduction of new food 
producing technologies into the society.  Several members of ENTRANSFOOD have contributed 
over the last years to the activities of expert panels, expert consultations, workshops, and 
congresses addressing the safety of foods derived from GM crops.  Participants have also 
participated in public meetings and hearings to communicate on the safety of foods derived from 
GM crops and other aspects of agricultural biotechnology.  These activities intend to place the 
consumer in a better position to judge the potential risks of GM foods and the impact of the new 
technology in the society. 
Objectives of the Thematic Network were: 
- To identify key issues of the safety evaluation of foods derived from GM food crops, and to 
examine whether current research methods are adequate to characterise specific safety 
hazards; 
- To evaluate current food safety assessment strategies, and to identify differences in 
approaches and interpretation; 
4- To design and evaluate new alternative (in-vitro) test methods for the safety evaluation of 
GM food crops; 
- To provide detailed guidance to notifiers and risk assessors to perform the safety assessment 
of GM food crops; 
- To assess the risks of transfer of recombinant DNA from GM crops to microbes or human 
cells; 
- To examine the fate of GM raw materials and processed products throughout food production 
chains (traceability); 
- To examine new strategies for the detection of GM raw materials, processed products, and 
food ingredients; 
- To examine societal aspects and consumers attitudes towards the introduction of foods 
derived from GM food crops; 
- To establish a communication platform of producers of GM foods, scientists involved in food 
safety research and in societal aspects of GM food introduction, regulatory authorities, 
retailers, and consumer groups. 
Participants of the ENTRANSFOOD Consortium were recruited from academia, research centres, 
biotech and breeding companies, food industries, food retailers, regulatory agencies, and 
consumer groups across Europe.  Forty-five Research Centres participated in the RTD projects, 
and 62 experts in the Working Groups.  Many of the Working Group members are also actively 
involved in the research projects.  Total costs involved in ENTRANSFOOD are € 12.302.449, 
with an EU contribution of € 8.390.776. 
Structure and Working Procedure of ENTRANSFOOD (see Figure Ex-1) 
Research was carried out in five European Commission-funded shared cost projects involving 
researchers from the public and private sector: 
1.  New methods for the safety testing of transgenic food (SAFOTEST, QLRT-1999-00651). 
2.  New methodologies for assessing the potential of unintended effects in genetically modified 
food crops (GMOCARE, QLK1-1999-00765). 
3.  Safety evaluation of horizontal gene transfer from genetically modified organisms to the 
microflora of the food chain and human gut (GMOBILITY, QLK1-CT-1999-00527). 
4.  Reliable, standardised, specific, quantitative detection of genetically modified foods 
(Qpcrgmofood, QLK1-1999-01301).
5.  New Technology in Food Science Facing the Multiplicity of New Released GMO 
(GMOChips, G6RD-CT2000-00419).
Evaluation and review activities have been carried out in five Working Groups: 
1.  Design of safety assessment strategies for transgenic foods  
2.  Design of strategies for the detection of unintended alterations in GM food crops due to the 
process of genetic modification  
3.  Evaluation of the risks of gene transfer from GM foods to micro-organisms in the human 
digestive tract or to human cells  
4.  Evaluation and design of strategies for detection and traceability of GM foods and food 
components  
5.  Understanding of societal responses to GM foods 
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Figure Ex-1: Structure of ENTRANSFOOD activities
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6The project was initiated in February 2000 with an inaugural meeting in Wageningen, the 
Netherlands, and concluded with a Conference in May 2003 in Rome.  Plenary meetings of 
ENTRANSFOOD were held twice a year in order to (i) outline and further develop the project 
strategies, (ii) report on progress of the research projects, (iii) report on progress of the Working 
Groups, and (iv) establish inter-project and Working Group exchanges.  Working Group meetings 
were held in connection with the plenary meetings or separately.  Each research project was 
independently co-ordinated and held separate progress meetings.  Two Integrated Discussion 
Platform Meetings were held with invited experts from various stakeholder groups to comment 
on the progress of ENTRANSFOOD; their inputs shaped the subsequent course and outcomes of 
the Network. 
Results of the RTD projects have been and will be published in peer reviewed scientific journals.  
Each Working Group will publish a scientific paper in a special issue of the journal Food and 
Chemical Toxicology.  This European Commission–published Overarching Report summarises 
the main findings of the Working Groups to inform stakeholders, policy makers, consumer 
groups, and interested public.  All ENTRANSFOOD participants have contributed to writing the 
paper. 
Extension of the project by six months allowed increased focus on integration of societal aspects 
and scientific and regulatory aspects.  The main lesson from this project is that the interaction of 
all members of diverse working groups with diverse backgrounds needs to be attended to in a 
proactive manner, possibly by considering establishment of more formal organisational structures 
and processes for deliberation on cross-cutting issues, such as the definition and assessment of 
uncertainties about specific aspects of the safety assessment and the implementation of 
regulations. 
Future activities on risk analysis of new food production technologies and food production 
systems need similar integrated approaches and can further build on ENTRANSFOOD 
experiences.  In fact, the establishment of a Permanent Evaluation and Discussion Platform on 
GMOs in Europe as a follow-up of ENTRANSFOOD would significantly contribute to further 
development of risk analysis models, which must include new effective procedures for public 
involvement in the risk analysis process. 
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EXECUTIVE SUMMARY 
1. ENTRANSFOOD has identified and discussed the main issues concerning the introduction of 
foods derived from GM crops. These issues are (i) safety testing methods; (ii) unintended 
effects; (iii) gene transfer; (iv) detection, labelling, and traceability; (v) consumer acceptance; 
(vi) regulatory framework; and (vii) interdisciplinary deliberations. 
2. Worldwide, the consumption of foods derived from genetically modified crops (GM crops) is 
rising rapidly. Since the first GM crop was introduced in the market for large-scale 
cultivation in 1996, the global area of cultivation has risen to 67.7 million hectares in 2003 
(James, C., 2003. Global Status of Commercialized Transgenic Crops: 2003, ISAAA Briefs 
No. 30: Preview, International Service for the Acquisition of Agri-biotech Applications, 
Ithaca).  In 2003, GM soybeans, maize, cotton, and oilseed rape accounted for 61%, 23%, 
11%, and 5% of the total global acreage of GM crops, respectively.  The first generation of 
GM crops contain new genes that protect the crop against certain insect pests, or that confer 
tolerance to broad-spectrum herbicides facilitating weed control.  The rate of adoption varied 
across countries: plantings in the US, Argentina, and Canada accounted for 63%, 21%, and 
6% of the total global area of cultivation.  In Europe, GM crops were grown in Romania 
(70,000 hectares of GM soybean), Spain (32,000 hectares of insect-protected maize), 
Germany, and Bulgaria.  Genetic modifications of crops that are being developed for future 
commercialisations include more complex modifications, such as enhanced stress-tolerance 
or nutritional characteristics. 
3. The much slower adoption of GM crops in Europe demonstrates that rigorous safety 
assessment is necessary but not sufficient for gaining societal acceptance of agricultural 
applications of biotechnology.  If public confidence in science, technology, and food safety is 
to be regained, it is important to take consumer concerns and attitudes into account in risk 
analysis. The agro-food chain consists of stakeholders with diverse interests, including 
farmers, traders, distributors, processors, retailers, and end-consumers, while the interests of 
each stakeholder may differ from one market to another.  Improved processes for stakeholder 
engagement in deliberations on technological risks are required. 
4. ENTRANSFOOD has brought together representatives from academia, research centres, 
biotechnology and breeding companies, food industries, food retailers, regulatory agencies, 
and consumer groups across Europe to address food safety and societal issues of the 
introduction of foods derived from GM crops.
5. Safety considerations for foods derived from GM crops are fundamentally the same as those 
for conventional foods.  Scientists concerned with product development and regulation in 
general rely on the same approach for the safety assessment of foods derived from GM crops.  
The approach defines the type of data to be considered in the safety assessment of individual 
products.  Each individual GM crop is compared to an appropriate comparator that is 
generally accepted as safe for food use, based on its extensive prior use as a human food. 
6. ENTRANSFOOD’s deliberations are grouped under five headings: the safety assessment of 
foods derived from GM crops; identification of unintended effects from genetic modification; 
assessment of risks emanating from gene transfer across species; development of detection 
methods, standards for labelling and traceability, and their implementation; and societal 
aspects of adopting GM crops in the agro-food chain. 
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The safety assessment of foods derived from GM crops 
7. Working Group 1 developed a systematic approach how to tailor the safety assessment of 
foods derived from GM crops to the specific characteristics of the modified crop and the 
introduced trait.  The corner stone of the safety assessment of foods derived from GM crops 
is the concept of substantial equivalence.  This concept prescribes the comparison of the GM 
crop to a suitable comparator with a long history of use that allows the identification of any 
significant differences that might impact human health.  These differences then become the 
focus of further analytical, toxicological, or nutritional analyses.  The safety assessment of 
foods derived from GM crops is divided into four steps: characterisation of the parent crop; 
characterisation of the transformation process; toxicological evaluation of new gene 
product(s) and allergenicity assessment; and nutritional, toxicological, and allergenicity 
evaluation of the GM crop/derived food.  The objective of the tests is to assess whether foods 
derived from GM crops are as safe as foods produced from conventional crops. 
8. ENTRANSFOOD recommends the concept of substantial equivalence, which has been 
widely adopted in both the public and private sector, as the best available approach to safety 
assessment of GM crops.  Contrary to what the critics say, guidelines to its implementation 
are becoming evermore standardised and detailed.  For example, the Organisation for 
Economic Cooperation and Development (OECD) is compiling consensus documents for 
certain crop species that provide the information considered of most relevance for the 
characterisation of the parent crop.  These consensus documents guide the application of the 
concept of substantial equivalence. 
9. Discrete substances, such as newly introduced recombinant proteins and metabolites, are 
characterised by describing what is known about their structure and function.  Classic 
toxicological methods were originally developed for the safety assessment of chemicals in 
foods, such as food additives. These toxicological methods, including toxicity studies in 
animals, can be applied for the assessment of the characterised substances. 
10. ENTRANSFOOD recommends to conduct repeated dose studies with recombinant proteins 
or derived substances to identify potential adverse long-term effects unless there is sufficient 
information to confirm the lack of toxicity or pharmacological activity of the recombinant 
proteins and metabolites, or if there is extensive experience with these substances (for 
instance from a history of safe use). 
11. The current approach recommended by experts under FAO/WHO and the Codex 
Alimentarius for the assessment of the potential allergenicity of GM foods involves five 
steps: the characterisation of the source organism of the novel protein; the analysis of amino 
acid sequence similarity of the protein and known allergens; study of physico-chemical 
properties; where the protein is derived from an allergenic source organism or where there are 
other indications of potential allergenicity, such as structural similarity to known allergens, 
these tests are complemented with immunological tests and, where deemed appropriate, 
further investigations.  Methods for the assessment of the sensitisation potential of proteins 
need to be improved, such as through the development and validation of animal models, to 
allow the transfer of proteins that might share certain structural or physico-chemical 
characteristics with allergens.  The possibility of changes in the allergenicity of the whole 
crop should also be considered. 
12. A more detailed understanding of protein allergy will enhance further safety assessment of a 
protein’s potential for allergic sensitisation.  ENTRANSFOOD considers of particular value 
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the development of an animal model that would permit the identification and characterisation 
of potential food allergens.  Progress in this area will be facilitated by a more thorough 
appreciation of the factors that confer to proteins the potential to induce allergy and what 
distinguishes these from non-allergic proteins.  Further research on the structure-function 
relationship of allergens is encouraged. 
13. The comparison of the GM crop to its counterpart relies on a targeted approach of parameters 
indicative of the overall plant metabolism and possible changes from genetic modification 
that might have health implications.  This involves the assessment of composition, 
physiology, morphology, and agronomic performance.  Such targeted approaches can identify 
unintended changes from the genetic modification.  Parameters for comparison are usually 
indicators of the functioning of major physiological and biochemical pathways of the crop.  
The focus on key nutrients and anti-nutrients in food crops corresponds to the focus on 
identifying those changes in food crops that may have implications for human health. 
14. Animal tests with whole foods derived from GM crops are considered to contribute with 
useful information to the safety assessment.  We recommend such tests should only be a 
requirement in cases where the composition of the GM food crop differs significantly from 
that of its unmodified counterpart or if other tests provide any indications of a potential 
hazard associated with the genetic modification.  In these cases, dietary sub-chronic rat 
studies (usually, these are of 90 days duration, assessing the classic toxicological endpoints) 
are recommended to demonstrate the safety of the food.  If adverse effects are observed, 
further toxicological studies on long-term effects should be considered in cases where the 
product is still deemed fit for marketing.  Further standardisation of test protocols for animal 
feeding trials with novel foods, including foods derived from GM crops is recommended, 
including recommendations on when, how, and how often the diet is administered, 
performance of the animal experiment, and choice of toxicological and nutritional endpoints. 
15. The described approach to safety assessment is also applicable to new generations of GM 
food crops with extensive compositional changes.  For GM crops that have been modified 
extensively such that there is no single crop that is a conventional counterpart suitable for 
comparison, all new substances or existing substances whose levels have been altered should 
be assessed on a case-by-case basis; safety studies with the whole crop should also be 
conducted.  The safety assessment of GM crops that are intentionally designed to be 
compositionally different requires increased attention to two issues: the choice of an 
appropriate comparator and the estimate of the anticipated exposure.  One example of a 
compositionally altered GM crop currently under regulatory review is oilseed rape that 
contains lauric acid, a fatty acid not normally found at elevated levels in oilseed rape oil.  The 
product was developed as a substitute for tropical oils (for instance, palm oil) in certain food 
applications.  The comparator with safe use in this case was palm oil. 
16. ENTRANSFOOD considers the current safety assessment approach adequate to determine 
whether foods derived from GM crops are as safe as their conventional counterparts.  The 
issue of long-term effects of the consumption of foods derived from GM crops has been 
addressed by the FAO/WHO Expert Consultation held in 2000, and was endorsed by 
ENTRANSFOOD.  Very little is known about the potential long-term effects of any food, 
and such effects are difficult to assess at the population level due to the complex and 
changeable diets that prevent attributing specific health effects to individual food 
components, as well as the variable susceptibility to diverse health impacts across individuals 
within a population.  On a case-by-case basis, randomised controlled trials in humans could 
be performed to investigate medium/long term effects of foods. 
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17. ENTRANSFOOD does not recommend post-market monitoring of foods derived from GM 
crops as a routine practice.  Such studies with commodity crops are unlikely to provide 
meaningful information.  Post-market monitoring might be considered for identity-preserved 
GM crops with changed nutritional characteristics in order to confirm the pre-market safety 
and nutritional assessment.  A clear test hypothesis in form of a causal relationship of food 
intake and health impact must be formulated. 
18. Genomic research adds a new dimension to our understanding of plant biology and provides 
powerful new tools to study induced changes in gene expression.  Increased knowledge of the 
structure of plant genomes, functions of individual genes, and a plant’s responses to its 
environment at the molecular level will improve our understanding of the characteristics of 
the parent crop that pertain to food safety assessment of GM crops.  The establishment of 
international systems for improved access to crop genome databases and latest bio-
informatics methods in order to facilitate and harmonise the future analysis of such data are 
key. 
19. The availability of sequence information of entire plant genomes also allows for the 
development of micro-array systems to assay induced changes in gene expression patterns.  
This will in future also allow assessing potential changes in gene expression in genomic 
regions in proximity of the insertion locus.  The interpretation of such data will, however, be 
challenging, as a greater understanding of gene functions and changes in expression levels is 
required before the safety implications of any such change in gene expression can be 
assessed. 
Assessment of unintended effects 
20. Uncertainties in the safety assessment associated with unintended changes in plant genomes 
through the insertion of recombinant DNA should always be considered in the light that crop 
genomes are constantly changing through a broad range of natural and man-mediated 
mechanisms.  Uncertainty associated with food safety of GM crops is no greater than 
uncertainty associated with conventionally bred crops.  Unintended effects that alter the 
composition of food crops are as likely to occur through natural recombination and 
mutagenesis approaches used in plant breeding as through genetic modification.  Variety 
selection and registration requirements for both GM crops and conventionally bred 
counterparts that involve the assessment of physiology, morphology, and performance are 
sound indicators of unintended effects that may potentially impact human health. 
21. The application of profiling techniques providing fingerprints of a crop samples’ gene 
expression profile, protein levels, and metabolite levels promises to rapidly expand our 
understanding of metabolic and compositional variations of crop plants.  Profiling methods 
are, however, not suitable as yet as a commonly used tool for the safety assessment of GM 
crops.  Genomic research and new tools of molecular biology such as high-throughput DNA 
detection and characterisation methods will also greatly increase our understanding of crops 
and their genomes, their interaction with their environment, and implications to health from 
their consumption.  In vitro and in vivo test systems using genomic and micro-array 
technologies in order to provide sensitive biomarkers for biological responses to food 
components and possibly whole foods may in future allow more specific prediction of which 
health endpoints are affected by specific toxins, by improving knowledge of human metabolic 
and cellular processes and by having the possibility of monitoring subtle changes in gene 
expression levels.  Further development of these methods is encouraged. 
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22. Several issues need to be addressed before profiling approaches can become a proven and 
useful tool in standard risk assessment procedures.  The interpretation of outputs (data) 
remains a significant challenge.  Much work remains to be done in the development and 
standardisation of sampling procedures and approaches for data collection and handling.  
Inter-laboratory “ring” testing and validation of these methods will also be required.  In 
addition, a more comprehensive understanding of natural variation in, for example, the levels 
of metabolites in crops needs to be developed to allow any unintended changes in a GM crop 
plant to be properly “benchmarked”.  Most importantly, approaches will be needed to 
interpret the biological relevance and toxicological significance of any observed differences.  
The identification of possible differences between traditionally used and novel crops that 
might have adverse effects on human health is the overall aim of both targeted and non-
targeted approaches. 
23. ENTRANSFOOD recommends international research efforts for the development of profiling 
methods and international databases on natural variation in gene expression, protein, and 
chemical composition of crops.  The allocation of public sector research funds to this aim is 
important.  These methods will contribute to improving our understanding of the foods we eat 
and their potential implications for human health. 
Assessment of risks of gene transfer across species 
24. Gene transfer between organisms is common in nature and has been a driving force in 
evolution.  There is no inherent risk in the transfer of DNA between organisms, since DNA is 
not toxic.  The risk of gene transfer of recombinant DNA from GM crops to microbes or 
human cells has to be evaluated with respect to the risk of a similar event occurring in nature.  
The potential impact largely depends on two factors: first, on the function of the transferred 
DNA in the recipient cell; and secondly on whether the recipient cell may have acquired the 
same gene from a source other than the GM crop. 
25. The risks of gene transfer from GM crops that are currently commercial are deemed 
negligible.  Transfer to microbes by transformation is a possibility, but only consequential if a 
new trait is expressed and confers selective advantage.  Uptake of GM crop-derived DNA, 
including the transgenes by human cells of the gut or the immune system, cannot be ruled 
out; it is, however, very unlikely that transgenic DNA is stably integrated in somatic cells or 
taken up in germline cells.  Even if it should be taken up, the trait conferred by the gene may 
not be expressed in human cells. 
26. The risk of use of antibiotic resistance markers for selection of transformed plant cells should 
be judged on a case-by-case basis, considering their frequency of occurrence in bacterial 
populations and the extent of clinical use of the antibiotics to which resistance is conferred 
(and whether the antibiotic is of importance as a last resort).  Some antibiotic resistance 
markers such as the nptII gene and the hygromycin resistance gene can be used without the 
risk of compromising the use of important clinically used antibiotics. 
27. The transformation strategy and the recombinant DNA for insertion into the GM crop should 
be designed with care.  Guidelines on best practice recommend minimising recombinant 
DNA sequences transferred to GM crops in order to simplify the molecular characterisation 
and reduce uncertainty on potential genetic rearrangements and unstable gene expression.  
Agrobacterium-mediated gene delivery is considered the most controlled gene delivery 
system that facilitates obtaining GM crops with single, simple and hence minimal inserts.  
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The design of recombinant DNA transferred to GM crops should minimise the risks of DNA 
sequences that might foster independent transfer, expression of the DNA in microbes or 
viruses, and recombination in bacterial or viral genomes, where possible. 
28. Further research and development on transformation methods and methods for the 
elimination or replacement of selectable markers is encouraged, in particular in the public 
sector.  Public access to such methods is important.  Improvements in methods for crop 
transformation aim at simplifying the safety assessment of GM crops by reducing the 
introduced recombinant DNA in GM crops to a minimum.  The risks, costs, and benefits of 
established and potential new transformation technologies should however be systematically 
compared before novel technologies are officially recommended for broad adoption in 
product development. 
Detection, labelling, and traceability of GMOs 
29. The General Food Law provides an integrated approach to ensuring food safety across the EU 
Member States and across the food and feed sectors.  The General Food Law provides for one 
decision-making procedure for all food products that require EU-level approvals, such as 
food additives, pesticide residues in food, novel foods, and genetically modified organisms 
(GMOs).  The European Commission Directorate General for Health and Consumer 
Protection administers the decision process.  The European Food Safety Authority reviews 
the risk assessment submitted by applicants intending to place food additives, pesticides, 
novel foods or foods derived from GMOs on the European market.  The law also clarifies 
accountability of all legal entities involved in food production and regulation in the EU by 
describing general food safety requirements that are imposed on both the Member States and 
business operators.  General principles in the law include the protection and information of 
consumers through comprehensive labelling schemes; provisions for traceability, that is the 
ability to trace back to the origin and to understand the distribution of foods and food 
ingredients; and the application of the precautionary principle in instances of significant 
uncertainty in the risk assessment. 
30. In June 2003, the European Council of Ministers adopted two new Regulations specific for 
foods and feeds derived from GMOs.  Regulation (EC) No 1829/2003 on GM food and feed 
provides the legal basis for the approval procedure for GMOs as specified in the General 
Food Law.  The European Food Safety Authority's Scientific Expert Panel on Genetically 
Modified Organisms assesses the safety of foods derived from GMOs.  The panel also 
assesses the food safety, environmental, and animal health aspects of GMOs ("one-door-one-
key" principle). 
31. Regulation (EC) No 1830/2003 concerning the traceability and labelling of GMOs and the 
traceability of food and feed products produced from GMOs requires labelling of all food 
products derived from GMOs, including those that do not contain detectable traces of 
recombinant DNA or novel protein such as highly refined oils (not materially distinguishable 
from other oils not derived from GMOs). 
32. ENTRANSFOOD considers that current thresholds for labelling requirements for foods 
containing or consisting of GM crops are very stringent and pose challenges for 
implementation.  The threshold of GM crop content above which a food needs to be labelled 
is 0.9% for GM crops that have been approved for import or cultivation in the EU and 0.5% 
for a GM crop reviewed by an EU scientific committee, but that has not been as yet approved.  
Given the significant administrative burden from the implementation of current labelling 
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legislation and standards on governments and producers, ENTRANSFOOD recommends to 
develop diversified sampling plans, more stringent plans for those cases where the safety of 
the food supply is at stake, and more lenient sampling regimes for other cases.  Clear 
rationales for labelling of products should drive the determination of such standards.  Closer 
collaboration between consumer groups, scientists, and legislators, in particular in standard 
setting, is required to ensure agreement on standards that can be implemented and enforced. 
33. Prerequisites for the implementation of the new labelling and traceability provisions include 
the establishment of systems for documenting the distribution of individual GM crops in the 
agro-food chain and analytical methods for verification of this information.  Sampling and 
detection methods for verification of presence or absence of GM crops require qualitative and 
quantitative approaches.  Qualitative detection methods are required for high-throughput 
screening of large quantities of samples or distinguishing approved from non-approved GM 
crops.  Development of such methods requires reference materials and product information 
for all individually transformed GM crops that are in development or commercialised 
anywhere in the world.  The European Network of GMO Laboratories was set up for this 
purpose; a similar system, however, needs to operate globally.  Guidelines are required 
outlining detailed standards for the purity and type of reference materials and additional 
information on the GM crop that needs to be provided. 
34. Sampling plans depend on the quality and nature of the detection method that is used and on 
the threshold set.  Appropriate sampling schemes for bulk loads where GMO-derived 
materials may be mixed in a very heterogeneous way will require the analysis of large 
numbers of samples per load.  Reliability and costs of sampling and testing depend very 
much on the test material in terms of the non-uniformity of distribution of GMO-derived 
material in the sample and the ‘food matrix’ from which DNA or the protein have to be 
extracted for detection.  Given the burden on administrations and producers, 
ENTRANSFOOD recommends developing diversified sampling plans, more stringent plans 
for those cases where the safety of the food supply is at stake, and more lenient sampling 
regimes for other cases. 
35. The three specific objectives of legal provisions for traceability are to facilitate withdrawal of 
products should an unforeseen risk to human health or the environment be established; 
targeted monitoring of potential effects on human health or the environment, where 
appropriate; and control and verification of labelling claims.  The fundamental objective is to 
restore consumer trust through providing information and choice.  Traceability of foods and 
food ingredients, including imported foods, also requires, however, the establishment of 
international systems allowing traceability of traded foods. 
36. ENTRANSFOOD recommends considering whether additional testing for verification of 
claims on GM crop content should not only be carried out at critical control points in the food 
supply chain.  In some cases, paper-based or electronic traceability systems may be adequate. 
37. At present, the lack of tools for detection of diverse GM crops released into the environment 
poses significant challenges for the food industry to comply with EU labelling legislation.  
Enforcement of the law is equally difficult.  Furthermore, EU law requires separate 
registration of seeds in which two different traits obtained by genetic modification (such as 
insect resistance and herbicide tolerance) have been combined by breeding, often called 
‘stacked genes’.  Enforcement of this requirement would also require detection methods that 
can distinguish between two traits that were stacked into one seed by breeding and two seeds 
of which each seed contains one trait.  In the analysis of commodity shipments that may 
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contain both types of seeds (single trait and stacked trait seeds), drawing such distinctions is 
impossible with current detection methods. 
38. Traceability represents a valuable tool to face problems related to the introduction of GMOs 
in food and feed chain and to gain the confidence of the consumer toward this novel food.  It 
is clear, however, that the implementation of any suitable system implies a substantial 
increase in overall cost of food production that will have to be absorbed by both producers 
and consumers.  This holds true unless a traceability system also helps to save on current 
costs, such as their use as a tool for more effective inventory- and supply chain-management. 
Societal aspects of introducing GM crops in the agro-food chain 
39. The public framing of questions on risk often differs from the framing of scientists.  For 
instance, there is a concern on potential long-term effects from adopting GM crops.  Whether 
society ‘needs’ the technology is also considered important.  If public confidence in the 
technology and its regulation is to be regained, it is important to explicitly incorporate public 
concerns into the risk analysis process through developing new and influential methods of 
stakeholder involvement and consultation (including consumers).  Once public concerns and 
the values on which they are based are understood, they can be more effectively introduced 
into innovation strategies, risk assessment, and risk management practices. 
40. Surveys conducted in this project supported that consumers may prefer labelling of products 
on the basis of both process and product characteristics.  Research is needed to determine the 
most effective form for food labels, which take due account of cross-cultural differences in 
information preferences where they exist. 
41. Questions for further research on societal aspects of GM foods include the following:  How 
can public concerns be incorporated into this process? How can effective and inclusive public 
participation in risk management and science and technology policy be developed?  What is 
the best way to involve the public in the debate about genetic modification of foods? How 
might information about the difference this has made to public policy be communicated back 
to the public?  What changes to institutions need to be made in order to accommodate these 
processes?  How should they restructure themselves to make it easier for the voice of the 
public to be heard?  
The need for an integrated platform for deliberation on food production and biotechnology 
42. The ENTRANSFOOD project has highlighted the need to continue interdisciplinary 
deliberations on agricultural biotechnology to better understand potential impacts from 
adoption and diverse approaches to regulation of the technology.  Four types of questions 
should be considered more systematically, integrating a wide range of different perspectives: 
what is the objective of a new product or technology for food production, who will benefit 
from it, who might incur risks (environmentally, health-wise, economically, or culturally), 
and how can we ensure that we will learn from the experience?   
43. ENTRANSFOOD recommends the establishment of a Permanent Evaluation and Discussion 
Platform that explores both scientific and societal issues of diverse current practices in food 
production, i.e. intensive agricultural production, low-input/organic production, and genetic 
modification-facilitated production practices.  Regulators, academics, and stakeholders from 
the private sector and consumer organisations should work together to map areas where there 
is agreement, disagreement, and the need for further research.  Such a Platform could have 
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several functions, such as organising events to frame questions on risk for expert 
deliberations, guide the assembly of the knowledge base for experts, review draft expert 
advice, and review proposed draft regulations and standards.  Deliberations on how 
institutions can continually improve their approaches to governing risks from biotechnology 
could also be part of the remit of such a platform.  Coordinators of such an integrated 
deliberation platform should also consider on how they should interact with 
intergovernmental organisations working on guidelines and policy recommendations on agro-
food production and biotechnology, such as the Codex Alimentarius, the Organisation for 
Economic Coordination and Development, and Organisations of the United Nations. 
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INTRODUCTION 
Worldwide, the consumption of foods derived from genetically modified crops (GM crops) is 
rising rapidly.  Since the first GM crop was introduced in the market for large-scale cultivation in 
1996, the global area of cultivation has risen to 67.7 million hectares in 2003 (Figure In-1; James, 
2003).  An increasing number of countries approved an increasingly diverse array of crops with 
new traits.  A large share of the harvest enters the agro-food chain.  In 2002, three crops largely 
shared the total global acreage of GM crops: GM soybeans, maize, cotton, and oilseed rape 
accounted for 61%, 23%, 11%, and 5%, respectively.  The rate of adoption varied across 
countries:  plantings in the US, Argentina, and Canada accounted for 63%, 21%, and 6% of the 
total global area of cultivation; in Europe, GM crops were grown in Romania (70,000 hectares of 
GM soybean), Spain (32,000 hectares of insect-protected maize), Germany, and Bulgaria.  The 
first GM crops that are currently marketed have been genetically modified to facilitate cultivation 
and to reduce the environmental impact of agriculture.  These crops contain new genes that 
protect the crop against certain insect pests, or that confer tolerance to broad-spectrum herbicides 
facilitating weed control.  GM crops with more complex modifications that affect a crop’s 
metabolism or physiological processes, such as the enhancement of properties relating to a crop’s 
food safety or nutritional characteristics.  For instance, rapeseed with higher levels of vitamin E 
and rice containing pro-vitamin A and/or iron are in development, and research is being 
conducted to lower the levels of natural allergens in rice and peanuts.  The removal of other 
natural toxins is also being considered.  Regulatory authorities are considering some such crops 
for approval, as for example soybeans and rapeseed with altered fatty acid composition. 
Figure In-1 Global cultivation of GM crops (James, C., 2003. Global Status of Commercialized Transgenic 
Crops: 2003, ISAAA Briefs No. 30: Preview. International Service for the Acquisition of Agri-biotech 
Applications, Ithaca)
The Thematic Network ENTRANSFOOD provided a platform for deliberation on the 
interdependent scientific, regulatory, and societal aspects of food safety assessment of GM crops 
by a multidisciplinary group of researchers and administrators.  The underlying premise of 
deliberations on the food safety of GM crops under the auspices of ENTRANSFOOD has been 
the comparison of the safety of food crops produced by conventional means to foods derived 
from GM crops. 
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Alterations of plant genomes at the molecular level occur through similar mechanisms in plant 
breeding and the application of methods of agricultural biotechnology, and hence are thought to 
occur even in similar regions of plant genomes; what differs is the range of source organisms 
from which new genetic variation can be introduced.  Plant breeding relies on systematically 
identifying beneficial changes in crops resulting from natural genetic variation and on selecting 
these improved varieties for further propagation and finally cultivation.  Breeders have also used 
artificial means to enhance genetic variation; these include the use of chemical or gamma 
irradiation mutagenesis to increase the error rate in DNA replication processes in plant breeding.  
The extent to which DNA structure and integrity are modified in these accepted breeding 
approaches is unknown.  What is clear is that the genetic structure of plant populations has been 
widely changed by breeding practices, indicating the deep influence of breeding practices on the 
genetic make-up of plant crops.  Genetic engineering of crop plants largely relies on two methods 
used to introduce foreign DNA into plant cells: biolistic (microprojectile) bombardment and 
Agrobacterium-mediated transformation.  The biolistic method is based on a physical delivery of 
DNA-coated gold or tungsten microprojectiles into plant target tissue by acceleration.  
Agrobacterium-mediated transformation exploits the biological ability of this soil-borne 
bacterium to copy and transfer a specific portion of DNA (termed T-DNA) present on a tumour 
inducing (Ti) plasmid into the plant cell nucleus, where it can be integrated into chromosomes. 
Scientists rely on the same fundamental approach to assess the safety of individual GM crops.  
Each individual GM crop is compared to an appropriate comparator that is generally accepted as 
safe for food use, usually based on its extensive prior use as a human food.  The much slower 
adoption of the technology in Europe, however, demonstrates that rigorous safety assessment is 
necessary but not sufficient for gaining societal acceptance of agricultural applications of 
biotechnology. 
Regulatory frameworks and decisions on prerequisites for the safe and sustainable adoption of the 
technology differ across jurisdictions.  The United States amended existing product legislation 
including the Federal Plant Pest Act and the Food, Drug and Cosmetics Act to regulate GM crops.  
Over the last nine years, the United States regulatory agencies have permitted commercial 
cultivation of over 50 different GM crops products.  In the European Union, new legislation was 
drawn up specifically for the regulation of genetically modified organisms (GMOs).  Only 
thirteen GM crops have been approved for environmental release before October 1998, and none 
since then.  In June 1999, five Member States declared that new authorisations for the 
environmental release of GM crops shall be suspended until a more rigorous and transparent 
regulatory framework is adopted that requires environmental monitoring where appropriate, 
monitoring, and the labelling and traceability of all foods derived from GM crops.  Thirteen GM 
crop-derived processed food products are approved for consumption in the EU. 
Consumer and environmental organisations have challenged official risk assessment and risk 
management procedures, largely on the ground that uncertainties on long-term effects of GM 
food crops on both health and the environment are not adequately addressed.  The need to ensure 
that consumers can choose whether to consume foods derived from GM crops through labelling 
and traceability requirements was emphasised.  Regulatory institutions and the industrial players 
attempting to commercialise products have now taken measures they perceive to be in the 
public’s interest.  In particular since the series of food scares in Europe culminating with BSE, 
trust in Europe’s food safety system (assessment methods, legislation, and institutions) needs to 
be rebuilt.  European Commission officials hope that the recent adoption of a new regulation on 
foods and feeds derived from GMOs and a regulation on the labelling and traceability of foods 
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derived from GM crops by the Council will provide an appropriate basis for Member States to 
resume the regulatory process for decisions on individual products. 
Introducing a new technology in society requires awareness of the interests and values 
stakeholders associate with the technology and repercussions from technology adoption on each.  
The agro-food chain is complex, consisting of elements with diverse interests, including farmers, 
traders, distributors, processors, retailers, and end-consumers.  Food processors and retailers are 
often more sensitive to concerns of the end-consumer than organisations at the natural resource 
extraction-end of the value chain (such as Agbiotech providers and seed companies).  
Furthermore, interests of end-consumers and entities in the agro-food chain closest to them 
(retailers and food processors) may be different in diverse markets. 
This report, a synthesis of deliberations of the food safety of GM crops of five Working Groups 
with members from diverse backgrounds, is divided into seven chapters.  Chapter 1 provides an 
introductory overview on food safety regulation of GM crops and international guidelines for risk 
analysis and safety assessment of GM crops.  The subsequent five chapters summarise outcomes 
of deliberations of ENTRANSFOOD’s five working groups.  The five working groups each 
covered the following topics: safety assessment; unintended effects; horizontal gene transfer; 
detection, labelling and traceability; and societal aspects.  Chapter 2 describes how to tailor safety 
assessment strategies for specific GM crops in a systematic and stepwise manner.  Chapter 3 
outlines how to characterise and reduce uncertainties in the detection of unexpected effects 
possibly due to the genetic modification.  Considerations on whether there may be risks inherent 
in GM crops that are not associated with crops improved through conventional breeding 
technologies were central to the deliberations.  Chapter 4 describes the potential risks from the 
transfer of recombinant DNA from GM crops to microbes or human cells.  Chapter 5 identifies 
scientific, methodological, and institutional prerequisites for the implementation of proposed 
legislation on labelling and traceability.  Chapter 6 considers what influences public attitudes to 
the technology, and trust in institutions and information.  Chapter 7 presents conclusions, 
discussing the limitations and successes of this project. 
ENTRANSFOOD is a successful example of how issues of food safety assessment, uncertainties, 
regulation, and societal impacts can be elucidated from a range of different perspectives, 
including from scientists, regulators, firms, and civil society organisations.  One limitation 
discussed in more detail in Chapter 7 stems from the project’s focus on food safety and attitudes 
to agricultural biotechnology in Europe.  The scope precluded more detailed consideration of 
attitudes to and impacts from adoption of alternative farming practices comparing organic 
farming practices, conventional approaches relying on use of agro-chemicals, and use of GM 
crops in Europe or elsewhere in the developed or developing world.  Questions on distributional 
effects from regulation, and liability and insurability of risks, including risks from regulations that 
are difficult to comply with, also were beyond the scope of ENTRANSFOOD.  Detailed 
consideration of ethical issues and assessment of the impact of adoption of the technology on 
diverse interest groups and stakeholders were, however, beyond the scope of this work.  These 
aspects, central to a more comprehensive assessment, need to be considered in future research 
projects.  Although we could not address them in more detail, we consider all the above questions 
central to society’s debate on the future of agricultural biotechnology. 
The ENTRANSFOOD project has highlighted the need to continue interdisciplinary deliberations 
on agricultural biotechnology to better understand potential impacts from adoption of the 
technology from diverse perspectives of groups defending distinct sets of values.  Four types of 
questions should be considered more systematically, integrating a wide range of different 
perspectives: what is the objective of a new product or technology, who will benefit from it, who 
23
might incur risks (environmentally, health-wise, economically, or culturally), and how can we 
ensure that we will learn from the experience? Chapter 7 presents conclusions and 
recommendations for future research and a proposal to establish an improved integrated 
discussion platform for general deliberations on food production and biotechnology, building on 
experience gained in ENTRANSFOOD. 
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CHAPTER 1 
REGULATION AND RISK ANALYSIS OF FOODS DERIVED FROM GM CROPS: AN 
OVERVIEW 
Food safety analysis and control systems, comprising institutions, policies, laws, and guidelines 
for assessments, continually evolve over time.  The evolution of such systems in individual 
jurisdictions is affected both by science and society: Scientific advances improve our 
understanding of health implications of foods and lead to the development of new foods that 
might require regulatory oversight.  Changing societal values and norms can lead to shifts in 
emphasis in consumer protection policies and regulatory and institutional change.  Regulation in 
turn can affect both innovation and risk perception. 
Regulatory frameworks differ across jurisdictions.  The European Union (EU) regulatory system 
is representative of this "process-based" approach.  Separate legislation for the environmental 
release and the food and feed derived from GM crops was created.  In other legal systems, such as 
the US, existing product legislation is amended to apply to GM crop-derived foods.  The US 
Federal Food Drug and Cosmetics Act, the scope of which was broadened to include foods 
derived from GMOs, is an example of vertical, "product-based" regulation.  Regulatory decisions 
on product approvals and regulatory prerequisites for the sustainable deployment of agricultural 
biotechnology differ: the US has continued to approve GM crops for commercial cultivation; the 
EU has instituted a de facto moratorium since 1998.  The EU advocates establishing a system for 
process-based labelling and traceability of foods derived from GM crops as a prerequisite for GM 
crops entering the global food chain.  Whilst regulatory frameworks and decisions differ across 
jurisdictions, the same approach to the safety assessment of foods derived from GM crops was 
adopted in most countries.  The approach is based on general principles for risk analysis and 
international guidelines for the safety assessment of foods derived from GMOs. 
This chapter provides an overview on the regulation of foods and GM crops in the EU.  
Subsequently it describes general concepts of risk analysis, food safety assessment, and 
international guidelines on how to apply the principles of risk analysis and food safety assessment 
to the assessment of foods derived from GM crops. 
1.1 Regulation of food safety and of GM crops in the European Union 
In the 1980s, the main motivation for establishing a common food policy amongst Member States of the 
European Economic Community was the creation of the single market; this required harmonising 
Member State standards and labelling schemes that might hinder trade if too distinct.  The early 
cautious approach to harmonisation of food law of the EU Member States resulted in a large number of 
fragmented laws, which include horizontal framework directives with general provisions on food 
additives, labelling, and hygiene of foods, and vertical product-specific directives, such as those with 
hygiene provisions for specific animal-derived food products.  Overall, the main objective of helping to 
establish the single market was achieved, but the resulting set of directives was often criticised as 
opaque, fragmented, incoherent, and as in general not adding any benefit to existing EU Member State 
legislation.  The late 1980s and early 1990s also saw the implementation of directives for the regulation 
of food additives, pesticide residues in foods, and contaminants in foods. 
Before 1997, foods and feeds containing GMOs were approved through Directive 90/220/EEC on 
the deliberate release and placing on the market of GMOs.  The directive, administered by 
Directorate General for the Environment, regulates the deliberate release of all live GMOs 
regardless of their field of application.  Only the placing on the market of GMOs with medical 
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uses, such as live vaccines, and of foods containing or consisting of GMOs are exempt as 
regulated elsewhere.  Two GM crops were approved for import and food use under this directive: 
Monsanto’s herbicide-tolerant soybeans and Syngenta’s insect-protected corn (developed by Ciba 
Geigy).  In June 1999, five member States (Denmark, France, Greece, Italy, and Luxembourg) 
declared: “in accordance with the precautionary principle, new marketing authorizations shall be 
suspended”.  The declaration called for the adoption of a more rigorous and transparent 
regulatory framework that, among other improvements, sets out provisions for monitoring 
requirements of transgenic crops.  The consequence, although not officially declared, is a de facto
moratorium on the commercial cultivation of transgenic crops in the EU (see for lists of approved 
or pending products, European Commission, 2004). 
Later in the 1990s, the Bovine Spongiform Encephalopathy (BSE) crisis was the single most 
important trigger for regulatory reform of the current food safety analysis and control systems in 
the European Union.  First, it highlighted the need for improved coordination in the adoption of 
risk management measures in the area of food safety across the Member States.  The BSE crisis 
and the spread of dioxin-contaminated feed batches also highlighted the need for a vertically 
integrated approach to the governance of feed and food safety that addresses all stages of 
production ‘from farm to table’.  The crises also undermined consumer confidence in Europe’s 
food safety systems. 
Institutional and legislative changes ensued.  Institutional changes included the creation of the 
European Commission Directorate General for Health and Consumer Protection (DG SANCO), 
in 1997, and the creation of the European Food Safety Authority (EFSA) in 2002.  Legislative 
changes include the final agreement between Member States, the Commission, Parliament, and 
the Council on the long negotiated Regulation (EC) No 258/97 concerning novel foods and food 
ingredients (henceforth Novel Foods Regulation).  The Novel Foods Regulation gave the 
European Commission a clear role in the governance of food safety.  This role was strengthened 
with the publication of the Regulation (EC) No 178/2002 on the general principles of food law 
and the establishment of the European Food Safety Authority (hence forth the General Food 
Law). 
The Novel Foods Regulation provides an EU-wide regulatory approval system for novel foods 
that "have not hitherto been consumed to a significant degree in the EU".  This includes foods 
derived from GMOs.  Each EU Member State appointed a national competent authority for 
administration of the law at the national level.  The regulation is at present being revised in order 
to be adapted to provisions of the 2002 General Food Law.  The Novel Foods Regulation, which 
entered into force in 1997, provided for two alternative decision-making procedures for the 
placing on the market of foods derived from or containing GM organisms.  The determination of 
"substantial equivalence" of the novel food to an appropriate comparator with an accepted 
standard of safety by the rapporteur Member State serves as regulatory clearance for marketing of 
the product and is notified to the European Commission.  Processed oil from GM oil seed rape 
and cotton, and processed products derived from GM corn are amongst the products notified 
based on a determination of substantial equivalence under the Novel Foods Regulation.  For lists 
of approved or pending products see European Commission (2004).  Novel foods that are not 
deemed substantially equivalent needed to undergo a more complex authorisation procedure 
involving a review by all EU Member States.  One ambiguity under the Novel Foods Regulation 
relates to the definition of the term substantial equivalence that determines the choice between the 
two distinct procedural options for marketing foods. 
The 2002 General Food Law now provides an integrated approach to ensuring food safety across 
the EU Member States and across the food and feed sectors.  General principles in the law state 
26
that risk analysis is based on scientific risk assessment conducted by the recently instituted 
European Food Safety Authority (EFSA).  The law establishes an EU-level authorisation 
procedure for all types of regulated foods.  Other general principles include the protection and 
information of consumers through comprehensive labelling schemes; provisions for traceability, 
that is the ability to trace back to the origin and to understand the distribution of foods and food 
ingredients; and the application of the precautionary principle in instances of significant 
uncertainty in the risk assessment.  Furthermore, the new law clarifies accountability of all legal 
entities involved in food production and regulation in the EU by describing general food safety 
requirements that are imposed on both the Member States and business operators. 
The primary responsibility of compliance with the EU food law is placed on business operators at 
all stages of the producing, processing, manufacturing, or distributing of food.  This is to be 
achieved through implementation of self-checking provisions relying on the Hazard Analysis 
Critical Control Points systems (HACCP).  The Member State competent authorities are to 
monitor and verify compliance of private sector entities with the law.  The law also provides a 
legal basis to the Commission’s coordination of an EU-wide rapid alert and crisis management 
system network of national institutes and competent authorities, in which DG SANCO plays an 
important role. 
Furthermore, the General Food Law provides for one decision-making procedure for all products 
that require EU-level approvals, such as food additives, pesticide residues in food, novel foods, 
and GMOs.  The procedure is as follows: the European Commission DG SANCO administers the 
review process.  As provided for in the General Food Law, EFSA reviews the risk assessment 
submitted by applicants intending to place a novel food on the European market.  It is up to the 
administrators in European Commission DG SANCO to draft proposals based on the risk 
assessment and other broader considerations that may affect choice of policy options.  A 
regulatory committee of representatives of Member States competent authorities then decide 
whether to accept the Commission proposal through a weighted voting system.  If the regulatory 
committee’s opinion is not in accordance with the proposed measure or if no opinion is delivered, 
the question is referred to the Council of Ministers.  The Council of Ministers can approve or 
reject a Commission proposal given a qualified majority of Member States support the position.  
If rejected, the European Commission has to prepare a new proposal.  If the Council of Ministers 
takes no decision within three months, or does not reach a qualified majority indicating that it 
opposes the proposal, the European Commission shall adopt the proposal. 
Regulation of GMOs 
Currently, Directive 2001/18/EC on the deliberate release and placing on the market of GMOs 
govern environmental releases of GM crops.  It repeals the former Directive 90/220/EEC.  Unlike 
in the US, lines of GM crops that contain two traits that have previously been registered in 
separate crop lines, but that are combined in one crop through breeding require separate 
registration.  The revised directive strengthens the existing rules of the risk assessment and the 
decision-making process on the release of GMOs into the environment.  In particular, it defines 
mandatory information that must be given to the public and introduces general rules on 
mandatory labelling and traceability at all stages of the placing on the market.  Authorisations 
will be granted for a period of 10 years, subject where appropriate to a post-market monitoring 
plan.
The Regulation (EC) No 1829/2003 on food and feed derived from GMOs was adopted in July 
2003.  There is one single authorisation procedure for the food use, feed use, and commercial 
release of GMOs that corresponds to the procedures described in the General Food Law (see also 
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Box 1-1).  This ‘one-door-one key’ regulatory strategy is in line with the European Commission’s 
effort to integrate food and feed regulation across sectors and to enhance the efficiency and 
coherence of the review system.  It is also hoped that this strategy will help to avoid fiascos such 
as the finding of Aventis’ Starlink™ insect-protected corn in the food chain, although it had only 
been approved for local cultivation and feed use in the US. 
BOX 1-1 
EU LEGISLATION ON GM FOODS
 Environmental release
  Directive 2001/18/EC on the deliberate release into the environment of GMOs and repealing 
Council Directive 90/220/EEC 
GM food and feed
  Regulation (EC) No 1829/2003 on GM food and feed
Contained use of GM micro-organisms
  Council Directive 90/219/EEC on the contained use of GM micro-organisms
  Council Directive 98/81/EC amending Directive 90/219/EEC on the contained use of GM micro-
organisms
Labelling of GM food and feed
  Council Regulation (EC) No 1139/98 concerning the compulsory indication of the 
labelling of certain foodstuffs produced from GMOs of particulars other than those 
provided for in Directive 79/112/EEC 
  Commission Regulation (EC) No 49/2000 amending Council Regulation (EC) No 
1139/98 concerning the compulsory indication on the labelling of certain foodstuffs 
produced from GMOs of particulars other than those provided for in Directive 
79/112/EEC 
  Commission Regulation (EC) No 50/2000 on the labelling of foodstuffs and food 
ingredients containing additives and flavourings that have been genetically modified or 
have been produced from GMOs 
  Regulation (EC) No 1830/2003 concerning the traceability and labelling of GMOs and 
the traceability of food and feed products produced from GMOs and amending Directive 
2001/18/EC 
Labelling, traceability, and consumer choice 
The European Commission’s role in consumer protection has grown together with its increasingly 
political remit since entry into force in 1987 of the Single European Act.  This priority has been 
further highlighted in the Treaty of Amsterdam.  The website of the European Commission DG 
SANCO spells out that provision of consumer information and choice through labelling and 
product information is considered an important element required to re-establish consumer trust in 
the EU food safety analysis and control system after the BSE and other food safety crises.  
Information should be provided on health-related issues and on salient matters related to food 
production processes. 
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In the 1970s, European Community law to harmonise Member State approaches to labelling, 
presentation, and advertising of foodstuffs were established to protect from unfair competition 
(different label provisions across Member States prevented free movement of goods) and to 
protect and provide information to the consumer.  The resulting Directive 79/112/EEC on 
labelling is complemented by some sectoral product-specific requirements in EU law relating to 
hygiene or quality requirements for specific food products.  The labelling provisions were 
recently consolidated and simplified by Directive 2000/13/EC on the labelling, presentation, and 
advertising of foodstuffs.  The Directive applies to pre-packaged foodstuffs to be delivered as 
such to the ultimate consumer or to restaurants, hospitals, canteens, and other similar mass 
caterers.  It does not apply to products intended for export outside the Community.  Labelling 
provisions in the General Food Law are that labelling and product presentation should allow 
consumers to make informed choices and that consumers shall not be misled. 
The 1997 Novel Foods Regulation’s Article 8 provides that food and food ingredients that are 
deemed to be no ‘longer equivalent’ to existing products need to be labelled for consumer 
information purposes, additionally to health, safety, and nutritional considerations.  This labelling 
policy provides for consumer information on changes in composition due to production 
processes, even if such changes may not impact human health.  Specific labelling is not required 
where recombinant DNA and/or protein derived from the genetic modification is present in the 
food or food ingredient in a proportion no higher than 1%, provided there is evidence that this 
presence is not intended but occurred inadvertently during cultivation, harvest, transport, storage 
and processing (Regulation (EC) No 49/2002).  These provisions also applied to the two GM 
crops in foods approved before the Novel Foods Regulation entered into force: Bt-176 maize and 
Roundup ReadyTM soybean. 
In July 2003, the Council of Ministers adopted Regulation (EC) No 1830/2003 concerning 
traceability and labelling of GMOs and traceability of food and feed products produced from 
GMOs.  According to the regulation, labelling shall be process-based: even highly refined oils 
that do not contain detectable traces of recombinant DNA or novel protein from GMOs, and 
hence are not materially distinguishable from other oils not derived from GMOs will need to be 
labelled.  The three specific objectives of legal provisions for traceability are to facilitate 
withdrawal of products should an unforeseen risk to human health or the environment be 
established; targeted monitoring of potential effects on human health or the environment, where 
appropriate; and control and verification of labelling claims.  The fundamental objective is to 
restore consumer trust through providing information and choice.  Traceability of foods and food 
ingredients, including imported foods, also requires, however, the establishment of international 
systems allowing traceability of traded foods. 
Establishment of an international system that allows to trace back to the origin and to understand 
the distribution of foods would depend on agreement on at least three of the system’s elements: 
each product must have a unique identifier (a bar code, lot identification number, or container 
identification marking in case of commodities); guidance must be given on what specific 
information is recorded; and all points in the production and distribution chain at which this 
information is recorded must be reliably linked.  Audits for verification of the implementation of 
the system are also required. 
Transparency and participation 
Over the last decade a series of more general calls for openness and participation have been 
introduced into primary and secondary European Community law.  Article 1 of the Treaty of the 
European Union establishes as a general principle that decisions are to be taken as openly as 
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possible and “as closely as possible to the citizen”.  There are no or few legal obligations that 
specify concrete procedural mechanisms to foster transparency and participation, other than that 
the provisions of scientific committees of the European Commission have to be posted on the 
internet; this also holds true for the majority of the individual decision-processes in the various 
Member States.  The few procedural windows are, however, a modest contribution towards 
institutional transparency: the value to the citizen of internet postings of expert opinions is very 
limited, as there are usually no links to data considered by experts, explanations of the relevant 
EU-level decision-making processes, and the role of expert opinions in it.  In conclusion, 
insufficient light is shed on such processes to allow an average citizen to understand or even to 
contribute to them.  In consequence, consultation with stakeholders, if it occurs, is a lot less 
formal and transparent than in the US, since there are no formal procedures based in law in place 
to ensure that ‘all’ viewpoints are considered.  The Scientific Steering Committee of the 
European Commission has also recommended seeking processes to foster public engagement in 
the process of risk assessment (European Commission, 2003). 
1.2 Risk analysis of foods 
The general principles for risk analysis were first established for evaluation of health effects from 
potentially toxic chemicals.  Risk is defined as the likelihood that, under particular conditions of 
exposure, an intrinsic hazard will represent a threat to human health.  Risk is a function of hazard 
and exposure.  Hazard is defined as the intrinsic potential of a material to cause adverse health 
effects; implicit in the definition is the concept of severity and adversity of the effect 
(FAO/WHO, 1995; FAO/WHO, 1997; Codex Alimentarius Commission, 2003). 
In most international and European policy documents and guidelines on risk analysis and food 
safety (see for example European Commission, 2000), a distinction is drawn between science-
based risk assessment (usually conducted by experts), risk management, and risk communication.  
Risk management is defined as “the process of weighing policy alternatives to mitigate risks in 
the light of risk assessment and, if required, selecting and implementing appropriate control 
options, including regulatory measures” (FAO/WHO, 1995; FAO/WHO, 1997).  Risk 
management strategies include authorisation, and implementation of risk management measures 
to minimise the risk.  Examples of risk management for conditional approvals include labelling 
requirements to inform the target group at risk, as done for food products that contain major 
allergens.  Risk communication is defined as the exchange of information and opinion on risk 
between risk assessors, risk managers, other interested parties, and the general public 
(FAO/WHO, 1995; FAO/WHO, 1997).  Recently, the European Commission has undertaken an 
initiative for harmonisation of risk assessment procedures (European Commission, 2003b).  In 
Figure 1-1, the various components of risk analysis are depicted as described in the report of this 
initiative.  The report further recommends to involve stakeholders in two stages of the risk 
analysis process, namely before- and after- the risk assessment process.  In this way, the risk 
issues that are important to stakeholders can be taken into account and these stakeholders can also 
comment on the outcome of the risk assessment (European Commission, 2003b). 
Some social scientists warn that considering risk assessment and risk management as two 
separate processes in policy-making can blindfold to the notion that risk is also a product of 
societal circumstances; the salience of expert advice to concerns of policy makers and the public 
is thus potentially reduced (Jasanoff, 1990; NRC, 1994; NRC, 1996; Presidential/Congressional 
Commission on Risk Assessment and Risk Management, 1997).  The importance of framing 
questions on risk such that assessments address socially salient concerns has been much 
emphasised, see Figure 1-2). 
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Figure 1-1 The "Risk Cycle" (European Commission, 2003b)
Figure 1-2 Understanding risk: informing decisions on risk in a democratic society (US National Research
Sciences, courtesy of the National Academies Press, Washington, D.C.
(US National Research Council; NRC, 1996) Reprinted with permission from the National Academy of
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The ENTRANSFOOD project has addressed such concerns to some extent by inviting consumer 
groups and industry representatives to participate in the project; the basic concepts of risk 
assessment and risk management, as defined in current international and European policy 
documents, however, were maintained.  The achievements and lessons from the attempt of 
addressing both scientific and societal aspects of the placing on the market of GM food crops in 
the ENTRANSFOOD project are further discussed in Chapter 7. 
The international guidelines for risk assessment are largely based on the 1983 report of the 
National Research Council on risk assessment in the Federal US government; international expert 
groups under the auspices of Codex Alimentarius, the FAO, and the WHO further elaborated the 
concepts described in this report.  Risk assessment involves gathering information on severity of 
the effect that a hazard might create and on the potential degree of exposure to hazardous 
substances.  This originates from a concept already formulated in the middle ages by Paracelsus 
at the turn of the 16th Century, who stated  “All substances are poisons, there is none which is not 
a poison; the right dose differentiates a poison and a remedy”.  Risk assessment is often grouped 
into four activities: hazard identification, hazard characterisation, exposure assessment, and risk 
characterisation.  The first step in risk assessment is thus to identify a hazard, by establishing its 
potential to cause harm using toxicological experiments and assessing information on the relation 
of exposure and effect across whole populations. 
Hazard characterisation aims to evaluate in qualitative and quantitative terms the nature of the 
identified hazard.  This usually involves an analysis of dose-response relationship of harmful 
effects in a test animal or other test system and characterisation of the severity of the effect.  In 
routine toxicological analysis, animals are administered usually three doses, including a dose that 
exceeds anticipated human exposures by several orders of magnitude.  Observation and autopsy 
of animals helps to establish the highest dose levels at which no adverse effect occurs – the No 
Observed Adverse Effect Level (NOAEL). 
Information on the quantity and distribution of a potentially hazardous substance in the 
environment is then required in order to determine where populations are expected to come into 
contact with the substance; for foods, dietary intake assessments of populations are required.  
Particular attention is paid to expected average and worst-case intake levels of the most sensitive 
subgroups of a population.  This information is used to determine the population groups that may 
be at risk and the distribution of such risks.  These are the elements that allow estimating the 
probability that harm will occur.  Exposure assessment often needs to take into account important 
societal factors necessary to anticipate behaviour of a wide range of individuals that might affect 
their exposure. 
Risk characterisation then combines information about the probable extent, nature, and duration 
of exposure with considerations of hazard characteristics and relevance of those hazards for 
humans into an integrated view of the likely risk to human health.  Any uncertainties inherent in 
the risk assessment should be highlighted.  This information then constitutes the basis for a 
determination of a dose that is deemed to be safe.  If the expected intake exceeds that dose, risk 
mitigation measures, such as restrictions on use of a chemical, have to be adopted.  Recently, the 
EU Concerted Action "Food Safety in Europe (FOSIE)" has reviewed risk assessment strategies 
and methods for chemicals in food and diet.  Building on FOSIE’s findings, one objective of 
ENTRANSFOOD was to assess the merits and limitations of using existing toxicological 
methods developed for the assessment of chemicals, such as food additives and pesticides, for the 
safety assessment of whole GM plant-derived foods. 
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1.3 Risk assessment strategies for whole foods 
Health is a common association with plant-derived foods; such foods are known to be sources for 
beneficial dietary components, such as nutrients, minerals, and vitamins.  However, some food 
crops and vegetables also contain toxic compounds: potatoes contain glycoalkaloids, and raw 
courgettes contain coumarins that, at high intake levels, are considered carcinogens.  The 
regulator’s awareness that traditional plant-derived foods are associated with both benefits and 
risks has been heightened by deliberations on how to assess the safety and wholesomeness of GM 
food crops. 
Few plant-derived foods have been tested using toxicological methods.  Most countries require 
measuring the levels of known natural toxicants for the registration of new traditionally bred crop 
varieties.  Testing whole foods in laboratory animals is challenging.  Two basic questions need to 
be addressed:  Can we feed the test animal with doses that are sufficiently high to induce adverse 
effects?  Can we compose a diet for the test animal that respects the nutritional needs of the 
animals?  Whether animal tests can provide meaningful information towards the safety 
assessment of a plant-derived food depends on the type of food and the level and type of anti-
nutritional compounds in food.  The safety of whole plant-derived foods is usually based on a 
long-term experience and history of safe use, even though such foods may contain anti-nutritional 
or toxic substances.  This concept is the starting point for the safety assessment of foods derived 
from GM crops. 
1.4 Safety assessment strategies for foods derived from GM crops 
Do risks associated with foods derived from traditionally bred crops and GM crops differ?  
Techniques for genetic modification allow the transfer of genetic material across species.  
Changing the genome can result in changes in the plant’s development and metabolism.  Safety 
assessment of GMOs therefore requires a detailed understanding of the transformation process, 
the introduced genes and gene products, and possible alterations in the composition of a modified 
plant (see Figure 1-3).  Potential hazards to human health may result from changes of the content 
of toxicants, allergens, or nutrients; potential adverse consequences from the transfer of the 
recombinant DNA from modified plants to other organisms, such as microbes in the human gut, 
should also be considered (horizontal gene transfer is addressed in more detail in Chapter 4). 
The challenge in assessing the safety of GM crops is to characterise the properties of new gene 
products and potential changes in levels of endogenous plant constituents, and to identify 
potential unintended (unexpected) effects due to the genetic modification that may have adverse 
impacts on human health or the environment.  Changes in plant genomes due to unintended 
effects from genetic modifications can also occur in traditional breeding (see Chapter 3 for a 
more detailed discussion of this point).  Experts under the auspices of the OECD and the United 
Nations' World Health Organisation (WHO) and Food and Agricultural Organisation (FAO) have 
developed approaches for the safety assessment of foods derived from GMOs.  The European 
Commission also recently published a more detailed guidance document on data requirements for 
the safety assessment of GM crops. 
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Figure 1-3 Risk assessment strategy for GM food crops (designed by G.A. Kleter) 
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The safety assessment of foods derived from GM crops relies on the comparison to foods derived 
from a close non-modified counterpart that has a long history of safe use.  Most methods for the 
safety assessment of foods derived from GM crops are adapted from methods used to assess the 
safety of chemicals found in foods, such as pesticides and food additives.  The application of this 
concept of Substantial Equivalence serves to identify potential differences between the GM food 
crop and its counterpart.  Any identified changes are then the subject of assessment in order to 
determine their potential impact on human and animal health.  The concept of substantial 
equivalence is thus a guiding principle, or starting point for the safety assessment of new foods, 
not an endpoint of a chemical comparison between the new and the traditional product (see Box 
1-2). 
BOX 1-2 
SAFETY ASSESSMENT OF FOODS DERIVED FROM GM CROPS 
  Comparative safety assessment taking conventional crops as safety standard 
  Comparative analysis of the agronomic and compositional properties of the GM crop and 
its traditional counterpart 
  Safety and nutritional assessment of identified differences 
  A product-specific safety assessment is carried out in case of GM foods with no 
traditional counterpart 
Critics of biotechnology pertain that current targeted testing approaches do not sufficiently 
address putative unintended and unexpected effects and cannot rule out occurrence of potential 
long-term effects that result from sustained human exposure to crops with potentially hazardous 
subtle changes in a plant’s composition.  The use of the concept of Substantial Equivalence has 
been seen as an excuse to avoid extended toxicological testing with animals.  The same critics are 
concerned that a targeted risk assessment approach based on chosen parameters is insufficient, as 
it does not address the risk of activation of putative, previously silent and unknown genes for 
allergens or biosynthetic pathways of toxic secondary metabolites.  Furthermore, critics complain 
that there is too little guidance for producers on what parameters should be measured for the 
comparison, by what methods such data should be obtained, and how samples should be obtained 
from which type and number of field trials in order to allow a statistically sound analysis of the 
data.  Many of the criticisms of the Concept of Substantial Equivalence also are based on a 
misunderstanding that the concept is used as an endpoint and assessment outcome, rather than as 
a guide to further testing of identified changes.  However, no alternative approaches to the 
concept of substantial equivalence for the safety assessment of GM food crops have been 
proposed. 
The current approach for the safety assessment of GM crops that is based on the concept of 
substantial equivalence has been widely adopted in both the public and private sector; it is 
considered the best available approach.  Guidelines to its implementation are becoming ever-
more standardised and detailed.  For example, the Organisation for Economic Cooperation and 
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Development (OECD) is compiling consensus documents for certain crop species that provide the 
information considered of most relevance for the characterisation of the parent crop.  Two types 
of consensus documents are available for the world’s major food crops: the first describes a 
crop’s biology, focusing on attributes that are relevant to the environmental safety assessment, 
and the second describes a crop’s compositional characteristics that are of most importance for 
the food safety assessment.  All documents are on Internet (OECD, 2004ab).  Guidelines on the 
application of the concept will become increasingly detailed and differentiated for different 
product categories. 
Scientific concepts, including the concept of substantial equivalence, continue to develop driven 
by science and society.  It is important to acknowledge that, like our understanding of science, 
our understanding of risk will always remain "incomplete", but that decisions on risks and 
benefits of new technologies should be taken regardless of knowledge waiting to be discovered.  
Scientists, regulators, politicians, and citizens alike should embrace this political dimension of 
our understanding and weighing of risks. 
In conclusion, approaches to regulation and conditions for the approval of GM crops differ across 
jurisdictions.  The same approach to the safety assessment is, however, adopted by regulatory 
authorities and public and private firms developing GM crops for commercial use in most 
countries.  Continued improvement of methods for the assessment of transgenic crops will in 
future allow further reductions of some of the uncertainties associated with genetic modification.  
Dialogue between experts and civil society may contribute over time to further clarify and 
structure regulatory and risk analysis and strategies to improve the salience of assessments to 
address concerns of policy makers and the public. 
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CHAPTER 2 
SAFETY EVALUATION STRATEGIES FOR FOODS DERIVED FROM GM CROPS 
Food safety is a relative concept.  International guidelines on food safety declare a food safe 
when "there should be reasonable certainty that no harm will result from intended uses under the 
anticipated levels of consumption" (OECD).  Since the first hunter-gatherers turned into settlers, 
continued improvement of food crops to enhance yields and facilitate cultivation has been central 
to development in all societies.  All traditional food crops we consume every day have been 
steadily improved through selection and breeding over millennia; however, few have been 
subjected to a formal safety assessment.  During the last two decades, more attention has been 
directed to food safety; novel foods and chemicals that enter the food chain are regulated and now 
have to undergo a testing regime.  This chapter explains the strategy and the methods used to 
assess whether foods derived from GM crops are as safe and nutritious as other plant-derived 
foods that have become staples in our diet. 
In this chapter, we present a systematic approach how to tailor the safety assessment of GM crops 
to the specific characteristics of the modified crop and the introduced trait.  The approach is built 
on existing international guidelines for the food safety assessment of GM crops, provides, 
however, more detailed and explicit instructions on the selection of appropriate test methods (for 
a more elaborate description of this approach, please refer to König et al., 2003).  First, we 
provide an overview on existing test methods developed for chemicals, including food additives, 
examining each method’s suitability to test the safety of foods derived from GM crops.  Second, 
we summarise how to determine whether the GM crop is ‘as safe as’ a suitable comparator with a 
history of human consumption.  Traditionally bred crops serve as a safety standard: the safety of 
foods derived from GM crops is assessed through comparison to foods that have a history of safe 
use.  Third, we outline the main implications of advances in molecular biology and the 
development of new in vitro and in vivo test methods for the future refinement of food safety 
assessment strategies. 
2.1 Methods for toxicity testing  
Regulatory requirements for chemicals such as food additives and pesticides, many of which were 
first instituted in the 1970s, have led to the development of a battery of tests to assess the safety 
of chemicals in foods.  Strategies for assessing the food safety of chemicals usually combine three 
lines of evidence: investigation of the structure/function relationship for indications of potential 
toxicity and allergenicity; in vitro assays with enzymes, receptor proteins, or cultured cell lines; 
and in vivo animal studies.
Investigating the structure/function relationship.  A test substance’s physico-chemical properties, 
structure, and function can in some cases provide indications for potential adverse health effects.  
This information helps to frame the test approach.  Some toxicants show a clear structure/function 
relationship and their mechanism of toxicity is fully understood; other classes of toxicants just 
share common structural elements or physico-chemical properties that may be indicative of 
toxicity.  A molecule’s physico-chemical properties help for instance the prediction of its 
propensity to intercalate in DNA and interfere with DNA replication; such interference can lead 
to mutations and cancer.  Computer data bases help to assess whether a molecule shares 
characteristics of known toxicants: some data bases provide lists of toxicants and their properties; 
others use algorithms to predict a molecule’s function through structural and physico-chemical 
characteristics. 
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In vitro methods.  In vitro, or test tube methods were developed to test chemicals, including food 
additives, to serve as indicators for specific toxic effects.  Some assays can help to assess whether 
molecules are stable under diverse conditions.  Other assays assess whether molecules bind to, 
inhibit, or stimulate proteins with specific functions.  Yet other assays test whether substances 
affect cell growth of diverse cell types.  The methods can, in theory, serve either as screening 
systems to assess potential toxicity of a compound, or for investigations of a toxicological 
mechanism underlying a specific effect observed in vivo or predicted from the structure of a 
molecule.  Very few in vitro tests are, however, validated formally, or used for safety tests 
submitted in regulatory applications.  The interpretation of results from in vitro tests is 
challenging in vivo situations; uncertainties have to be clearly stated.  The existence of potential 
harmful effects from ingestion of a substance should not be inferred from in vitro methods alone; 
such methods, in particular where they might indicate a potential adverse effect, should be used in 
conjunction with other test methods, including animal testing. 
Animal models.  Animal methods provide a holistic approach to safety assessment.  A variety of 
standardised and validated laboratory animal tests have been designed to identify and characterise 
health hazards associated with exposure to single defined chemicals.  In routine toxicological 
analysis, animals are administered usually three distinct doses of the test substance ranging from 
high to low.  The high dose, where possible, exceeds anticipated human exposures by several 
orders of magnitude.  The use of animal methods is, however, not without challenges; these 
challenges include the need to extrapolate from responses induced in animals to likely impacts on 
human health.  These uncertainties are usually taken into account by adopting safety factors.  
Observation, clinical investigations, and autopsy of animals establish the highest dose levels at 
which no adverse effects occur: the No Observed Adverse Effect Level (NOAEL).  The NOAEL 
is the basis for establishing best estimates of safe exposure levels or an Acceptable Daily Intake 
level for humans (ADI; Figure 2-1).  For instance, in order to determine an ADI for humans from 
a rat study, the NOAEL is divided by an uncertainty factor, normally 100, in order to account for 
the following uncertainties: extrapolating test results from rodents to humans and differences in 
susceptibilities for toxic effects of the chemical between individuals in the human population.  
Animals can be used for the identification of acute toxicity, usually involving administration of a 
large single dose followed by 14 days of observation.  Sub-acute, sub-chronic, and chronic 
toxicity or carcinogenicity is tested in animals over prolonged periods of one or several months, 
or the lifetime of an animal. 
Animal tests for whole foods are much more challenging to design than tests for a discrete 
chemical or protein: difficulties include that animals (or man) cannot ingest multiples of the 
anticipated human consumption levels of the test substance due to its sheer volume.  Furthermore, 
nutritional imbalances can arise if an animal’s diet contains large proportions of a food it does not 
habitually eat.  In laboratory tests, each animal species has its own specific dietary requirements 
of certain minerals and vitamins.  Studies in which the test material is administered at the 
expected level of intake and at low multiples of that level, and in which the nutritional balance of 
the animal’s diet is not disturbed, can provide safety assurance that the consumption of certain 
amounts of the new food will not induce adverse effects in animals. 
Some of the methods developed for chemicals have been adapted for use in assessments of foods 
derived from GM crops.  For example, an understanding of the structure-function relationship of 
newly introduced metabolites and proteins is the first step in any assessment of a GM crop.  
Databases exist for proteins with toxic or allergenic properties.  The resistance of proteins to 
proteolytic digestion in the gastro-intestinal tract is measured by determination of stability in a 
simulated gastric fluid and sometimes also in a simulated intestinal fluid.  Animal methods, if 
deemed necessary, can be adapted to test for potential adverse effects of recombinant proteins or 
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novel metabolites.  Animal tests can, in some cases, also provide worthwhile information for the 
assessment of whole foods derived from GM crops.  These methods are described in more detail 
below.
Figure 2-1 Safety evaluation of chemicals 
2.2 Strategy for safety assessment of foods derived from GM crops 
Safety considerations for foods derived from GM crops are fundamentally the same as those for 
conventional foods.  The safety of whole plant-derived foods is a fundamental assumption based 
on a long-term experience and history of safe use, well knowing that such foods may contain anti-
nutritional or toxic substances (see Section 1.3).  This concept is the starting point for the safety 
assessment of foods derived from GM crops.  The safety assessment therefore determines 
whether the GM crop is as safe as its conventional counterpart by identifying significant 
differences that occurred through the genetic modification that might potentially adversely affect 
human health.  Furthermore, uncertainties associated with unintended changes in plant genomes 
through the insertion of recombinant DNA should always be considered in the light that crop 
genomes are constantly changing through a broad range of natural and man-mediated 
mechanisms.  Subtle unanticipated changes in a plant’s composition that may be difficult to 
detect using this approach can occur through genetic modification, traditional breeding methods, 
and natural genome rearranging processes.  Therefore, studies with the whole food derived from 
GM crops may be carried out. 
The safety assessment is conducted in four steps: the description of the parent crop; the 
description of the transformation process; the safety and allergenicity assessment of the gene 
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- Identification of target(s) and critical effect(s)
- Dose-Response 
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products and metabolites; and the combined safety and nutritional assessment of the whole plant 
(see also Chapter 1 and Figure 2-2).  These steps are considered in turn. 
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Figure 2-2 A fully integrated and iterative approach to the hazard assessment and characterisation 
of all elements involved in producing a new GM variety (König et al., 2004) 
Description of the parent crop.  The parent crop, and in some cases close relatives, should be 
characterised to understand whether the crop contains toxicants, allergens, or substances with 
pharmacological, or anti-nutrient effects.  The characterisation of the parent crop then guides the 
choice of test parameters for the comparison of the GM crop to a close comparator, which is 
usually the non-modified parent crop.  The OECD has developed consensus documents on the 
biology and compositional characteristics for the major crop species.  These are intended to guide 
the description of the parent crop and the subsequent assessment of the GM crop. 
Description of the gene donor, transgenes, and delivery process.  Organisms from which the 
recombinant DNA has been derived, all transferred genetic elements, and the gene delivery 
process require a full description.  The introduced DNA should be shown to be unrelated to any 
characteristics of the donor organisms that could be harmful to human health.  A risk assessment 
of gene transfer to human cells or microbes should also be conducted where appropriate (see 
Chapter 4). 
The provision of sequence information on the junction of the inserted recombinant DNA and the 
plant genome is required under European Community law to allow the development of 
transformation-event specific detection methods by regulatory authorities (see Chapter 5).  Such 
sequences may help to characterise the insertion locus to predict if important plant endogenous 
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genes might have been disrupted through the genetic insertion event and ensure that no 
unintended fusion protein is produced at the junction of the plant and recombinant DNA. 
Assessing recombinant proteins or metabolites.  The first step in a hazard assessment is usually to 
understand the mechanism of action of the test substance.  For example, recombinant proteins that 
confer resistance to insects derived from Bacillus thuringiensis are toxic to selected insects, but 
not to mammals.  Binding to the insect gut triggers a conformational change, the protein then 
forms a pore through the gut cell membrane causing damage to the insect gut.  Mechanistic 
studies have shown that these proteins bind to specific receptor proteins on the insect gut wall 
with differing selectivity and at alkaline pH, but do not bind to cell surfaces in the human gut. 
The purified proteins and/or metabolites should be thoroughly investigated using classical 
approaches for defined chemical substances described for chemicals, provided such data do not 
already exist.  Proteins that can confer desirable traits to crops are subjected to toxicological 
testing before a decision is taken on their use for development of a product for commercialisation.  
Any significant unexpected changes in levels of substance(s) detected during compositional 
analysis will require identification, characterisation, and safety assessment.  If fusion proteins are 
expressed, these would need to undergo the same safety assessment as intentionally introduced 
recombinant proteins. 
Knowledge of the amino acid sequence of the recombinant protein allows screening computer 
databases for any sequence similarities with known protein toxins and allergens.  Limitations of 
the method include that not all structural properties that mediate allergenicity may be detected or 
that there can be false positive matches of a protein’s structural element that is similar to an 
allergen’s structure, but that does not mediate allergenic effects.  A protein’s physical stability 
and its stability in simulated digestive conditions are deemed to be indicative of potential 
induction of allergic responses and/or adverse health effects.  The test is one indicator as to 
whether the recombinant protein shares the characteristic of stability to digestion under these 
conditions that is common to many allergens. 
Repeated dose studies with recombinant proteins or derived substances are recommended to 
identify potential adverse long-term effects unless there is sufficient information to confirm the 
lack of toxicity or pharmacological activity of the recombinant proteins and metabolites, or unless 
there is extensive experience with these substances (for instance, from a history of safe use).  It 
can, however, be difficult to obtain sufficient quantities of purified recombinant proteins for 
testing animals over prolonged periods of time.  Protein levels in plant material are often too low 
to justify its use in animal tests.  The assessment of protein toxicity therefore often requires 
purifying sufficient amounts of the heterologous protein from the GM crop or from other hosts 
(e.g. bacteria, yeasts) that have been genetically modified to over-express the protein for testing.  
Expression of genes in different organisms (plants or bacteria) can potentially result in 
differences in folding or post-translational modification of proteins; these need to be taken into 
account in the assessment.  Typical parameters considered in demonstrating the equivalence 
between a protein that is produced in a plant and the same protein produced by bacteria include 
molecular weight, amino-acid sequence similarity, post-translational modification (e.g. level of 
glycosylation or phosphorylation), immuno-equivalence, and the activity and specificity of the 
reaction when the gene product is an enzyme.
The judgment on whether a protein is a likely allergen is based on a weight of evidence approach, 
and results of all tests must be taken into consideration, since no single test is sufficiently 
predictive.  First, it is assessed whether the protein shares primary amino acid sequence similarity 
with known protein allergens.  In addition, there appears to exist an association between the 
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ability of proteins to induce food allergy and the ability to resist digestion in the intestinal tract, 
and therefore the stability of proteins in simulated gastric fluids is considered as a useful criterion 
in the assessment of the potential allergenicity of GM foods.  However, it is emphasised that 
novel proteins may exist that are stable for digestion and not be allergenic.  Where the protein is 
derived from an allergenic source or where there is significant sequence similarity with a known 
allergen, assessments are made using serum from allergic patients to determine whether these 
exists serological identity with known allergenic proteins.  This approach has allowed the 
identification of plant allergens in the past: For example, the development of soybeans with 
improved nutritional characteristics for feed use by transferring a protein from Brazil nut was 
terminated, when the allergenicity assessment revealed that the selected protein was allergenic; 
the product was therefore never developed for commercialisation.  The Codex Ad Hoc Task 
Force on Foods Derived from Biotechnology suggests that further improvement of methods for 
targeted screening of novel proteins with serum of allergic patients and the development and 
validation of animal models could enhance in future this weight of the evidence approach; it also 
recommends the establishment of international serum banks for such purposes and further 
research into T-cell epitopes and other structural motifs associated with allergens. 
Combined safety and nutritional assessment of the whole plant.  The GM crop is compared with 
the parent crop in order to identify all major differences between them.  Any significant 
differences in agronomic, physiological, and compositional characteristics between the GM crop 
and the conventional counterpart are then subject to further testing to assess potential health 
implications.  Knowledge of the characteristics of the crop species that is transformed, the 
introduced recombinant material, and the source organism of the recombinant material guides the 
selection of the parameters for this comparison.  Parameters can also be selected based on 
knowledge of the plant genome sequences at the recombinant DNA insertion site. 
Selected compositional parameters are representative of the main metabolic pathways in the plant 
and reflect potential consequences from the introduced trait.  The assessment focuses on those 
that might affect human health, such as key nutrients, anti-nutrients, and allergens.  This targeted
approach is deemed appropriate for the evaluation of "first generation" of GM crops with 
relatively simple genetic modifications that are largely aimed at improving specific agronomic 
characteristics.  It is important that these comparative studies on the composition are carried out 
under well-defined conditions at different locations and identical for the parent and the modified 
crop.  Statistical analysis of the results is required. 
Animal tests with whole foods derived from GM crops are considered to contribute useful 
information in the safety assessment if the composition of a GM food crop is modified 
substantially, or if there are any uncertainties on the equivalence of its composition to a 
traditional counterpart.  In these two cases, dietary sub-chronic rat studies are recommended to 
demonstrate the safety of the food.  Sub-chronic dietary studies with rats serve as an indicator that 
there are no unintended changes in foods derived from GM crops that might render it less safe, or 
more hazardous to health, than the comparator.  Carefully designed diets, selection of doses, and 
feeding protocols are required to address challenges in animal studies with whole foods described 
in Section 1.3.  Any potential preliminary evidence on unexpected changes that potentially 
adversely effect human health, but which may not necessarily indicate that the new food is not 
suitable for consumption, requires further nutritional or toxicological investigation if such 
preliminary indications do not deter plans for the product’s commercialisation. 
In order to complement classic toxicological studies in rodents, studies in young fast-growing 
animals such as broilers are sometimes used for investigating potential effects of whole foods on 
the growth rate of individuals.  Ethical consideration should, however, also guide decisions on the 
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use of animals in testing and the design of test protocols.  Many scientists consider that studies in 
fast-growing species should only be deemed necessary in cases where there is reason to believe 
that a plant’s metabolism may be altered such that its nutritional or toxicological characteristics 
are changed (see also Box 2-1). 
BOX 2-1 
LIMITATIONS OF ANIMAL FEEDING STUDIES WITH WHOLE FOODS
Bulkiness of test material 
Formulation of diets 
Palatability 
Limited dose-range 
Small safety margins, if any 
Confounding factors / interactions between food components 
Nutritional imbalances 
Insufficient sensitivity for specific endpoints 
Exposure and safety assessment.  Human exposure to foods derived form a particular GM crop 
can be estimated combining data on the consumption of the traditional food crop with estimates 
of the proportion of that crop that is genetically modified.  Potential changes in intake pattern due 
to the new trait have to be taken into account. 
2.3 Considerations for GM crops with altered nutritional properties  
The safety testing strategy described is also applicable to new generations of GM food crops with 
extensive compositional changes.  For GM crops that have been modified extensively such that 
there is no single crop that is a conventional counterpart suitable for comparison, all new 
substances or existing substances whose levels have been altered should be assessed on a case-by-
case basis; safety studies with the whole crop should also be conducted. 
The safety assessment of GM crops that are intentionally designed to be compositionally different 
requires increased attention to two issues: the choice of an appropriate comparator and the 
estimate of the anticipated exposure.  One example of a compositionally altered GM crop 
currently under regulatory review is oilseed rape that contains lauric acid, a fatty acid not 
normally found at elevated levels in oilseed rape oil.  The product was developed as a substitute 
for tropical oils (for instance, palm oil) in certain food applications.  The comparator with safe 
use in this case was palm oil. 
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2.4 Post-market monitoring 
Past attempts to investigate the correlation of incidence of adverse health outcomes and food 
intake by post-market monitoring of foods have proven difficult.  In an OECD survey, responding 
government authorities indicated practical difficulties monitoring health effects associated with 
food consumption; challenges included defining the exposure groups and levels of exposure, as 
well as establishing a cause-effect link between eating a certain food or food ingredient and the 
manifestation of a particular health effect.  Interactions between various food components with 
beneficial and adverse effects are usually too complex to allow proof of associations of a specific 
health endpoint with an individual food component.  Furthermore, the definition of individual 
health effects to be monitored is difficult.
To date, no foods derived from GM crops have been placed on the market for which post-market 
monitoring was deemed necessary.  The British Food Standards Agency (FSA) has commissioned 
a feasibility study to determine whether long-term monitoring of novel foods is possible.  This 
study assesses the government’s ability to detect variations of food purchasing and consumption 
at the district level in Great Britain, as this is seen as an indicator for the feasibility to detect and 
to link such variations to health outcomes. 
The success of a post-market monitoring regime to assess health effects of foods derived from 
GM crops largely depends on whether specific health endpoints for monitoring can be identified, 
and on the marketing strategy of the particular food.  A cause-effect hypothesis must exist, the 
testing of which is the objective of the post-market monitoring program.  Health effects suitable 
for monitoring have clear symptoms with strong manifestations that occur shortly after food 
intake (such as an allergic reaction).  Conversely, monitoring for longer-term or weaker effects is 
challenging, if not impossible.  In the US, for example, it was attempted to monitor blood levels 
of vitamins and carotenoids in olestra consumers, as clinical trials demonstrated that olestra 
consumption reduces the absorption of such fat-soluble nutrients.  Subjects ate less than expected; 
conclusions of the study are therefore only tentative: no effects were observed. 
The marketing strategy of products also matters for the success of identifying exposed 
populations groups for post-market monitoring: consumption of branded products in which the 
product was effectively the sole route of intake of the ingredient of interest can be monitored 
successfully.  Estimating intakes of the same food component from different sources may be 
difficult, as each company can only monitor its own products.  Post-market monitoring of health 
implications of certain commodity crops used in a wide variety of food products that are 
consumed in parallel is likely impossible (see Box 2-2). 
Post-market monitoring of foods derived from GM crops is therefore not recommended as a 
routine practice.  It is expensive, sequesters scarce resources for studies of health and food, and is 
unlikely to provide meaningful information.  Post-market monitoring might be considered for 
identity-preserved GM crops with changed nutritional characteristics in order to confirm the pre-
market assessment: a clear test hypothesis in form of a causal relationship of food intake and 
health impact must be formulated. 
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BOX 2-2 
FEASIBILITY OF POST-MARKET MONITORING 
  Post-market monitoring may be considered to: 
  - Confirm the pre-market safety assessment 
  - Identify unexpected adverse effects which remained unnoticed during the pre-
market safety assessment. 
  Can health endpoints for monitoring be identified? 
  Does a cause-effect hypothesis  exist? 
  Can consumption of the branded GM product/ingredient  via a sole route of intake be 
monitored? 
  Intake of the GM foods via different sources is difficult to estimate 
  Health implications of commodity GM foods/ingredients are difficult if not impossible to 
assess. 
2.5 Developments in food safety research 
Advances in molecular biology, biochemistry, and nutrition will over time facilitate the 
development of new crop varieties.  Applying new insights to refining and adapting safety 
assessment approaches to advances in product developments will be important.  
Recommendations on priorities for research and development of test methods and strategies are 
provided below, considering advances in molecular biology, allergenicity assessment, and safety 
and nutritional testing in turn (see also Box 2-3). 
Molecular biology.  Genomic research adds a new dimension to our understanding of biology and 
provides powerful new tools to study induced changes in gene expression.  Our improved 
understanding of the structure of plant genomes, functions of individual genes, and a plant’s 
responses to its environment at the molecular level will improve our understanding of the 
characteristics of the parent crop that pertain to food safety assessment.  Results from large scale 
sequencing projects are rapidly increasing our understanding of plant genomes and of their 
evolution, regulation, and plasticity.  The recent completion of the first draft sequences of the rice 
genome and the availability of the Arabidopsis sequence information now allow whole genome 
comparisons between different types of plants.  More than 80% of the genes that were annotated 
in Arabidopis were also found in rice.  Evolutionary biology and reverse genetics provide 
important information about the functions of individual genes.  Improved understanding of plant 
genomes will reduce uncertainties of consequences of single insertions of recombinant DNA in a 
plant genome.  The establishment of international systems for improved access to crop genome 
databases and latest bio-informatics methods in order to facilitate and harmonise the future 
analysis of such data is key.  Our enhanced understanding of food crops and implications of 
consumption of diverse plant-derived foods on human health will, in the long term, also reduce 
uncertainties in food safety assessment. 
48
BOX 2-3 
FUTURE TARGETS FOR FOOD SAFETY RESEARCH
  Development of micro-array systems for gene expression studies 
  Analysis of structure-function relationships of proteins that have the potential to cause 
allergic sensitisation 
  Development and validation of animal models for the prediction of allergenicity of 
proteins 
  Application of micro-array and proteomic technologies for the identification of new 
biomarkers for health effects of bioactive compounds in foods 
  Integration of in vivo and in vitro systems of animal and human origin for food safety 
testing 
The availability of sequence information of entire plant genomes also allows the development of 
micro-array systems to assay induced changes in gene expression patterns.  This will, in future, 
also allow assessing potential changes in gene expression in genomic regions that are adjacent to 
the insertion locus.  The interpretation of such data will, however, be challenging, as a greater 
understanding of gene functions and changes in expression levels is required before the safety 
implications of any such change in gene expression can be assessed (see Chapter 3 for a more 
detailed discussion). 
Future targets in allergenicity testing. In future, an increasing number of GM crops may be 
developed with proteins to which humans have not as yet been exposed; this highlights the need 
for further refinement of tools for assessing the allergenic potential of novel proteins.  A more 
detailed appreciation of the ways in which protein structure can impact on allergenic activity will 
facilitate the development of robust methods for identifying and characterising proteins with the 
potential to cause allergic sensitisation.  There is also a requirement for biochemical and 
immunobiological research investigating how protein digestibility influences the sensitising 
potential of proteins. 
There is a growing consensus that the safety assessment of certain novel proteins to which there 
was no documented human exposure will require the use of appropriate validated animal models 
for characterisation of the allergenic potential.  Several models have been proposed and some of 
these show promise.  However, none has yet been fully evaluated or validated.  The requirement 
is for the most promising animal models for allergenicity to be evaluated fully with a range of 
sensitising and non-sensitising proteins so that their sensitivity and selectivity can be assessed.  
At present, animal models for predicting and characterising protein allergenicity are based upon 
assessment of induced antibody responses.  However, it should be possible soon to consider 
alternative or supplementary endpoints based on a more detailed understanding of the 
immunobiological basis for sensitisation and an appreciation of why proteins differ in their 
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sensitising potential.  Research in this area will be facilitated by the availability of micro-array 
and proteomic technologies that should aid in the definition of appropriate markers. 
Safety and nutritional assessment of foods.  Advances in genomics and developments of 
toxicological methods will improve our understanding of health impacts of exposure to various 
substances in the longer term.  The use of such methods as part of routine risk assessment strategy 
is, however, still some way in the future, as deduction of health impacts in populations is fraught 
with uncertainties and as such methods will require validation.  For example, the development of 
genomic expression profiling using micro-array systems prompts research into biomarkers that 
will allow to assay and compare changes in gene expression upon exposure to specific toxicants 
and nutrients in different test systems: in cultured cell lines, animal models, and, where 
appropriate, humans.  However, the extrapolation from changes in gene expression to 
manifestations of disease symptoms is challenging.  The merits and limitations of profiling 
methods are described in detail in Chapter 3 that discusses their use for characterising unintended 
effects of the genetic modification.  If reliable protocols for DNA micro-array systems that allow 
the detection of such subtle changes can be developed and validated, the comparison of in vitro
responses of cell lines and animal models using such methods may help towards a more detailed 
understanding of some aspects of similarities and differences between in vitro and in vivo test 
methods.  By comparing in vitro test systems with the same cell lines derived from different 
species or comparing in vivo test results in different species, such methods will also provide 
information on inter-species and inter-individual variations of responses. 
One research project under ENTRANSFOOD investigates strategies for food safety assessment 
relying on the combination of novel diverse, but not as yet validated test methods: the 
SAFOTEST project investigates GM rice containing lectins, well-known toxicants in plants.  Rat 
feeding trials are performed with diets containing parent rice, GM rice, or GM rice spiked with 
the lectin at a relatively high dose level that is known to be toxic.  These experiments are 
paralleled by in vitro experiments on the digestibility and cytotoxicity of the recombinant proteins 
in intestinal epithelial cell lines derived from humans and rats.  Changes in gene expression 
profiles in rat and human intestinal epithelial cell lines upon exposure to sub-cytotoxic 
concentrations of the lectins and their peptic-tryptic digests are determined using DNA micro-
arrays.  These in vitro profiles are then compared with the expression profiles in intestinal 
samples taken from live rats exposed to the same proteins during feeding experiments.  This 
allows the comparison of results obtained from in vivo and in vitro systems of animal and human 
origin; if correlations are observed, both tests together have a greater (but still limited) predictive 
power than just one of them. 
Finally, advances in information management will contribute to facilitating the safety assessment 
of GM crops.  The establishment of international databases with information on the genome and 
the chemical composition of specific crops, as well as nutritional and toxicological tests 
conducted with both crops and individual compounds, including nutrients and toxicants, would 
immensely facilitate the case-by-case assessment of individual GM crops, in particular if such 
databases are linked such that they can be searched at the same time. 
2.6 Conclusions 
Safety considerations for foods derived from GM crops are fundamentally the same as those for 
conventional foods.  The safety of widely consumed whole plant-derived foods is a fundamental 
assumption to this safety assessment approach, which is based on a long-term experience and 
history of safe use, well knowing that such foods may contain anti-nutritional or toxic substances.  
Uncertainties in this assessment associated with unintended changes in plant genomes through the 
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insertion of recombinant DNA should always be considered in the light that crop genomes are 
constantly changing through a broad range of natural and man-mediated mechanisms. 
We developed a systematic approach how to tailor the safety assessment of GM crops to the 
specific characteristics of the modified crop and the introduced trait.  The cornerstone of the 
safety assessment of novel foods, including foods derived from GM crops, is the concept of 
substantial equivalence.  This concept prescribes the comparison of the GM crop to a suitable 
comparator with a long history of use that allows for identification of any significant differences 
that might impact human health.  These differences then become the focus of further analytical, 
toxicological, or nutritional analyses.  The safety assessment of foods derived from GM crops is 
divided into four steps: characterisation of the parent crop; characterisation of the transformation 
process; toxicological evaluation of new gene product(s) and allergenicity assessment; and 
nutritional and toxicological evaluation of the GM crop/derived food. 
We recommend to conduct repeated dose studies with recombinant proteins or derived substances 
to identify potential adverse long-term effects unless there is sufficient information to confirm the 
lack of toxicity or pharmacological activity of the recombinant proteins and metabolites, or if 
there is extensive experience with these substances (for instance, from a history of safe use). 
Current strategies for the assessment of potential allergenicity of recombinant proteins, as 
developed by the Codex Alimentarius Commission, are adequate.  The judgement on whether a 
protein is a likely allergen is based on a case-by-case and weight of evidence approach.  Methods 
for the assessment of the sensitisation potential of proteins need to be improved to allow the 
transfer of proteins that might share certain structural characteristics with allergens. 
A more detailed understanding of protein allergy will enhance further safety assessment of a 
protein’s potential for allergic sensitisation.  We consider of particular value the development of 
an animal model that would permit the identification and characterisation of potential food 
allergens.  Progress in this area will be facilitated by a more thorough appreciation of the factors 
that confer to proteins the potential to induce allergy and what distinguishes these from non-
allergic proteins.  Further research on the structure-function relationship of allergens is 
encouraged. 
Animal tests with whole foods derived from GM crops are considered to contribute with useful 
information to the safety assessment.  We recommend such tests should only be a requirement in 
cases where either the composition of the GM food crop differs significantly from that of its non-
modified counterpart or the safety assessment approach provided any other indications for 
significant changes through the genetic modification that may potentially have adverse health 
impacts.  In this case, dietary sub-chronic rat studies are recommended to demonstrate the safety 
of the food.  Further standardisation of test protocols for animal feeding trials is recommended in 
terms of design of the diet, when, how, and how often the diet is administered. 
ENTRANSFOOD does not recommend post-market monitoring of foods derived from GM crops 
as a routine practice.  It is expensive, sequesters scarce resources for studies of health and food, 
and is unlikely to provide meaningful information.  Post-market monitoring might be considered 
for identity-preserved GM crops with changed nutritional characteristics in order to confirm the 
association with a specific health effect: a clear test hypothesis in the form of a causal relationship 
between food intake and health impact must be formulated. 
Genomic research adds a new dimension to our understanding of biology and provides powerful 
new tools to study induced changes in gene expression.  Our improved understanding of the 
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structure of plant genomes, functions of individual genes, and a plant’s responses to its 
environment at the molecular level will improve our understanding of the characteristics of the 
parent crop that pertain to food safety assessment.  The establishment of international systems for 
improved access to crop genome databases and latest bio-informatics methods in order to 
facilitate and harmonise the future analysis of such data is key.  Our enhanced understanding of 
food crops and implications of consumption of diverse plant-derived foods on human health will 
in the long-term also reduce uncertainties in food safety assessment. 
In summary, it can be argued that the current safety assessment approach allows for the 
determination whether foods derived from GM crops are as safe as their conventionally bred 
counterparts; in some cases, GM crops are even better characterised than other non-regulated 
plant-derived foods.  In conclusion, the current regulatory requirements and testing regimes are 
much more rigorous for GM crops than for conventionally bred crops.  The safety testing strategy 
described here is also applicable to new generations of GM food crops with extensive 
compositional changes. 
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CHAPTER 3 
IDENTIFICATION AND ASSESSMENT OF UNINTENDED EFFECTS 
Unintended effects are commonplace in attempts to improve plant varieties through both genetic 
modification and conventional breeding methods.  Safety implications of unintended changes in 
plant-derived foods are difficult to assess, as plant foods are complex mixtures of constituents, 
many of which are bioactive.  Few plant-derived foods have been subjected to safety testing.  
Science knows little about health implications of most minor constituents of plant foods.  
Furthermore, the levels of most constituents in plants vary depending on cultivation conditions 
and crop variety; for most plant constituents, the extent of natural variation is not as yet well 
understood.  We define unintended effects resulting from genetic modification as "any significant 
difference in composition, morphology, or physiology between the new improved crop variety 
and the parent crop that is not related to the intentionally introduced trait".  Evidence for 
significant unintended changes in crops is the trigger for further investigation in order to assess 
whether the changes may have any health implications. 
In this, chapter we compare the origin and uncertainties in the assessment of unintended effects 
from genetic modification with those from traditional breeding.  We also provide an overview on 
current and proposed future methods to identify and assess safety implications of unintended 
effects. 
3.1 Sources of uncertainty about changed crop composition 
Unintended effects from attempts to improve crop varieties may occur due to changes in the 
plant’s genome or its protein content: the plant genome may be disrupted or changed at the site of 
insertion of recombinant DNA in the process of genetic modification, or from genomic 
rearrangements that occur frequently in the breeding process.  Unexpected interactions can, 
however, also occur between introduced proteins (be it novel recombinant proteins or proteins 
from a related variety or species) and the recipient plant’s metabolism, developmental, or 
physiological processes. 
Unintended effects on the composition of a crop are of significance in a risk assessment if they 
adversely affect human health.  Changes that have the potential to affect human health include 
increased levels of existing plant endogenous toxins or allergens; activation of the expression of 
previously silent genes encoding allergens or biosynthetic pathways for toxins; and lower levels 
of a nutrient essential in the human diet.  Genetic changes in gene-rich and active regions of 
chromosomes are therefore more likely to have safety implications than changes in other regions.  
Natural recombination and genetic changes through plant breeding or genetic engineering are, 
however, more likely to occur in active regions of chromosomes than in inactive regions. 
Natural plant genetic recombination mechanisms can be grouped into the two major mechanisms: 
(i) homologous recombination and (ii) illegitimate recombination.  Recombination often occurs as 
a consequence of a double-stranded DNA breaks that occur during DNA replication or cell 
division.  The cell’s DNA repair proteins either fuse two DNA segments that have high sequence 
similarity (homologous recombination) or, occasionally and at a lower frequency, join the ends of 
two non-similar DNA strands (one form of this process is illegitimate recombination).   Errors in 
these DNA repair processes that change the original sequence occur at relatively high frequency.  
The frequency of recombination varies across species.  Some plant species, such as maize, 
contain transposons, selfish DNA elements that copy themselves and insert such copies 
spontaneously into new chromosome locations.   Active transposons in plants can stimulate 
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homologous and illegitimate recombination in the vicinity of transposon-insertion sites.  
Transposon-induced recombination between direct repeated sequences and between sequences on 
different chromosomes has been reported.  It has also been estimated that such transposon-
induced recombination events between different chromosome segments could occur at 
frequencies of 10-3 to 10-5 per cell division.   Induced DNA double-strand breaks can be repaired 
through recombination with DNA sequences from other chromosome segments.   For a specific 
transposon in maize, it has been estimated that this process could result in chromosome 
inversions, deletions, or translocations 0.1% to 10% of the time.   
Plant breeding relies on systematically identifying beneficial changes in crops resulting from 
natural genetic variation and on selecting these improved varieties for further propagation and 
finally cultivation.   Breeders have also used artificial means to enhance genetic variation; these 
include the use of chemical or gamma irradiation mutagenesis to increase the error rate in DNA 
replication processes in plant breeding.   The extent to which DNA structure and integrity are 
modified in these accepted breeding approaches is unknown.   What is clear is that the genetic 
structure of plant populations has been widely changed by breeding practices, indicating the deep 
influence of breeding practices on the genetic make-up of plant crops.   
Genetic engineering of crop plants largely relies on two methods used to introduce foreign DNA 
into plant cells: biolistic (microprojectile) bombardment, and Agrobacterium-mediated 
transformation.  The biolistic method is based on a physical delivery of DNA-coated gold or 
tungsten microprojectiles into plant target tissue by acceleration.  Agrobacterium-mediated 
transformation exploits the biological ability of this soil-borne bacterium to copy and transfer a 
specific portion of DNA (termed T-DNA) present on a tumour inducing (Ti) plasmid into the 
plant cell nucleus, where it can be integrated into chromosomes.  Uncertainty on whether the 
genetic modification of a crop may result in unintended effects results largely from our lack of 
knowledge of the insertion location of the recombinant DNA in the plant genome.  Unintended 
effects from the genetic modification may, for example, result if the insertion of recombinant 
DNA in the plant genome disrupts a plant gene, produces a fusion protein of recombinant and 
plant endogenous DNA, or alters gene expression levels in adjacent chromosome regions. 
The process of transgene integration is identical to the preferred recombination mechanism that 
occurs in plant cells, especially during mitosis.  Transgene integration in plants occurs through 
the natural ability of the plant’s DNA repair system during DNA replication and cell division to 
join the ends of non-homologous DNA sequences.  It is the same error-prone process that also is 
responsible for introducing several types of natural recombination events during the repair of 
double strand breaks in DNA.  Gene disruptions, the production of novel fusion proteins, or 
changes in expression levels of plant genes may, however, also occur through natural genome 
rearranging processes (e.g. transposition as occurs in maize) and the use of traditional breeding 
methods. 
Since transgene integration occurs in plants through illegitimate recombination mechanisms, in 
which no homology is required, it is not surprising to find that there is no preference for specific 
sequences in the genome for the integration process.  At present, it is not possible to predict, from 
its nucleotide sequence, the fate and the site of the integration of a particular transgene construct 
in the plant genome.  However, transgenes, in particular those containing T-DNA, do have 
preferences for gene-rich regions.  Similarly, in traditional breeding, DNA recombination is 
frequent in gene-rich regions, thus giving rise to allelic variants that can be selected for if the 
effects are beneficial.  Thus actively transcribed genes per se are hot spots for recombination in 
plants, regardless of whether the recombination event is inconsequential, leads to unintended 
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effects, benefits the breeding process, or serves to insert a recombinant DNA sequence during the 
process of genetic modification. 
3.2 Identifying and assessing risks from unintended effects 
Potential unintended effects from the genetic modification may be more easily detected than 
those from natural recombination events or mutagenesis events induced by man.  For the former, 
the tools of molecular biology can be used to identify recombination sites based on the 
knowledge of the inserted DNA sequence, for the latter there is no knowledge on the DNA 
sequence at the recombination site.  On the other hand, knowledge on epigenetic effects is still in 
its infant phase. 
Plant breeding is an iterative process requiring experience with diversity in available genetic 
resources and familiarity with the variability within the species.  In the early stages of 
conventional breeding, "low grade" selection processes are normally used to discard those plants 
that show visible changes that appear undesirable.  Selection according to the optimal "visible 
phenotype" and screening for disease resistance can be included, for example, at an early stage.  
As the selection process continues, the sophistication of the parameters measured increases 
(facilitated by a reduction in the number of progenies) to encompass yield and quality traits.  
Extensive backcrossing procedures are applied in order to remove undesired unintended effects.  
Selection of the starting parental material is paramount in the breeding process.  Due to the 
common practice of selecting favourable lines and discarding those exhibiting unwanted 
properties, unintended effects in conventional breeding are not frequently reported.  The extent to 
which unintended effects occur during the course of a traditional breeding programme is almost 
impossible to assess.  Unintended effects routinely occur and are propagated, some of which may 
have safety implications: for instance, potato cultivars were withdrawn due to unacceptably 
increased levels of neurotoxic glycoalkaloids, toxins present at low levels in all potatoes. 
In GM crops, the knowledge of the introduced recombinant DNA sequence allows the 
identification of the insertion site in the plant genome.  Sequence information obtained from the 
insertion site that bridges the recombinant DNA and the plant genome allows identification of 
potential fusions of recombinant and endogenous plant genes.  More importantly, sequence 
information often also helps to identify whether important plant genes were disrupted or 
otherwise affected through the introduced recombinant sequence.  It is then possible to formulate 
hypotheses on what might have been inadvertently changed in the GM crop.  Such approaches 
could indicate if the insertion event occurred, for example, within or close to an endogenous gene 
or regulatory sequence.  Our expanding knowledge of plant genomes and functions of individual 
genes, as well as the availability of associated bio-informatics and databases will increasingly 
help to reduce uncertainties on unintended effects from genetic modification. 
The safety assessment of GM crops required for marketing aims to identify all major changes in 
the GM crop compared to the parent crop that might affect human health (see also Chapter 2).  
Any significant differences in agronomic, physiological, and compositional characteristics 
between the GM crop and the conventional counterpart are then subject to further testing to assess 
potential implications.  The comparison is targeted according to predetermined criteria.  The 
selection of the parameters is guided by knowledge of the characteristics of the crop species that 
is transformed, the introduced recombinant material, and the source organism of the recombinant 
material.  Parameters can also be selected based on knowledge of the plant genome sequences at 
the recombinant DNA insertion site.  Selected compositional parameters are representative of the 
main metabolic pathways in the plant and reflect potential consequences of the introduced trait; 
the assessment focuses on those that might affect human health, such as key nutrients, anti-
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nutrients, and allergens.  Moreover, all GM crops that enter the market have also undergone 
classical breeding and other processes for improving plant varieties. 
BOX 3-1 
STRATEGIES FOR DETECTION OF UNINTENDED EFFECTS
  Targeted analysis Non-targeted profiling analysis
   Macro-, micro-nutrients   DNA analysis 
    Antinutrients, toxins   DNA / mRNA hybridisation 
    Specific secondary metabolites   Proteomics 
     Metabolomics 
3.3 Developments in detection of unintended effects 
The development of complementary approaches to the targeted safety assessment approach is also 
viewed as particularly valuable for enhancing our understanding of plant biology in general and 
facilitating the development and the assessment of GM crops with more complex modifications.  
Complex traits, such as nutritional enhancements or tolerance to abiotic stresses, can 
fundamentally change a plant’s metabolism and physiological processes.  The more complex the 
modifications of the crop’s composition, metabolism, or physiology, the more likely they are 
associated with unanticipated consequences.  One R&D project that is part of the 
ENTRANSFOOD cluster, the GMOCARE project, is exploring whether profiling methods might 
contribute to the detection of compositional differences between GM crops and parent crops that 
might not be detected using the targeted comparative approach. 
In order to increase the chances of detecting unintended effects, profiling methods have been 
suggested as tools to characterise changes in the composition of GM plants.  The non-targeted
approaches using DNA/RNA micro-array technology, proteomics, and metabolomics allow less 
biased analysis of possible changes in the physiology and metabolism of the modified host 
organism (Figures 3-1 and 3-2; Box 3-1).  Advances in the development of the three types of 
profiling methods for plants are rapid, but due to difficulties of data interpretation, the added 
value of use of profiling methods in food safety assessment still remains to be proven.  Potential 
merits and limitations of DNA and RNA micro-array technology, proteomics, and metabolite 
profiling are described in more detail below. 
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Figure 3-1 Profiling techniques for detection of unintended effects in food crops (designed by 
G.A. Kleter) 
GM crop Non-GM crop 
mRNA proteins metabolites 
electrophoresis gels cDNA microarrays LC-NMR spectra 
Identification of differences between GM- and non-GM- crop 
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Figure 3-2 Integrated analysis of (un)intended effects in foods derived from GM crops (adapted 
from Kuiper et al., 2001) 
Detection of altered gene expression.  Development of DNA and RNA micro-array technology is 
an important step forward in the history of analysis of gene expression, facilitating parallel gene 
expression studies on thousands of different genes.  Micro-array technology is based on 
hybridisation of mRNA to a high-density array (which consists of thousands of genes on an area 
no larger than a microscope slide) of immobilised target sequences, each corresponding to a 
specific gene.  The technology is being tested for application in many fields, including medical, 
agricultural, and environmental science. 
In order to study changes in patterns of gene expression in food plants, micro-arrays for the 
tomato and potato have been developed as model systems.  Genetic modification may affect key 
metabolic pathways involved in the production of natural toxins and/or health beneficial 
compounds.  Micro-arrays (and similar parallel gene expression technologies) allow simultaneous 
expression analysis of large numbers of genes thereby facilitating a broad-scale comparison of 
gene expression in the modified organism and its appropriate comparator.  Where differences in 
gene expression occur, the availability of the DNA sequences of the genes in question will 
provide a first lead for further investigations into putative health effects from the observed 
differences.  Observed differences in gene expression (i.e. mRNA levels) do not necessarily 
reflect parallel changes in the levels of the proteins the genes encode.  The assessment of whether 
Plant 
Tissue
DNA 
mRNA 
Proteins 
Metabolites
Phenotypic alterations 
Phenotypic alterations 
DNA analysis 
Genomics 
Proteomics 
Metabolomics 
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there are health implications associated with the identified differences would therefore be 
challenging. 
The construction of cDNA libraries representing different developmental stages of modified and 
non-modified organisms and subsequent hybridisation may yield important information on 
possible alterations in gene expression patterns.  In this way, sufficient insight may be obtained 
into the natural variation in gene expression during different stages of development of the tissues 
of interest and under different environmental conditions.  In the case of tomato, a green-specific 
library was prepared with the objective of isolating (amongst other genes) cDNAs that are related 
to the formation of natural toxins, such as tomatin.  In contrast, the library prepared from red 
(ripe) fruit contains cDNAs associated with the metabolism of nutritionally important compounds 
such as vitamins and flavonoids.  Thus, by constructing micro-arrays that are enriched in genes 
involved in several important pathways, the inadvertent effects of genetic transformation on such 
pathways can be monitored.  Similarly, a potato library has been constructed that aims to further 
elucidate the metabolic pathways that contribute to the synthesis of glycoalkaloids, which are 
natural toxins.  The outcome of these experiments will determine the usefulness of the micro-
array technology in the screening for unintended effects in GM varieties associated with the 
genetic modification itself.  From preliminary results, it can be shown that at least intended 
effects in GM tomato varieties can be monitored effectively. 
Proteomics.  Proteomics, that is the study of large set of proteins present in a cell, organism, or 
tissue under defined conditions, is a well-established technique that complements transcript (gene 
expression) profiling.  The main approach currently applied involves two-dimensional gel 
electrophoresis followed by excision of protein spots from the gel, digestion into fragments by 
specific proteases, analysis by mass spectrometry, and subsequent computer-assisted 
identification using databases.  This type of "differential display" proteomics has been applied to 
follow changes in polypeptide profiles and post-translational modifications induced by 
environmental factors or genetic mutations.  One of the major challenges is the quantification of 
proteins.  The range over which protein levels can be quantified is narrow. 
The applicability of proteomic techniques to identify unintended effects resulting from the genetic 
modification of crops is being studied within GMOCARE.  Detection of differences related to the 
genetic modification may, however, prove difficult, taking into account the large number of 
proteins present in a plant and the need to sub-fractionate the protein pool to detect minor 
components.  As with all profiling techniques, one challenge is the high level of background 
“noise”, that is non-specific signals; this noise can be largely attributed to non-representative 
sampling procedures and genotypic variability.  In order to overcome such challenges, it has been 
suggested that for safety assessment, a more targeted approach is more appropriate, such as a 
combination of immuno-blotting procedures and protein-micro-arrays, focussing on proteins 
involved in important metabolic pathways. 
Metabolite profiling.  The main approaches used for metabolite profiling are based on gas 
chromatography, high performance liquid chromatography, mass spectrometry, nuclear magnetic 
resonance, or Fourier-transform (near) infrared spectroscopy.  These techniques can be applied in 
both targeted and non-targeted ("unbiased") approaches.  By combining the various analytical 
approaches, it is possible to distinguish more than one thousand metabolites in plant extracts, but 
it is not yet possible to identify the majority of the constituents.  The development of extensive 
mass spectral databases to aid metabolite identity in plants is a major challenge.  There are 
several examples where metabolite analysis has detected unintended effects on metabolism.  This 
includes, for example, lowered glycoalkaloid levels in GM potatoes with modified sugar 
metabolism and increased ?-lycopene content in specific GM tomato fruit. 
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Within GMOCARE, targeted analysis of a range of GM potato lines and appropriate controls has 
been completed.  Some lines exhibited extreme phenotypes, whereas no consistent differences 
could be detected between the GM potatoes and wild-type controls in, for example, glycoalkaloid 
(toxin) content and profile, sugar balance, fatty acid profiles, isoprenoid content, vitamin C 
content, and trypsin inhibitor activity.  Similarly, using "unbiased" nuclear magnetic resonance 
analysis only one GM potato line with the most extreme stunted phenotype could be distinguished 
from its control (through modified proline content).  These lines are now being subjected to gas 
chromatography combined with mass spectrometry and liquid chromatography combined with 
mass spectrometry. 
To summarise, profiling technologies clearly provide powerful tools to enhance our 
understanding of changes in crop metabolism.  A particular strength of micro-arrays is that they 
can contain the entire genome (provided the genome has been sequenced, as is the case for rice 
and Arabidopsis.  Proteomic and metabolic profiling approaches are less comprehensive: plants 
contain many thousands of proteins and metabolites, only a fraction of which can be 
detected/identified/quantified using existing approaches.  The three methods yield complementary 
information. 
Profiling techniques yield large quantities of data Use of profiling to complement current 
approaches to safety assessment holds promises and challenges.  Several issues need to be 
addressed before profiling approaches can become a proven and useful tool in standard risk 
assessment procedures.  The method’s comprehensiveness promises to identify any difference 
between new and old varieties.  However, the interpretation of outputs (data) remains a 
significant challenge.  Much work remains to be done in the development and standardisation of 
sampling procedures and approaches for data collection and handling.  Inter-laboratory "ring" 
testing and validation of these methods will also be required.  In addition, a more comprehensive 
understanding of natural variation in, for example, the levels of metabolites in crops needs to be 
developed to allow any unintended changes in a GM crop plant to be properly “benchmarked”.  
For the comparison of large profiling data sets obtained for two different crop varieties, 
multivariate techniques, such as principal component analysis or hierarchical cluster analysis, are 
frequently applied.  Such multivariate methods are useful, but discrimination between intended 
effects and unintended effects at the metabolite level may not always be possible.  Therefore, 
perhaps most importantly, approaches will be needed to interpret the biological relevance and 
toxicological significance of any observed differences.  Interconnected databases containing 
information on gene transcript, protein, and metabolite profiles for specific crop species at 
different developmental stages and grown in diverse environmental conditions would be helpful. 
If, in future, reliable interpretation of results from profiling studies becomes a reality, such 
approaches will be useful to complement the current targeted safety assessment approach.  The 
identification of possible differences between traditionally used and novel crops that might have 
adverse effects on human health is the overall aim of both targeted and non-targeted approaches. 
3.4 Conclusions 
Unintended effects on the composition of crop plants from one generation to the next can occur 
through natural recombination, mutagenesis approaches used in plant breeding, and genetic 
modification.  There is no inherent unique risk in the deployment of recombinant DNA 
techniques.  Variety selection and selection of parameters for both GM crops and conventionally 
bred counterparts that involve the assessment of physiology, morphology, and performance 
provide sound indicators of unintended effects. 
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Uncertainty associated with food safety of GM crops does not seem to be greater than uncertainty 
associated with conventionally bred crops.  If anything, given current regulatory requirements 
specific for GM crops, they are better characterised than the conventional counterparts we eat.  
The safety assessment relies on a targeted approach of parameters indicative of the overall plant 
metabolism and possible changes from genetic modification.  Such targeted approaches have 
proven to be effective for identifying unintended changes that might have implications for human 
health or the environment. 
The application of profiling techniques will contribute to improving our understanding of the 
metabolic and compositional variations of crop plants and the potential alterations in gene 
expression, protein composition, and associated metabolic consequences that may stem from 
different cultivation conditions, breeding practices, or genetic modification.  However, profiling 
methods are not as yet suitable for use in formalised risk assessments before we have sufficient 
data to understand natural variation in different gene expression and compositional parameters of 
crop plants, and before we are able to assess swiftly whether any observed significant changes in 
gene expression or composition may impact human health. 
We recommend the allocation of public sector research funds to develop our understanding of 
food crops, including analyses using profiling methods.  The development of profiling methods 
and international databases on natural variation in gene expression, protein, and chemical 
composition of crops should be encouraged.  These methods will contribute to improving our 
understanding of the foods we eat and their potential implications for human health.  Such 
methods will also facilitate the development and safety assessment of GM crops with more 
complex traits, such as nutritional enhancement and tolerance to abiotic stresses.  Each of these 
methods, once further developed, may well be used to in future for certain categories of GM 
crops to complement the current targeted approach for the safety assessment of new crop 
varieties. 
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CHAPTER 4 
THE RELEVANCE OF GENE TRANSFER TO THE SAFETY OF FOOD AND FEED 
DERIVED FROM GM PLANTS 
What are the risks from the transfer of recombinant DNA from GM crops to microbes or human 
cells?  Since the first public discussions on genetic engineering in the mid-1970s experts agree 
that here is no inherent risk in the transfer of recombinant DNA between organisms, as all DNA 
is compositionally the same and not inherently toxic at typical human consumption levels.  
Although gene transfer between species is common in nature and has been a driving force in 
evolution, the risks from horizontal gene transfer of recombinant DNA from GM crops to other 
organisms should be assessed with care.  Consequences of any gene transfer, natural or mediated 
by man, entirely depend on the function of the transferred gene in the recipient cell.  In some 
cases, uncertainties in the assessment of the risks of gene transfer of a specific fragment of 
recombinant DNA may need to be addressed with further research or by improving the design of 
GM crops before a crop can be approved.  Like science, understanding of risk will never be 
complete.  This is, however, no reason to refrain from making decisions on new technologies that 
may hold some risks, but also promise benefits. 
Assessing risks of horizontal gene transfer of recombinant DNA in foods derived from GM crops 
requires estimating both the likelihood of transfer of recombinant DNA from GM crops to 
microbes or human cells and the impact of such a transfer event.  The risk is judged to be 
significant only if the recipient cell acquires a new function that may, directly or indirectly, have 
adverse effects on human health and if the acquisition of this gene by this cell type is significantly 
increased through marketing of the GM crop that contains the gene.  Risk assessment of gene 
transfer of recombinant DNA from GM crops has focussed predominantly on the possibility that 
genes conferring resistance to specific antibiotics in certain GM crops may be transferred to 
microbes.  In this chapter we discuss three issues central to the risk analysis of potential gene 
transfer from foods derived from GM crops to microbes or human cells: the occurrence and 
consequences of gene transfer between species; the risk assessment of antibiotic resistance genes; 
and best practices in the design of GM crops to reduce risks and uncertainties relating to gene 
transfer. 
4.1 Occurrence and consequences of gene transfer between species  
Rapid progress in sequencing genomes of diverse micro-organisms highlights the importance of 
horizontal gene transfer in microbial evolution: the identification of foreign DNA in microbial 
genomes provides evidence for frequent uptake and integration of foreign DNA.  Stable 
integration of foreign DNA in a cell’s genome and inheritance to subsequent generations requires 
four events: the uptake of foreign DNA, its effective replication in the recipient cells, expression 
of a new trait that confers the selective advantage, and a mechanism to pass the acquired DNA on 
to progeny in cell divisions.  The uptake of genes from the environment or the transfer of genes 
between microbes enables microbial populations to rapidly respond to environmental changes.  
Lasting environmental changes may lead to alterations in the genetic make-up of a population 
over just a few generations, as the genetically best-adapted individuals propagate most 
effectively. 
Genome sequences from complex multi-cellular organisms such as plants and animals provide 
evidence that gene uptake from the environment has not much contributed to genetic diversity.  
Mutations and the combination of different sets of chromosomes from two individuals through 
sexual propagation play a more important role in generating genetic diversity in higher 
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organisms.  The human genome sequence contained no plant-derived DNA, very few bacterially-
derived sequences, and many viral sequences; the sequences suggest that the integration of a 
foreign sequence in the human genome such that it is also found in germ line cells and inherited 
by subsequent generations takes place on a time scale of once in a thousand years.  The factors 
affecting the likelihood of gene transfer to microbes and human cells, as well as possible 
consequences of such transfer events are considered in more detail below. 
Gene transfer to microbes 
The ability of microbes to acquire new genetic material varies between and within species.  It can 
depend on environmental factors, such as nutrient availability and temperature.  There are three 
main mechanisms that are of most relevance in the assessment of risks from gene transfer to 
microbes: conjugation, transduction, and transformation. 
Microbes can exchange DNA by conjugation.  Conjugation relies on self-contained, 
independently replicated DNA elements, such as conjugative plasmids.  Genes contained on such 
plasmids usually include genes allowing adaptation to sudden changes in environments, such as 
genes conferring resistance to heavy metals or antibiotics, and functional elements allowing their 
replication and transfer from one cell to another.  Other classes of "selfish" DNA elements can 
replicate and integrate themselves into host genomes; they, however, lack the cell-to-cell transfer 
functions, such as in the case of simple transposons.  The most commonly used antibiotic 
resistance marker gene nptII, for example, was derived from Transposon Tn5 isolated from an 
Escherichia coli of a student’s gut.  Transposons are often found on conjugative plasmids.  There 
are numerous examples of inter-species and inter-genus transfer of DNA by conjugation in food 
and in the intestine.  In the risk assessment of gene transfer from GM crops, conjugation is of 
relevance, as any genes that are contained on conjugative elements that are wide-spread in 
microbial populations are more likely transferred between microbes via conjugation than via 
transformation.  Conjugation has been observed to occur in the intestine. 
Viruses can also transfer DNA from one cell to another by transduction.  When viruses replicate 
in cells, cellular DNA fragments are sometimes accidentally packaged into viral particles.  When 
these viral particles are released and infect new cells, the cellular DNA from the prior cell is 
transferred into the newly infected cell.  This process of transduction is, however, not considered 
of great relevance in the assessment of risks of horizontal gene transfer from GM crops to 
microbes or humans, as there are only few viruses that can infect both plant and microbial cells, 
or plants and animal cells.  Transfer of recombinant DNA between plant cells is considered 
inconsequential, in particular as the sequence of the rice and the Arabidopsis genomes provides 
evidence that viral DNA is not commonly transferred to germ line cells that would allow 
inheritance to subsequent generations. 
Most types of cells that can be cultured in laboratories can take up and integrate free DNA by 
transformation.  Transformation can be induced by a cell’s manipulation in laboratories.  In some 
microbial species, it is, however, also known to occur spontaneously in nature, given specific 
environmental conditions.  The uptake of DNA from GM crops by microbes, for example, would 
occur by transformation.  This may occur at any stage in the production or consumption of a GM 
crop: cultivation, transport and storage, processing, consumption, digestion, and subsequent to 
excretion.  Uptake of naked DNA by microbes is most likely to occur where there is a high 
density of both the DNA and bacteria that are competent to take up this DNA.  Highest microbial 
counts in plant-derived foods are found in food fermentation processes and after food intake 
during digestion in the large intestine.  The mouth micro-flora has also been demonstrated to be 
amenable to transformation.  The availability of plant-derived DNA in most environments is 
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largely determined by the break down of plant cells and by the stability of the free DNA in the 
environment.  The stability of DNA depends on the environmental determinants, such as acidity, 
temperature, shearing forces, and the presence of digestive enzymes, light, and oxygen. 
Gene transfer by transformation has been studied in vivo in the intestinal tract of germ-free 
animals that were populated with different microbial species.  It is expected that gene transfer of 
recombinant DNA to microbes can occur in the gastro-intestinal (GI) tract, but could, however, to 
date not be detected; it is therefore likely a very rare event.  Gene transfer to a Pneumococcus
strain was, however, demonstrated in blood sausage (certain Pneumococcus species are known to 
be competent to take up DNA in the presence of serum found in blood). 
The transfer of recombinant DNA from a GM crop to a microbe is, however, only consequential 
if the new the trait is expressed in the microbial cell, and if it is selected for within a population 
because it confers a competitive advantage. 
Gene transfer to human cells 
Transfer of recombinant genes to cells of multi-cellular organisms, including humans, may be 
consequential if the cell’s new properties are harmful to the organism, and if the recombinant 
genes are transferred to germ-line cells so that they are inherited by subsequent generations.  
Human cells of the gut and the immune system have been shown to take up DNA by endocytosis, 
a process that involves the folding-in of the cell’s outer membrane to form small intra-cellular 
compartments called endosomes.  In cows fed transgenic soybeans, some chloroplast DNA could 
be detected in blood cells that are part of the immune system.  It could, however, not be 
established whether the DNA had been stably integrated in the genome of these cells (unlikely) or 
whether they were merely contained in endosomes.  In mice fed with large quantities of virus-
derived DNA, the DNA could be detected in cells of the intestinal wall, liver, and immune system 
(spleen cells and leukocytes), as well as in some foetal cells, providing evidence for trans-
placental transfer of DNA.  The fate of the viral DNA that is single-stranded, circular, and super-
coiled, and hence more resistant to digestion, may differ from that of plant-cell contained double-
stranded DNA.  The experiments are significant as they do provide evidence that DNA that is 
ingested as part of our diet can be taken up by body cells, that this has occurred throughout 
evolution, and that this has not been harmful to the development of our (and other) species.  Little 
is known about mechanisms by which germ line cells might be able to take up DNA.  This has 
never been observed to occur in experimental set-ups.  The human genome sequence provides 
evidence that uptake of foreign DNA into the genome of human germ line cells that is 
subsequently inherited is an extremely rare event that may occur once on the timescale of 
millennia. 
Is gene transfer consequential? 
Expression of the newly acquired genes in the recipient cell is a prerequisite for adverse effects of 
gene transfer.  This usually involves transcription of the DNA into messenger RNA (mRNA) that 
in turn is translated into proteins.  Microbial, plant, and animal cells have quite distinct expression 
systems.  Therefore, genes transferred from one cell type to another are often not expressed at all 
or only at very low levels.  Interestingly, at least in currently commercial GM crops, a majority of 
the recombinant genes, such as the nptII gene and most genes conferring herbicide tolerance or 
insect resistance, are derived from bacteria; transfer of these genes to microbial gene pools hence 
can be seen to return them to their evolutionary origin.  The assessment of risks from horizontal 
gene transfer hence usually focuses on genes that may confer a selective advantage to microbial 
cells.  These include antibiotic resistance genes, which protect bacteria in environments with the 
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corresponding antibiotic.  If GM crops containing antibiotic resistance genes would contribute to 
the spread of antibiotic resistance in microbial populations, the potential impact may be the 
reduction of the clinical value of antibiotics.  The risk assessment of antibiotic resistance genes in 
GM crops is discussed next. 
4.2 Risk assessment of antibiotic resistance gene transfer in the human gut 
Can transfer of a specific antibiotic resistance gene from a GM crop to micro-organisms increase 
the spread of resistance in microbial pathogens and thereby compromise the medical and 
veterinary use of antibiotics (Figure 4-1)? This section discusses the use of antibiotic resistance 
genes as selectable markers in the transformation of GM crops.  The risk assessment and 
classification of antibiotic resistance genes are into three risk categories.  European Community 
legislation and policies on the use of antibiotic resistance markers are also discussed. 
Antibiotic resistance as selectable marker 
The use of an antibiotic resistance gene as a selectable marker in cell transformation procedures 
has been common practice in microbial and in plant genetic research for many years.  Selectable 
marker genes are linked to the trait-conferring gene before transformation to allow identification 
of the transformed plant cells.  The low efficacy of currently routinely used DNA-delivery 
technologies results in only a very small proportion of targeted plant cells actually integrating the 
recombinant DNA with the trait-conferring genes stably in the nucleus.  Genes that confer 
resistance to cytotoxic agents, like antibiotics, allow only transformed plant cells to grow on 
nutrient media that contain the toxic agent; cells that have not integrated the recombinant DNA 
will usually not grow on these nutrient media.  These markers are stably integrated in the nuclear 
genome of the GM crop; they have no function in the commercial product. 
Transfer of antibiotic resistance genes from GM crops to microbes – a rare event 
The risk of use of specific antibiotic resistance genes contained in certain GM crops should be 
judged on a case-by–case basis considering three main factors: the likelihood of transfer of an 
antibiotic resistance gene from the genome of a transgenic plant to that of a bacterium; the 
frequency of occurrence of the resistance gene in microbial populations; and the extent of clinical 
and veterinary use and importance of the relevant antibiotic(s).  These factors are considered in 
turn.
The assessment of food safety of GM crops containing an antibiotic resistance marker has to 
consider the risk of transformation of microbes in the human gut with this gene.  As discussed 
above, the frequency of transformation of microbes in the human gut is expected to be very low, 
while the chance of uptake of a particular and functional DNA fragment derived from a plant 
genome is very small.  In fact, it has been estimated to occur once in one hundred million years in 
the gut flora of an individual; this corresponds to once in ten years for a human population of six 
billion individuals.  Upon digestion of the plant cell matrix, nuclear DNA is released into the gut 
and can, in theory, be taken up by gut microbes through transformation.  All DNA released from 
plant and other cells in the digestion process competes for uptake, the nptII gene conferring 
resistance to kanamycin is for instance less than 0.000025% of the total maize genome of 2.2 
million basepairs. 
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Figure 4-1 Potential gene transfer of antibiotic resistance genes from GM foods to intestinal 
micro-organisms and its possible impact (designed by G.A. Kleter) 
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Predicting the rates of uptake of DNA by microbes in the gut is challenging, as the gut micro-
flora consists of relative large number of distinct organisms (predominantly less well 
characterised anaerobes).  Little is known about what proportion of these organisms may be 
amenable to transformation under conditions in the gut.  There are therefore considerable 
uncertainties in the risk assessment.  A better understanding of competence of the micro-flora to 
take up DNA under gut conditions is helpful to reduce uncertainties in the risk assessment; more 
research in this area is recommended.  Experiments in model gut systems have, however, so far 
failed to provide evidence for the occurrence of transformation of gut micro-flora with 
recombinant DNA derived from GM crops.  Furthermore, some microbes in the human gut 
contain conjugative plasmids or other easily transferable genetic elements, some of which contain 
certain antibiotic resistance genes.  Genes on such mobile genetic elements are much more likely 
transferred between gut microbes than taken up by transformation as plant-derived DNA. 
Some antibiotic resistance genes are widespread in microbial populations.  Diverse species of 
microbes produce antibiotics to fend off other microbial species that compete for nutrients in the 
same environment.  In what can be compared to an evolutionary arms race, certain species 
produced antibiotics, while competitors evolved to become resistant.  Some of these resistance 
genes are contained on conjugative plasmids that can rapidly be transferred across microbial 
populations, in particular in the presence of the antibiotic where resistant bacteria have a 
competitive advantage.  If the recombinant gene used for selection of the GM crop is already 
widespread in microbial populations in the soil and or human and animal guts, a rare transfer 
event may not contribute significantly to this spread. 
The extent of use of the antibiotic is important in risk assessment for two reasons.  First, the type 
and extent of use determines the selection pressure for the spread of microbial resistance in a 
clinical or farm environment.  The extensive use of antibiotics for medical and veterinary 
purposes and as growth promoters for farm animals has led to increased spreading of antibiotic 
resistance genes in the microbial population.  Second, the value of the antibiotic is not always 
proportional to extent of use.  Rarely used antibiotics may be saved as last resort on their own or 
as part of cocktails to combat multi-drug resistant pathogens.  If the gene is already widespread in 
microbial populations in the soil and or human and animal guts, a rare transfer event may not 
contribute significantly to this spread.  If the antibiotic is however very widely used or a tool of 
last resort, current uncertainties in the risk assessment relating to conditions of competence of a 
majority of the bacterial species in the gut and elsewhere may not be deemed acceptable.  Further 
research in this area is therefore warranted and the use of such genes should be avoided. 
Three risk groups  
Antibiotic resistance genes have been assigned to three risk groups based on frequency of 
occurrence in microbial populations and importance of clinical use of the relevant antibiotics (see 
also Box 4-1):  
? Group I contains antibiotic resistance genes that (a) are already widely distributed among soil 
and enteric bacteria and (b) confer resistance to antibiotics that have no or only minor 
therapeutic relevance in human and veterinary medicine.  The presence of these antibiotic 
resistance genes in the genome of transgenic plants is judged insignificant with respect to 
their occurrence in the environment.  The nptII gene conferring resistance to neomycin and 
kanamycin and the hph gene conferring resistance to hygromycin are assigned to this group.  
Genes in this group are considered safe for use as selectable markers. 
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? Group II contains antibiotic resistance genes that (a) are widely distributed in micro-
organisms and (b) confer resistance to antibiotics that are used for therapy in defined areas of 
human and veterinary medicine.  The presence of these antibiotic resistance genes in the 
genome of GM crops is not likely to contribute significantly to their spread in the 
environment, but the clinical value of the antibiotic however makes it harder to accept the 
uncertainties in the risk assessment.  This group contains the bla gene conferring resistance to 
ampicillin and structurally closely related drugs, the aadA gene that confers resistance to 
streptomycin and spectinomycin, and the cat gene conferring resistance to chloramphenicol.  
The risk of using such genes use in transformation has to be carefully evaluated on a case-by-
case basis. 
? Group III contains antibiotic resistance genes that confer resistance to antibiotics relevant for 
human therapy and therefore should be avoided in the genome of transgenic plants for 
reasons of a high-standard preventive healthcare.  The following antibiotic resistance genes 
are contained within this group: nptIII (conferring resistance to amikacin) and tetA (to 
tetracyclin). 
BOX 4-1 
ANTIBIOTIC RESISTANCE MARKER GENE CLASSIFICATION 
  Group I: 
  - Antibiotic resistance genes widely distributed among soil and enteric bacteria 
  - Confer resistance to antibiotics of no or only limited therapeutic relevance in 
human and veterinary medicine: nptII and hph gene 
  Group II:  
  - Antibiotic resistance genes widely distributed among micro-organisms 
  - Confer resistance to antibiotics which are used for human and veterinary 
medicine: bla and aadA gene 
  Group III:  
  - Antibiotic resistance genes which confer resistance to antibiotics relevant for 
human therapy: nptIII and tetA gene 
EU law and policies on the use of antibiotic resistance markers 
The recommendation to phase out transgenic crops with selectable markers that confer resistance 
to clinically used antibiotics has now a legal basis in Directive 2001/18/EC on the deliberate 
release and placing on the market of GMOs.  The concept of "antibiotic resistance markers in 
GMOs which may have adverse effects on human health or the environment" will be subject of 
interpretation in the first decisions under the new law, as such markers should be identified and 
phased out. 
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4.3 Best practices in the design of GM crops 
Several expert committees advising regulatory agencies are discussing recommendations on best 
practices for the design of GM crops.  It is often recommended to minimise introduced 
recombinant sequences in GM crops.  Improvements in methods for crop transformation can 
simplify the safety assessment of GM crops if they reduce the amount of recombinant DNA and 
recombinant proteins introduced into the GM crop.  DNA transferred to GM crops can be reduced 
to a minimum by avoiding insertion of multiple copies of recombinant DNA sequences at 
multiple insertion sites, and by avoiding use of - or removing - selectable marker genes.  We 
build on and refine these recommendations considering the choice of gene delivery technologies, 
the design of recombinant DNA inserts, and the use of selectable markers in turn. 
Gene delivery methods 
Improvements in methods for the delivery of recombinant DNA into plant cells are key to 
minimise recombinant DNA transferred to GM crops.  Improvements should aim at ensuring that 
no DNA sequences other than the trait-conferring gene and the marker gene are transferred and at 
increasing the proportion of transformed cells that have single simple inserts.  Two main delivery 
systems are used: Agrobacterium tumefaciens-mediated plant transformation and particle gun-
mediated transformation.  In most instances, DNA is integrated into the nuclear genome of the 
plant cells. 
In Agrobacterium-mediated transformation, the use of double border vectors, where the "transfer 
DNA" that is targeted for insertion into the plant genome is flanked by two "border sequences", 
allows for the transfer of only the necessary genes that are required for expression of the desired 
trait and for selection of transformed plant cells.  The system is imperfect, as the border 
sequences occasionally are overridden, resulting in the insertion of sequences outside these 
borders.  It is, however, still considered more reliable and more controlled than gene delivery to 
plant cells using the particle gun.  Agrobacterium-mediated transformation methods, formerly 
limited to application in dicotyledon plants, are now also being developed for use on 
monocotyledon plants (cereals). 
Improvements in transformation methodology over the past two decades have resulted in greater 
control over the DNA sequences that are transferred to the plant genome.  Repeated recombinant 
DNA sequences are undesirable, as molecular characterisation is more difficult, and as repeats 
may result in recombination and DNA rearrangement at the insert.  Gene silencing effects that 
have been observed where there are several copies of the same recombinant promoter and/or 
termination signal can introduce uncertainty on stable gene expression.  Agrobacterium- and 
particle gun-mediated transformation protocols were developed that, at least in some crop species, 
yield a higher proportion of GM crops with single simple inserts.  However, even with these 
improvements of plant cell transformation methods over time, the degree of control over the 
transformation process varies amongst crop species.  Physical delivery systems are less controlled 
than the Agrobacterium system in terms of copy number and molecular integrity of inserts.  
Furthermore, it is important to ensure the purity of the DNA preparation used.  Random DNA 
derived from any bacterium on the workbench may accidentally be co-inserted in transformation 
vectors or may be shot into the plant genome.  It should also be considered that, for instance 
during bombardment, pieces of plant chloroplast or mitochondrial DNA may be shot into plant 
nuclear DNA. 
Methods have also been developed to deliver DNA into organelles that contain their own DNA, 
like chloroplasts.  One advantage in terms of environmental safety considerations of chloroplast 
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transformation is that the recombinant DNA will not be present pollen, as these do not contain 
chloroplasts.  Out-crossing can therefore not spread the trait.  Another difference is that there are 
several thousands of chloroplasts in one cell compared to only one nucleus; the copy number of 
the insert is therefore accordingly increased.  Increased copy number on the one hand allows 
higher levels of gene expression, on the other hand it also maximises the chances of transfer of 
the recombinant DNA through other mechanisms than pollen flow.  Whether this is of 
consequence in the overall risk assessment of the crop, however, depends on the function of the 
transferred genes.  The increase in copy number has to be weighed against other benefits that can 
be derived from organelle transformation on a case-by-case basis. 
Selectable markers and elimination methods 
In spite of foreseeable future improvements in methods for delivery of recombinant DNA, 
transformation systems for most crops will still depend on the use of selectable markers for some 
years to come.  Several methods are being developed that will allow eliminating selectable 
markers after the transformation of the GM crop and before the product is marketed.  The main 
advantage of the deployment of such methods is that they allow for reducing the recombinant 
DNA in the commercially cultivated GM crop to a minimum.  Other advantages of marker 
elimination in product development include the possibility of re-transforming transgenic crops 
using the same marker gene to insert additional traits.  If multiple new traits are combined in one 
transgenic crop line using conventional breeding methods, the removal of marker genes reduces 
the risk of gene silencing that can occur due to the presence of several identical gene regulatory 
or coding sequences and may affect the stability of the expression of the trait.  The avoidance of 
repeated recombinant DNA sequences also reduces the risks of unintended effects from 
recombination between such sequences.  Methods that hold the most potential for allowing 
routine specific removal of DNA sequences, such as marker genes, from transgenic crops are co-
transformation and recombinase-mediated excision. 
Homologous recombination relies on the occurrence of base pairing between identical sequences 
that are in close proximity during the DNA replication process.  This can lead to the excision of 
DNA sequences that are located between the two repeated DNA sequences.  At present, 
recombination frequencies are, however, too low for the routine use of this method in product 
development to eliminate selectable markers. 
Agrobacterium-mediated co-transformation methods rely on creating two separate DNA 
sequences for insertion on the plant genome, one with the gene of interest, the other one with the 
selectable marker.  The aim is to obtain plant cells in which the gene(s) of interest and the marker 
gene integrate into non-linked genomic locations.  This allows segregation of the gene of interest 
and the selectable marker by breeding.  The method has already been deployed successfully in the 
development of commercial products.  It is, however, much less effective, as in experiments to 
date, only a maximum of 25% of the transformation events contained single copies of both the 
marker and the gene of interest in separate genomic locations that are suitable for further 
development. 
Site-specific enzyme-mediated excision systems rely on a recombinase enzyme that specifically 
cuts DNA at two short DNA recognition sites and then reseals the two DNA strands, leading to 
removal of all DNA between the sites.  Marker genes can be removed from GM crops if they are 
flanked by the specific recombination target sequences.  The likelihood of unintended 
recombination in transgenic crops developed with this method will need to be assessed. 
71
Expecting all GM crops developed hence forth not to contain markers is, however, premature.  
Putative novel risks associated with any of these methods have to be weighed against alternatives, 
such as the use of a selectable marker that remains in the crop.  In some cases, an established 
method may deemed to be preferable to a new method, even if it allows a reduction of the 
introduced DNA.  Many of the methods that promise marker gene elimination still require 
improved protocols before they can be routine deployed in research and development.  Patents 
restrict access to the sufficiently effective methods, such as co-transformation.  The choice of the 
transformation method should consider the relative safety, cost effectiveness, accessibility, and 
regulatory and public concerns associated with new methods compared to currently used 
methods, while research on such methods is encouraged. 
Design of inserted DNA 
Avoiding the use of DNA fragments that may be transcribed and translated in microbes greatly 
reduces the possibilities of realising any hazardous effect.  Selection of appropriate promoters and 
transcription termination signal sequences is required in order to avoid recombination events; if 
the recombinant DNA may be transferred from a GM crop to a virus or a microbe, the presence of 
multiple virus or microbe-derived DNA sequences on the recombinant DNA may foster genetic 
recombination between types of DNA that might never have occurred in nature.  Gene regulatory 
elements maximising transcription levels of introduced genes may not always be desirable, as 
they may also influence expression of genes adjacent to the inserted DNA. 
4.4 Conclusions  
Gene transfer between organisms is common in nature and has been a driving force in evolution.  
There is no inherent risk in the transfer of DNA between organisms.  The relative risk of gene 
transfer of recombinant DNA from GM crops to microbes or human cells has to be evaluated with 
respect to the relative risk of a similar event occurring in nature.  The potential impact largely 
depends on two factors: first, on the function of the transferred DNA in the recipient cell; and 
second, on whether the recipient cell may have acquired the same gene from a source other than 
the GM crop. 
We deem the risks of gene transfer from GM crops that are currently commercial negligible.  
Transfer to microbes by transformation is a possibility, but only consequential if a new trait is 
expressed and confers selective advantage.  Uptake of GM crop-derived DNA, including the 
transgenes by human cells of the gut or the immune system, cannot be ruled out; it is, however, 
very unlikely that transgenic DNA is stably integrated in somatic cells or taken up in germline 
cells.  Even if it should be taken up, the trait conferred by the gene may not be expressed in 
human cells. 
The risk of use of antibiotic resistance markers for selection of transformed plant cells has to be 
judged on a case-by –case basis, considering their frequency of occurrence in bacterial 
populations, the extent of clinical use of the antibiotics to which resistance is conferred, and 
whether the antibiotic is of importance as a last resort. 
We have defined three groups of antibiotic resistance marker genes: those that are suitable for use 
as selectable markers in crop transformation; those whose use has to be assessed on a case-by-
case basis for individual products, and those whose use presents an unacceptable risk or 
uncertainty to potentially undermine the therapeutic value of specific antibiotics.  We recommend 
that antibiotic resistance markers that have been assigned to Group I, such as the nptII gene and 
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the hygromycin resistance gene, can be used without the risk of compromising human or animal 
health. 
The transformation strategy and the recombinant DNA for insertion into the GM crop should be 
designed with care.  Guidelines on best practice recommend minimising recombinant DNA 
sequences transferred to GM crops in order to simplify the molecular characterisation and reduce 
uncertainty on potential genetic rearrangements and unstable gene expression.  Agrobacterium-
mediated gene delivery is considered the most controlled gene delivery system that facilitates 
obtaining GM crops with single, simple, and hence minimal inserts.  The design of recombinant 
DNA transferred to GM crops should minimise the risks of DNA sequences that might foster 
independent transfer, expression of the DNA in microbes or viruses, and recombination in 
bacterial or viral genomes, where possible. 
We encourage further research and development on transformation methods and methods for the 
elimination or replacement of selectable markers, in particular in the public sector.  Public access 
to such methods is important.  Improvements in methods for crop transformation aim at 
simplifying the safety assessment of GM crops by reducing the introduced recombinant DNA in 
GM crops to a minimum.  The risks, costs, and benefits of established and potential new 
transformation technologies, however, should be systematically compared before novel 
technologies are officially recommended for broad adoption in product development. 
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CHAPTER 5 
DETECTION AND TRACEABILITY OF GMOS IN THE FOOD PRODUCTION CHAIN 
The EU Regulation (EC) No 178/2002 on General Principles of Food Law (henceforth the 
General Food Law) establishes general provisions for the labelling of foods and the principle of 
traceability at all stages of the production and distribution chain in the food and feed sectors.  
Provisions in the General Food Law are that labelling and product presentation should allow 
consumers to make informed choices and that consumers shall not be misled.  The European 
Commission’s labelling policy provides for consumer information on changes in food due to 
production processes, even if such changes may not impact human health.  The European 
Commission Directorate General for Health and Consumer Protection (DG SANCO) considers 
provision of consumer information and choice through labelling and product information 
important to re-establish consumer trust in the EU food safety system after the BSE and other 
food safety crises.
In July 2003, the Council of Ministers adopted Regulation (EC) No 1830/2003 concerning the 
traceability and labelling of GMOs and the traceability of food and feed products produced from 
GMOs.  According to the new regulation, labelling shall be process-based: even highly refined 
oils that do not contain detectable traces of recombinant DNA or novel protein from GMOs, and 
hence are not materially distinguishable from other oils not derived from GMOs, will need to be 
labelled.  A system of traceability of GM crops at all stages of the food production and 
distribution chain is required to facilitate product recall in times of a crisis and the control and 
verification of labelling claims. 
Prerequisites for the implementation of the new labelling and traceability provisions include the 
establishment of systems for documenting the distribution of individual GM crops in the agro-
food chain, as well as analytical methods for verification of this information.  Sampling and 
detection methods for verification of the presence or absence of GM crops require qualitative and 
quantitative approaches.  Qualitative detection methods are required either for high-throughput 
screening of large quantities of samples or distinguishing approved from non-approved GM 
crops.  A specific area of concern is linking traceability systems across countries and between 
businesses, as food is exported and imported.  The development of such methods requires 
reference materials and product information for all individually transformed GM crops that are in 
development or commercialised anywhere in the world.  The implementation of labelling and 
traceability systems hence clearly requires more than just technical tools: international 
agreements on issues relating to detection and traceability are called for. 
In this chapter, we take a critical look at where the scientific community stands in the 
development of prerequisites to meet the standards for implementation of this regulation.  This 
chapter discusses currently agreed thresholds of levels of GM crops that trigger the labelling 
requirement, sampling, the development of detection methods, and systems for information 
management and international agreements required for international traceability systems in turn. 
5.1 Thresholds 
Quantitative detection of GM crops in food products is necessary to verify compliance with 
current legal provisions on the 1% threshold of adventitious presence that is deemed acceptable 
traces of approved materials in foodstuffs that are not labelled.  The recently adopted Regulation 
(EC) No 1830/2003 concerning traceability and labelling of GMOs allows for the presence of up 
to 0.9% for GM crops that are approved for import into the EU in food and feed items.  For GM 
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material which has benefited from a favourable opinion from the Community Scientific 
Committee(s) or the Authority, a threshold level of 0.5% will apply for adventitious or technically 
unavoidable presence.  Standardised and validated scientific methods are therefore required for 
obtaining representative samples and qualitative and quantitative detection methods for GM crops 
in diverse foodstuffs, including commodities and processed food products. 
These very low thresholds present a significant challenge to the implementation of labelling 
requirements: sampling steps and quantitative detection methods should have high resolution to 
reduce variance even at such low levels of content. 
5.2 Sampling 
A very important part of the accuracy of the quantitative detection of GM crops in diverse foods, 
including commodities and processed foods, depends to a large extent on the sampling protocol.  
Since in most cases, GMOs are non-uniformly distributed in the bulk food, the variance of GM 
content across samples will likely represent the major contribution to the overall variance 
observed in quantitative detection.  In general, sampling strategies have to take a wide variety of 
parameters into account, such as the nature of the sample for analysis, including the proportion of 
the different GM crops and non-GM crops and their distribution in the bulk.  The requested level 
of reliability of the sampling plan depends on the current regulatory threshold level for the 
adventitious contamination.  Sampling errors are strictly associated with the evaluation of both 
the risk for the consumer, defined as the acceptance of lots above predetermined limits, and the 
risk for the producer, defined as the rejection of lots below legal limits.  Consequences of error in 
sampling procedures and hence quantitative assessment of the GM content of foods or 
commodities can lead to false negatives and false positives: product lots above the GMO-content 
threshold may enter markets unlabelled, and product lots where adventitious contamination 
results in a GM content below the specified threshold may need to be labelled.  Therefore, the 
adoption of reliable sampling procedures and the definition of the error related to the sampling 
procedures are very relevant for all parties involved. 
Diverse sampling plans are currently available for bulk products with only some of them 
specifically designed for GM crops.  Recently, the European Network of GMO Laboratories was 
installed.  One of the first tasks of this European Network is to develop definitions of sampling 
and detection errors and approaches for statistical analysis that can be implemented across the 
agro-food chain.  Given the significant administrative burden from the implementation of current 
labelling legislation and standards on governments and producers, ENTRANSFOOD 
recommends to develop diversified sampling plans, more stringent plans for those cases where 
the safety of the food supply is at stake, and more lenient sampling regimes for other cases. 
5.3 GM crop detection and identification methods 
The detection of GM crops represents a relatively new area of diagnostics; public and private 
sector engagement in this area of research has increased rapidly since the implementation of the 
first labelling requirements based on the detectability of recombinant DNA and proteins from GM 
crops.  Rapid high-throughput methods for DNA and protein methods based on micro-array 
technologies are being developed.  Prerequisites for the development of reliable detection 
methods are: access to information on all globally marketed GM crops, their inserted recombinant 
DNA sequence, and reference materials, as well as international co-ordination and inter-
institutional ring-testing for the methods’ validation. 
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Methods for the detection of GM crops in commodity shipments or processed foods rely on 
identifying recombinant DNA or recombinant proteins (see Figure 5-1).  Protein-based detection 
methods have been developed and validated only for very few GM crops.  Principally, many 
methods that focus on fractionation, separation, and profiling of proteins and peptides, such as 
iso-electric focusing, affinity chromatography, and one- or two-dimensional separation 
approaches, might be applicable to the characterisation of GM crops when compared to the 
parental non-transgenic line.  Unfortunately, the resolution is often not sufficient or resolved 
patterns are too complex to clearly distinguish a novel GM crop-derived protein from the protein 
pattern of its conventional counterpart.  Several limitations are envisaged for quantitative 
determinations of protein-based methods.  Since expression levels of introduced traits are tissue-
specific and developmentally regulated, protein levels in unknown samples hardly can be 
compared to those in the reference material used, and an accurate statement is only possible if 
sample matrices are identical to the reference material or if matched standard materials or 
standards that have been validated for the matrix are available.  It seems therefore likely that the 
quantitative assessment of the GM crop component will be primarily done by DNA-based, rather 
than protein-based approaches. 
At present, the most commonly used DNA based methods involve amplification of a specific 
DNA with the PCR technique.  Real-time PCR is the most commonly used technology for 
(subsequent) quantification of the GM crop content.  The amount of product synthesised during 
the PCR is measured in real-time by detection of the fluorescence signal produced as a result of 
the amplification.  Also, new methodologies for DNA-based detection of GM crops have been 
developed in the past few years, one of the most important developments being the use of the 
micro-array technology.  The main principle of the micro-array technology is miniaturisation.  
Standard molecular biological or other biochemical methods can be performed on a much larger 
scale in much smaller volumes.  This makes it possible to analyse samples not just for the 
presence of an individual or a selected group of transgenic or control genetic elements, but to 
extend the analysis to thousands of probes in a single hybridisation experiment.  Increasingly 
sensitive micro-array systems are being developed in order to allow the detection of few genetic 
elements within the plant’s entire genome.  To increase the sensitivity, new array systems are 
currently in development.  An example of a promising new development in this area is the 
electro-array system where the fluorescently labelled negatively charged DNA fragments are 
guided to individual spots that are positively charged in order to increase the rate of hybridisation 
events.  Other systems increase the surface where hybridisation may occur considerably by using 
three-dimensional spot structures, reducing the risk of steric hindrance at the same time, such as 
gel-based DNA chips, or make use of mass spectrometrical methods based, for example, on the 
Matrix-Assisted Laser Desorption/Ionization Mass Spectroscopy-Time of Flight principle to 
analyse large biomolecules like proteins, but also oligonucleotides. 
Methods must be validated, quantitative (with little uncertainty or error), and high-throughput, as 
well as allow for distinction of different transformation events of the same crop with the same 
trait.  Only few of the available detection methods have so far been validated in a collaborative 
trial according to international harmonised protocols (cf. EC-JRC, 2003).  In future, methods will 
have to be harmonised internationally.  Several European and worldwide collaborative trials have 
been organised and draft European standards by the Centre Européen de Normalisation (CEN) 
and international standards of the International Standards Organisation (ISO) are already 
available.  The number of GM crops for which methods are available in these draft standards is 
very limited.  In this context, the role of the European Network of GMO Laboratories will be 
crucial from an EU perspective. 
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Figure 5-1 GMO detection methods 
1. Protein-based GMO detection methods 
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A key issue in deliberations on international standardisation of methods will be the determination 
of criteria for method validation, method acceptance, and test reports.  The starting point could be 
a currently constituted working group of Codex Alimentarius Commission (Codex Committee on 
Methods of Analysis and Sampling) where minimal requirements for the evaluation of data will 
be agreed.  The recently adopted EU legislation on food and feed derived from GMOs addresses 
the need for reference materials and sequence data: applicants proposing to place a GMO on the 
market are required to supply reference materials and a detection method to the European 
Commission.  However, the specifications on the types and quantities of materials required, the 
timeframe in which materials shall be made available, and the type(s) of detection methods 
requested are still being defined.  At present, these issues are being discussed in various fora, 
including the European Network of GMO Laboratories. 
The results of recent research projects and activities in the framework of the European Network 
of GMO Laboratories have demonstrated that several of the major challenges identified three to 
four years ago can or have been solved.  For instance, detailed characterisation of the 
transformation event at the sequence level is possible and has been demonstrated for a substantial 
number of GM crops.  However, homo- and hetero-zygous, as well as di-, tri-, and poly-ploid 
lines will yield divergent quantitative estimates of the GM crop content using any known 
molecular detection method.  It is also very unlikely that the DNA content per weight unit of 
grains or processed foods produced from different lines is the same, also when they have been 
subjected to different handling conditions.  The analytical steps from sampling to extraction of 
the sample for analysis (DNA or protein) are believed to contribute most to measurement 
uncertainty in the final quantitative estimate of the GMO content. 
Over one hundred different transformed food crops have been authorised for food and/or feed use 
globally.  And this is only a fraction of GM crops under development and in field trials.  As a 
result of GM crop production and the number of field trials increasing worldwide and seen 
against the background of the large-scale trade of agricultural goods between countries and 
continents, a co-mingling with unauthorised GM crops cannot be excluded.  Several cases have 
been reported of GM crops authorised elsewhere, but not in the EU, present in batches grown or 
marketed within the EU.  Authorisation requires risk assessment and approval under EU law.  
Validated methods to routinely detect or quantify the presence of unauthorised GM crops will not 
be available in the near future, especially since there is rarely access to sequence information and 
reference materials.  To overcome this problem, deposition of sequence information and reference 
materials would need to be co-ordinated internationally. 
At present, the lack of tools for detection of diverse GM crops released into the environment 
poses significant challenges for the food industry to comply with EU labelling legislation.  
Enforcement of the law is equally difficult.  Furthermore, EU law requires separate registration of 
seeds in which two different traits obtained by genetic modification (such as insect resistance and 
herbicide tolerance) have been combined by breeding.  Enforcement of this requirement would 
also require sampling detection methods that can distinguish between two traits that were stacked 
into one seed by breeding and two seeds of which each contains one trait.  In the analysis of 
commodity shipments that may contain both types of seeds (single trait and stacked trait seeds), 
drawing such distinctions is impossible with current detection methods. 
Regulatory compliance difficulties exasperate market risks from adoption of agricultural 
biotechnology, as food products that inadvertently contain unapproved GM crops (that were 
approved outside of the EU), or that have been inadvertently mislabelled, may need to be 
withdrawn from the market.  Given uncertainties on who is liable and which of these types of 
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damages are insurable, these laws have direct unfavourable repercussions on the adoption of 
agro-biotechnology in the agro-food chain. 
5.4 Traceability systems 
The General Food Law establishes the principle of traceability at all stages of the production and 
distribution chain in the food and feed sectors.  The objective of these general traceability 
provisions is to facilitate targeted individual withdrawals and/or to provide appropriate 
information to consumers or control officials.  Establishment of a system that allows to trace back 
to the origin and to understand the distribution of foods requires agreement on at least three of the 
system’s elements: each product must have a unique identifier (a bar code, lot identification 
number, or container identification marking in case of commodities); guidance must be given on 
what specific information is recorded; and all points in the production and distribution chain at 
which this information is recorded must be reliably linked.  Audits for verification of the 
implementation of the system are also required. 
Regulation (EC) No 1830/2003concerning traceability and labelling of GMOs contains three 
main provisions: operators shall have in place a system and procedures to identify to whom and 
from whom products are made available; operators shall transmit specified information 
concerning the identity of individual GM crops that a product contains or whether it is produced 
from GM crops; and operators shall retain specified information for a period of five years and 
make it available to competent authorities on demand.  The regulation does not specify means to 
transmit and retain this information as the European Commission, in the regulation's introduction 
on context to the law, holds that existing systems to do so are already in place in many 
organisations. 
The regulation’s three objectives, in-line with the General Food Law, are to facilitate withdrawal 
of products should an unforeseen risk to human health or the environment be established; targeted 
monitoring of potential effects on human health or the environment, where appropriate; and 
control and verification of labelling claims.  The first objective of allowing effective recall 
procedures through product tracing can prevent excessive economic losses and/or brand damage.  
The recent costs exceeding 1 billion US$ incurred through recall of food products that potentially 
were contaminated with StarLink™ maize and resulting calls for non-transgenic maize supplies 
demonstrate that the lack of mandatory traceability requirements imposed on all operators in the 
chain can result in larger than necessary costs associated with loss of trust in the system. 
The second objective to facilitate monitoring will only apply to certain future transgenic 
organisms with attributes that may lead to defined potential health or environmental impacts that 
can be monitored.  One example would be GM crops that are nutritionally enhanced and identity-
preserved.  Requirements in the regulation do, however, not suffice to allow for post-market 
monitoring for potential health impacts of GM crops.  Where this might be deemed necessary, 
additional measures to follow the distribution and consumption of foods that contain the GM 
crops would need to be implemented.  This will, in some cases, require transmission of specified 
information for individual GM crops, which is, however, not mandatory under this regulation. 
The third objective is to minimise the burden in terms of testing and sampling of operators.  The 
provision of paper or electronic information on whether transgenic material is present in a food is 
one way to minimise current testing practices carried out in the European food industry to comply 
with current food labelling provisions.  Sampling and testing for transgenic organisms is mainly 
required for analysis whenever reliable documentation is not available from exporting countries 
and for control and inspection purposes.  The regulation foresees that the Commission will 
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develop guidance on sampling and analysis in order to minimise legal uncertainty and alleviate 
the burden in terms of testing and sampling of operators.  Since the first generation of GM crops 
arrived on the market, the request for non GM crop-derived products has increased in several 
parts of the world, such as in Europe and Japan, and traceability of GM crops is at this moment 
mainly related to informing the consumer of the absence of GM crops from specific conventional 
or organic products. 
We recommend considering whether additional testing for verification of claims on GM crop 
content should not only be carried out at critical control points in the food supply chain.  In some 
cases, paper-based or electronic traceability systems may be adequate (Figure 5-2). 
In order to develop an international system of traceability across food production, processing and 
distribution that takes account of imports and exports of commodities, and processed food 
products, international co-ordination and agreement on these issues is required.  Therefore, the 
adoption of the proposed regulation on labelling and traceability will have considerable impact on 
the food and feed chains both at European and at international level.  The Codex Alimentarius 
Commission has therefore recently taken the leadership in the negotiations on definition of 
standards and guidelines on international systems of product tracing.  It is evident that the more 
marked the differences in regulation of GM crops worldwide in terms of provisions for labelling 
and number of authorised events will be, the more the impact on the trade of food and feed 
products will be; this will in turn affect implications and costs of traceability at country level.  
Diverse labelling provisions and standards across jurisdictions enhance the risk of non-
compliance with laws, and the situation of who is accountable for and liable for the resulting 
damages and financial losses is far from resolved.  Diverse regulatory approaches reduce the 
predictability of such risks and contribute to making insurers apprehensive of insuring such risks. 
5.5 Conclusions  
European labelling and traceability legislation has been established in part as a response to 
consumer concerns and undermined confidence in the food safety system. 
Although some progress has been made to develop detection methods and institutions supervising 
method development and testing, there are significant technical and political questions that must 
be addressed before current regulatory requirements can be implemented.  Crucial for the 
development of any GM crop detection method is the availability of DNA sequences specific to 
the genetic modification, as well as the relevant reference materials.  This information is needed 
for both EU-approved and non-approved GM crops, requiring global exchange of information of 
individual transformation events on the market and in development.  The establishment last year 
of the European Network of GMO Laboratories is an important achievement towards this goal, 
but much work remains to be done in a global perspective. 
Appropriate sampling schemes for bulk loads where GMO-derived materials may be mixed in a 
very heterogeneous way will require the analysis of large numbers of samples per load.  
Reliability and costs of the two steps of the sampling and testing are crucial factors for the 
traceability of GMOs in this respect.  Future improvements in detection methods and sampling 
plans to optimise traceability systems can be established once agreement is reached at the 
international level in relation to the availability of information and reference materials of GMO 
events on the world market and in development. 
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Given the burden on administrations and producers, ENTRANSFOOD recommends developing 
diversified sampling plans, more stringent plans for those cases where the safety of the food 
supply is at stake, and more lenient sampling regimes for other cases. 
Appropriate traceability and segregation systems may reduce the necessity for stringent sampling 
schemes.  The possibility to detect deviations from the documentation in traceability systems 
may, besides the administrative burden of the documentation itself, require additional measures 
such as storage of backup samples and additional testing.  An appropriate traceability strategy for 
all GMOs in the food supply chain for the purpose of post-marketing surveillance will require 
new labelling and information transfer systems.  It will be necessary to not only have the 
information on the label that GMO-derived materials have been used for the production of the 
food entity, but also which GM events composed the individual ingredients and to what extent. 
We recommend considering whether additional testing for verification of claims on GM crop 
content should not only be carried out at critical control points in the food supply chain.  In some 
cases, paper-based or electronic traceability systems may be adequate. 
At present, the lack of tools for detection of diverse GM crops like, for instance, crops with 
stacked genes poses significant challenges for the food industry to comply with EU labelling 
legislation. 
Traceability represents a valuable tool to face problems related to the introduction of GMOs in 
food and feed chain and to gain the confidence of the consumer toward this novel food.  It is 
clear, however, that the implementation of any suitable system implies a substantial increase in 
overall cost of food production that will have to be absorbed by both producers and consumers.  
This holds true unless a traceability system also helps to save on current costs, such as their use as 
a tool for more effective inventory- and supply chain management. 
The challenge to regulators will be to apply these efforts in the different GMO-related areas, to 
bundle the expertise, to expand information exchange systems outside the EU, and to come to 
optimal regulations and standards to suit all stakeholders in order to combine the guarantee of a 
safe food supply with the consumers’ right to informative labelling of food products in the 
marketplace. 
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CHAPTER 6 
SOCIETAL ASPECTS OF FOODS DERIVED FROM GM CROPS 
6.1 GM foods and the public: What has happened in the past 
The first major controversy associated with gene technology in Europe took place in the late 
1980s.  At this time, there were no products actually being sold to consumers.  In 1996, 
controversy over gene technology was triggered by the arrival of GM soybeans at European 
harbours.  The soybeans, coming from soy plants genetically modified to resist the herbicide 
Round-Up, represented the first large scale marketing of GM foods in Europe.  Other applications 
of biotechnology soon followed: events, such as the attempted commercialisation of GM maize 
and other commodities, focused public attention on transgenic crops, as did other biotechnology 
applications, such as animal and human cloning. 
The result of these events has been to focus public attention on the emerging biosciences more 
generally, and on GM foods in particular.  The public debate has resulted in the formation of non-
governmental organisations (NGOs) with explicit interest in debating the issues associated with 
the emerging biosciences.  There are also increased demands for public participation in the debate 
about regulation and science, and the rise of the “consumer citizen” who expresses acceptance or 
rejection of GM products through purchase decisions.  Understanding societal responses to GM 
foods is important if the public and science are not going to disagree about how to proceed with 
the introduction and commercialisation of new technologies in the future. 
6.2 Public acceptance or rejection of GM foods 
Public attitudes and risk perceptions 
In a democratic society where choice exists, people will not consume foods that they associate 
with some negative attribute.  Various factors may contribute to consumer concerns, for example 
harm to the environment as a result of agricultural practices, or perceptions that there is 
uncertainty associated with unintended human or animal health effects.  Ethical concerns about 
production processes are also important.  Some technologies may also be described as 
"transformative", as they have potential consequences for the way in which society is organised.  
An example might be human genetics, where some people believe that people with certain genes 
may become unemployable.  For this reason, considerable effort has been directed towards 
understanding people’s attitudes towards the applications of biotechnology, such as GM foods. 
6.3 Risk perception and behaviour 
People’s responses to different risks are socially constructed.  In other words, people's 
perceptions about a hazard influence people’s responses to it.  Research by Paul Slovic in the 
United States and elsewhere has consistently demonstrated that the technical risk estimates 
traditionally provided by experts do not influence people’s behaviours and responses in the same 
way as their risk perceptions.  For example, a risk that people perceive to be involuntary in terms 
of personal exposure is more threatening than one that that is perceived to be voluntary, even if 
the probability of harm is the same, or possibly even less.  People also tend to regard naturally 
occurring risks are less threatening than hazards that are technological in origin, and they fear 
potentially catastrophic hazards more than those that affect a similar number of individuals, but at 
different times.  Other concerns are very specific to particular hazard domains, such as food 
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safety.  Public perceptions of risk have often been dismissed on the basis of “irrationality”, and 
have tended to be excluded from policy processes by risk assessors and managers. 
Many different methodologies have been adopted to understand what consumers think about GM 
foods.  These have included opinion polls that aim to gauge the absolute level of favour or 
disfavour in the general public across different cultural and demographic groups (for example, the 
Eurobarometer surveys, published by the European Commission, see 6.5), to qualitative 
investigations involving in-depth interviews with consumers.  One factor that has emerged as 
being of great importance in understanding public acceptance of GM foods has been that of trust, 
whether in regulatory institutions and the motives of scientists, or in information about the risks 
and benefits of particular technological applications of science and technology.  The issue of trust 
appears to have wider application to the acceptability of risk management activities, as well as 
social policy more generally.  Trust will be considered in the context of the emerging biosciences 
applied to food production in the next section. 
Trust in risk regulation and risk management 
There is much debate about the need to increase public confidence in regulation and risk 
management, particularly in the context of established and emerging technologies.  Early efforts 
at science communication have demonstrated that simply conveying factual information about the 
risks and benefits of genetic modification (or indeed other technologies and technological 
practices) is unlikely to result in consumer acceptance of the products of these technologies.  
More recent attempts to include public perspectives in a direct way within risk policy frameworks 
begin to assume equality from the public and scientific experts in terms of inputs into 
deliberations on risk management.  Approaches to improving public confidence in risk 
management processes have included reassessing the way in which risks are managed by 
regulatory institutions and bodies.  Such attempts may focus on increased transparency in 
regulatory practice (increased tendencies to hold meetings of scientific advisory committee 
meetings in public, for example) and increased public participation and consultation in regulatory 
decision-making.  The extent to which increased public participation has an effect on public trust 
in scientific processes and regulatory processes is, however, largely unevaluated. 
6.4 Trust in institutions and information sources 
Understanding the importance of role of trust has resulted in substantial effort made by some 
governments, regulatory bodies, and other key stakeholders to direct resource to increasing 
transparency in decision-making processes.  One effect of this has been to open weaknesses in 
technical practices to public scrutiny (for example, in the case of the different uncertainties 
associated with risk assessment), increasing the need to develop more effective approaches to risk 
communication.  At another level, there are increased demands to change institutions, to facilitate 
more socially inclusive decision-making processes per se.  At both levels, the issue of increasing 
and maintaining public trust and confidence in institutional, scientific, and industrial practices is 
highly relevant to the future commercialisation of GM foods, as well as other technological 
innovations. 
6.5 The Eurobarometer results 
Five Eurobarometers have been conducted in the last decade to gauge the overall level of 
consumer attitudes towards biotechnology in the European Union (Eurobarometers 35.1 in 1991, 
39.1 in 1993, 46.1 in 1996, and 52.1 in 1999, Eurobarometer 55.2 in March 2002, - Europeans, 
science and technology).  The survey Eurobarometer 52.1 (European Commission, 2000) asked 
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approximately 16,000 European citizens to indicate their attitudes towards GM foods (Figure 6-
1).  Participants indicated how useful, risky, or morally acceptable different applications were, 
and whether their development should be encouraged.  Consumer attitudes tend to be more 
positive about the “first generation” of GM foods, and more negative about the “second 
generation” of products.  When compared to the results of the previous Eurobarometer survey 
(46.1 in 1996), consumers’ attitudes to both generations of GM foods have become more negative 
in terms of usefulness, moral acceptability, and whether the technologies should be encouraged, 
but have remained constant regarding risk perception. 
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Figure 6-1 Attitudes of Europeans to GM foods (data source: Eurobarometer 52.1). 
Consumer concerns 
Interviewing and focus groups have been used to understand consumer concerns.  Concerns 
identified in these studies ranged from more or less concrete unintended effects, such as out-
crossing and development of super-weeds, to worries prompted by concerns about unintended 
effects on human health and the environment, and the potential irreversibility of any negative 
impact.  Subsequent qualitative and quantitative research has elucidated the details of moral 
concerns related to GM foods, highlighting issues like unnaturalness, “tampering with nature”, 
animal welfare, the power balance between producers and consumers, democracy, and disparity 
between the industrialised world and the third world. 
The range of concerns voiced by consumers is remarkably constant over fields of applications.  
Some of these concerns are intrinsic to the technology itself.  Others appear, in part, to be 
expressions of worries about risks.  Perceived unnaturalness is one such example.  On the one 
hand, it appears as an expression of a fundamental concern over human interference with "the 
Order of Nature".  On the other hand, unnaturalness can also be an expression of concern about 
86
risk - people defending this view believe that there are inherent safety mechanisms present in 
nature and natural processes.  Another finding of recent research is that, although the public is 
concerned with the outcomes of technical risk assessments, they are also concerned about the 
uncertainty related to these outcomes.  People may suspect that risk assessments are based on an 
insufficient level of scientific knowledge. 
Public acceptance of particular applications of genetically modified foods 
The supposition that risk perceptions may be offset by perceptions of benefit has led many 
stakeholders to assume that if a particularly desirable benefit can be developed in the context of 
GM foods then public acceptance will result.  Problematically, how the public defines risk and 
benefit, and how the experts define the same issues, may be very different.  Furthermore, the 
public is not homogenous with respect to their opinions and attitudes.  Differences in perceptions 
of risk and benefit associated with various hazards exist between different countries and cultures, 
between different individuals within countries and within different individuals at different times 
and within different contexts.  The food industry will need to predict what kind of GM products 
will be acceptable as well as beneficial to consumers. 
Public demand for information about genetically modified foods 
A clear message from technical experts regarding risks and associated uncertainties, including the 
nature and extent of disagreements between different experts, is helpful.  In order to communicate 
this information to the public, decision-makers must themselves be aware of uncertainties 
associated with risk assessments, and should therefore have an interest in supporting research to 
further understand and reduce uncertainties, as well as communicate information about this 
activity to the public.  Research has shown that public distrust in regulators, scientists, and 
industry is increased if people perceive there to be any uncertainty associated with a particular 
hazard being hidden by these institutions.  There is evidence that regulators and industry have, 
until recently, assumed the converse to be true – that admitting uncertainty will fuel public 
distrust in their risk analysis activities! This perhaps explains why public distrust in risk 
assessment and risk management has continued to increase in recent years.  In the case of GM 
foods, it is important to communicate information about potential unintended effects on human 
and animal health, and the environment, as well as information about what is being done by 
scientists and regulators to reduce this uncertainty.  Examples might include the introduction of 
novel allergens into food for human consumption, or examples of potential environmental impact 
(for example, the case of the monarch blue butterfly in the United States). 
For many consumers, labelling is a primary source of information about a food product.  From 
this, one might deduct that the large majority of European consumers would prefer to have 
information about GM foods available, and an overwhelming majority wants to be able to make 
an informed choice, necessitating the labelling of GM foods.  Moreover consumers expect an 
assessment of known or potential risks and a precautionary management of these risks before a 
GM food is granted approval for marketing in the European Community. 
The issue of traceability of genetically modified foods and ingredients
As part of the ENTRANSFOOD network, an empirical investigation into the needs of consumers 
regarding the labelling of GM foods and food ingredients was conducted in three European 
countries, Italy, Norway, and England.  Participants did not believe that a labelling strategy for 
foods containing GM ingredients could be effective unless accurate traceability mechanisms are 
developed.  Otherwise, there would be no way of identifying where such ingredients are actually 
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located within the food chain.  People in all three countries wanted “clearer labelling of 
genetically modified foods on food packaging”.  People approved of enforcing ingredient 
traceability once they were made aware of its potential.  The results indicated that public distrust 
in GM foods is, in part, driven by lack of personal control over exposure to products, together 
with reduced opportunities for consumer choice over consumption.  Inability to trace GM foods 
from field to table will act to reduce public confidence in food safety.  Failure to implement an 
effective traceability strategy for GM foods and ingredients may have a negative long-term 
impact on consumer confidence in safety, particularly in the current climate of consumer distrust 
in food safety, science and risk regulation. 
An alternative view is that, as cross-contamination may also occur between GM and non-GM 
plants, cross-contamination will occur in the fields and so all foods must be labelled as 
genetically modified – in this case, of course, improved traceability is unlikely to make any 
difference to consumer confidence and acceptance. 
6.6 Public participation as a way forward 
It is often argued that decisions over gene technology should be left to the free market, in so 
much that consumers can choose to buy, or not buy, GM products.  This argument, however, 
ignores some structural barriers that prevent “the market” serving as a conveyer of democratic 
decisions.  These barriers include factors related to gene technology per se, as well as 
assumptions concerning relations between the market and the consumer. 
6.7 The public and policy development 
Some people have argued that the concern over GM foods reflects the failure of the authorities 
and industry to take due account of what was driving public concern.  Thus the motives of those 
developing the framework appeared suspect and unconcerned with public and environmental 
welfare.  Failure to take account of societal concerns associated with emerging technologies may 
jeopardise the legitimacy of the regulatory framework and regulatory agencies with responsibility 
for developing that framework.  Similarly, the public may also cease to trust industry, which may 
be perceived to be protecting a vested interest in developing self-regulation regarding technology 
implementation.  However, private companies need to commercialise novel products in the 
context of appropriate regulation, particularly in controversial areas like gene technology - this is 
a prerequisite for successful business.  Public authorities, on the other hand, must be accountable 
to secure that the regulation at least to some extent reflects the public views - the alternative being 
a “technocracy” unacceptable in most countries. 
In response to the perceived decline in trust, regulatory bodies have increasingly stressed the 
importance of transparency in decision making processes, as well as developing mechanisms in 
order to understand the concerns and values of the general public.  One outcome has been an 
increased interest in participatory procedures to involve the public in the decision making process 
in some way.  This development has in turn led to a growing interest in funding social scientific 
research into understanding public attitudes to technology (as is the case for GM foods). 
There are a variety of pragmatic and ethical reasons for policy-making bodies to involve lay 
people in decision-making on issues in which the public has a stake.  Political theorists and 
ethicists discuss concepts such as democracy, procedural justice, and human rights, in providing 
the moral basis for involvement; but it is now recognised that making decisions without public 
support is liable to lead to public dissatisfaction, dispute, and confrontation.  Failure to involve 
the public is widely assumed to have compromised the legitimacy of governance in policy 
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development.  As a response, there has been increased activity relating to public participation in 
strategy associated with emerging sciences.  Consequently, governmental agencies and 
independent institutions have played a major role in the development of the participatory tools 
that may facilitate this development.  Examples of public engagement exercises in the area of 
genetic modification of food and agricultural crops include those sponsored by the Danish Board 
of Technology (http://www.tekno.dk/index.php3?language=uk), the Rathenau Institute in The 
Netherlands (http://www.rathenau.nl/uk/default.asp), the Agency for Diffusion of Technological 
Information in France (http://www.adit.fr/adit_edition/index.php?page), and the Institute for 
Technology Assessment and Systems Analysis in Germany (http://www.itas.fzk.de/).  Examples 
from the UK have included the Biotechnology and Biological Sciences Research Council 
Consensus on Agricultural Biotechnology (1994), and, at time of writing, the 2003 public 
consultation and debate on the environmental release of GM crops sponsored by the Agricultural 
and Environmental Biotechnology Commission. 
This process continues to be taken forward.  For example, the European Commission has 
emphasised the need to introduce "new institutional relationships and forms" reinforcing the 
process of mutual learning between the public and the scientific community.  In particular, the 
"science and society" agenda identifies the need to change institutional terms of reference and 
procedures, with the development and use of broader, more inclusive public consultation and 
dialogue on risk issues and more transparent institutional processes.  In the case of transgenic 
technologies, the policy community has recognised that public concerns about emerging 
bioethical issues, the potential for unintended effects, and the societal consequences of 
technology applications are liable to affect public reactions to technology implementation.  These 
societal factors need to be taken into account by policy makers if novel bioscience applications 
are to reach the commercialisation stage. 
Despite the implementation of widespread public consultation processes, there has also been 
criticism relating to whether public participation makes a difference.  Questions have been raised 
regarding whether the consultation methods are appropriate, and whether the outputs of 
consultations make any difference to policy development.  There is therefore a need for explicit 
assessment of the impact of public consultation on policy development.  Consulting the public 
will be viewed negatively by society if the information resulting from these processes is not 
incorporated into policy in a transparent and measurable way that can be explicitly evaluated 
against some criteria of successful implementation.  If the output of a public consultation cannot 
be used, the reasons why should be communicated back to participants and the public more 
generally. 
6.8 Conclusions 
Much of the controversy associated with the commercialisation of GM foods has been the result 
of regulatory bodies failing to take account of the actual concerns of the public, which has fuelled 
public distrust in the motives of regulators, science, and industry.  In part, this may be because 
communications about food safety issues (including genetic modification) that are based on 
scientific risk assessments do not reassure the public. 
In the case of GM foods, communication efforts have focused on adverse health effects whereas 
public concern has been much broader, focusing on risk (and risk perception), benefit and need.  
Risk assessment per se does not deal with public concerns.  If public confidence in science and 
technology is to be regained, it is important to explicitly incorporate public concerns into the risk 
analysis process, through developing new and influential methods of stakeholder involvement 
(including consumers) and consultation.  Once public concerns (and the values on which they are 
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based) are understood, they can be more effectively dealt with in risk assessment and risk 
management practices. 
BOX 6-1 
QUESTIONS TO BE ADDRESSED IN FUTURE RESEARCH
 How best should information about what risks are assessed within risk analysis be 
communicated to the public? How can public concerns be incorporated into this process? 
How can effective and inclusive public participation in risk management and science and 
technology policy be developed? 
 What is the best way to involve the public in the debate about genetic modification of 
foods? How can any impact of public participation in policy processes be measured? 
 What changes to institutions need to be made in order to accommodate greater public 
participation? How should they restructure themselves to make it easier for the voice of 
the public to be heard? 
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CHAPTER 7 
CONCLUSIONS AND RECOMMENDATIONS 
The much slower adoption of the technology in Europe demonstrates that rigorous safety 
assessment by scientists and regulators is necessary, but not sufficient, for gaining societal 
acceptance of agricultural applications of biotechnology.  Introducing a new technology in 
society requires awareness of who the stakeholders are and what repercussions there may be for 
each.  ENTRANSFOOD has brought together representatives from academia, research centres, 
biotechnology and breeding companies, food industries, food retailers, regulatory agencies, and 
consumer groups across Europe to address food safety and societal issues of the introduction of 
foods derived from GM crops. 
Five Working Groups under ENTRANSFOOD addressed the following five topics:  Working 
Group 1 on the safety assessment of foods derived from GM crops developed a systematic 
approach how to tailor the safety assessment of GM crops to the specific characteristics of the 
modified crop and the introduced trait.  Working Group 2 on the identification and assessment of 
unintended effects from genetic modification provided an overview on profiling methods and 
approaches that will help our understanding of crop composition, interaction with environment, 
and natural variation.  Working Group 3 on the assessment of risks from gene transfer across 
species placed horizontal gene transfer from plants to humans into perspective of nature’s other 
gene transfer processes, and provided recommendations on best practices for the design of GM 
crops, including on the use of antibiotic resistance markers.  Working Group 4 took a critical look 
at regulation of GM crops including detection, labelling and traceability provisions, standards and 
their implementation, and assessed prerequisites for implementation of current regulatory 
requirements.  Working Group 5 analysed societal aspects of adopting GM crops in the agro-food 
chain, paying particular attention to the merits and limitations of labelling foods derived from 
GM crops to foster their societal acceptance.  The main conclusions and recommendations from 
each working group are reiterated in turn.  After detailing ENTRANSFOOD’s achievements, we 
conclude with an analysis of the limitations of the project’s structure, scope, and outcomes, 
drawing lessons for future multidisciplinary deliberation platforms. 
The safety assessment of foods derived from GM crops 
Safety considerations for foods derived from GM crops are fundamentally the same as those for 
conventional foods.  The safety of widely consumed whole plant-derived foods is a fundamental 
assumption based on a long-term experience and history of safe use, well knowing that such 
foods may contain anti-nutritional or toxic substances.  Uncertainties in this assessment 
associated with unintended changes in plant genomes through the insertion of recombinant DNA 
should always be considered in the light that crop genomes are constantly changing through a 
broad range of natural and man-mediated mechanisms. 
ENTRANSFOOD developed a systematic approach how to tailor the safety assessment of GM 
crops to the specific characteristics of the modified crop and the introduced trait.  The cornerstone 
of the safety assessment of foods derived from GM crops is the concept of substantial 
equivalence.  This concept prescribes the comparison of the GM crop to a suitable comparator 
with a long history of use that allows the identification of any significant differences that might 
impact human health.  These differences then become the focus of further analytical, 
toxicological, or nutritional analyses.  The safety assessment of foods derived from GM crops is 
divided into four steps: characterisation of the parent crop; characterisation of the transformation 
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process; toxicological evaluation of new gene product(s) and allergenicity assessment; and 
nutritional and toxicological/allergenicity evaluation of the GM crop/derived food. 
ENTRANSFOOD recommends the concept of substantial equivalence as the best available 
approach to safety assessment of GM crops.  The concept is widely deployed to guide the safety 
assessment by scientists in governments and firms alike.  Contrary to what the critics say, 
guidelines to its implementation are becoming evermore standardised and detailed.  For example, 
the Organisation for Economic Cooperation and Development (OECD) is compiling consensus 
documents for certain crop species that provide the information considered of most relevance for 
the characterisation of the parent crop.  These consensus documents guide the application of the 
concept of substantial equivalence. 
Discrete substances such as recombinant proteins and metabolites that are newly introduced or 
the levels of which have been enhanced through genetic modification are characterised by 
describing what is known about their structure and function.  Classic toxicological methods were 
originally developed for the safety assessment of chemicals in foods, such as food additives. 
These toxicological methods, including toxicity studies in animals, have been adapted for the 
assessment of recombinant proteins and introduced metabolites. 
Repeated dose studies in laboratory animal species are recommended with recombinant proteins 
or derived substances to identify potential adverse long-term effects (often, but not necessarily, 
over a period of twenty-eight days), unless there is sufficient information to confirm the lack of 
toxicity or pharmacological activity of the recombinant proteins and metabolites, or unless there 
is extensive experience with the compound, for instance due to a history of safe use or prior 
approval for human food consumption based on state of the art toxicological studies. 
The current approach recommended by experts under FAO/WHO and the Codex Alimentarius for 
the assessment of the potential allergenicity of GM foods involves five steps: the characterisation 
of the source organism of the novel protein; the analysis of amino acid sequence similarity of the 
protein and known allergens; study of physico-chemical properties; where the protein is derived 
from an allergenic source organism or where there are other indications of potential allergenicity, 
such as structural similarity to known allergens, these tests are complemented with 
immunological tests and, where deemed appropriate, further investigations.  The possibility of 
changes in the allergenicity of the whole crop should also be considered.  Methods for the 
assessment of the sensitisation potential of proteins need to be improved, such as through the 
development and validation of animal models, to allow the transfer of proteins that might share 
certain structural or physico-chemical characteristics with allergens. 
The comparison of the GM crop to its counterpart relies on a targeted approach of parameters 
indicative of the overall plant metabolism and possible changes from genetic modification that 
might have health implications.  This involves the assessment of composition, physiology, 
morphology, and performance.  Such targeted approaches allow identifying unintended changes 
from the genetic modification.  The focus on key nutrients and anti-nutrients in food crops allows 
for focussing on identification of those changes in food crops that may have implications for 
human health. 
Animal tests with whole foods derived from GM crops are considered to contribute with useful 
information to the safety assessment.  We recommend such tests should only be a requirement in 
cases where the composition of the GM food crop differs significantly from that of its unmodified 
counterpart, or if other tests provide any indications of a potential hazard associated with the 
genetic modification.  In these cases, dietary sub-chronic rat studies (usually, these are of 90 days 
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duration, assessing the classic toxicological endpoints) are recommended to demonstrate the 
safety of the food.  Further standardisation of test protocols for animal feeding trials is 
recommended, in terms of design of the diet, when, how, and how often the diet is administered. 
The described approach to safety assessment is also applicable to new generations of GM food 
crops with extensive compositional changes.  For GM crops that have been modified extensively 
such that there is no single crop that is a conventional counterpart suitable for comparison, all 
new substances or existing substances whose levels have been altered should be assessed on a 
case-by-case basis; safety studies with the whole crop should also be conducted.  The safety 
assessment of GM crops that are intentionally designed to be compositionally different requires 
increased attention to two issues: the choice of an appropriate comparator and the estimate of the 
anticipated exposure.  One example of a compositionally altered GM crop currently under 
regulatory review is oilseed rape that contains lauric acid, a fatty acid not normally found at 
elevated levels in oilseed rape oil.  The product was developed as a substitute for tropical oils (for 
instance, palm oil) in certain food applications.  The comparator with safe use in this case was 
palm oil. 
The issue of long-term effects of the consumption of foods derived from GM crops has been 
addressed by the FAO/WHO Expert Consultation held in 2000, and was endorsed by 
ENTRANSFOOD.  Very little is known about the potential long-term effects of any food, and 
such effects are difficult to assess at the population level, largely due to the complex and 
changeable diets that prevent attributing specific health effects to individual food components, 
and to the genetic variability in the human population.  If repeated dose studies with new proteins 
or metabolites or with the whole GM food would yield indications for potential adverse effects, 
further toxicological and nutritional studies are warranted before market release may be 
considered. 
Post-market monitoring of foods derived from GM crops is not recommended as a routine 
practice.  It is expensive, sequesters scarce resources for studies of health and food, and is 
unlikely to provide meaningful information.  Post-market monitoring might be considered for 
identity-preserved GM crops with changed nutritional characteristics in order to confirm the 
association with a specific health effect: a clear test hypothesis in the form of a causal relationship 
between food intake and health impact must be formulated. 
In summary, it can be argued that the current safety assessment approach allows the 
determination whether foods derived from GM crops are as safe as their conventionally bred 
counterparts; in some cases, GM crops are even better characterised than other non-regulated 
plant-derived foods.  In conclusion, the current regulatory requirements and testing regimes are 
much more rigorous for GM crops than for conventionally bred crops. 
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Working Group 1 Recommendations: 
1.  Studies of the structure of plant genomes, functions of individual genes, and a plant’s 
responses to its environment at the molecular level will improve our understanding of the 
characteristics of food crops that pertain to food safety assessment.  Such fundamental research 
on food crops should be encouraged and publicly funded, as public access to genome sequences 
of food crops is of paramount importance. 
2.  The availability of sequence information of entire plant genomes allows the development of 
micro-array systems to assay induced changes in gene expression patterns.  This might, in future, 
facilitate the assessment of potential unintended effects from the genetic modification, by helping 
to identify potential changes in gene expression in genomic regions that are adjacent to the 
insertion locus.  The interpretation of such data will, however, be challenging, as a greater 
understanding of gene functions and changes in expression levels is required before the safety 
implications of any such change in gene expression can be assessed.  
3. ENTRANSFOOD considers of particular value the development of an animal model that 
would permit the identification and characterisation of potential food allergens.  Progress in this 
area will be facilitated by a more thorough appreciation of the factors that confer to proteins the 
potential to induce allergy and what distinguishes these from non-allergic proteins.  Further 
research on the structure-function relationship of allergens is encouraged. 
4.  Advances in genomics and developments of toxicological methods will improve our 
understanding of health impacts of exposure to various substances in the longer term.  The 
development of genomic expression profiling using micro-array systems prompts research into 
biomarkers that will allow to assay and compare changes in gene expression upon exposure to 
specific toxicants and nutrients in different test systems: e.g. cultured cell lines, animal models, 
and, where appropriate, humans. 
Assessment of unintended effects 
Uncertainties in this assessment associated with unintended changes in plant genomes through the 
insertion of recombinant DNA should always be considered in the light that crop genomes are 
constantly changing through a broad range of natural and man-mediated mechanisms.  
Uncertainty associated with food safety of GM crops is no greater than uncertainty associated 
with conventionally bred crops.  Unintended effects that alter the composition of food crops are 
as likely to occur through natural recombination, mutagenesis approaches used in plant breeding, 
and genetic modification.  Variety selection and the assessment of physiology, morphology, and 
performance for both GM crops and conventionally bred counterparts are sound indicators of 
unintended effects that may potentially impact human health.  Given current regulatory 
requirements specific for GM crops, they are better characterised than the conventional 
counterparts we eat.  The safety assessment relies on a targeted approach of parameters indicative 
of the overall plant metabolism and possible changes from genetic modification.  Such targeted 
approaches have proven to be effective for identifying unintended changes that might have 
implications for human health or the environment. 
The application of genomic, proteomic, and metabolite profiling techniques will contribute to 
improving our fundamental understanding of metabolic and compositional variations of crop 
plants and of potential alterations in gene expression, protein composition, and associated 
metabolic consequences that may stem from different cultivation conditions, breeding practices, 
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or genetic modification.  However, profiling methods are not suitable yet for use in formalised 
risk assessments before sufficient data are available to understand natural variation in different 
gene expression and compositional parameters of crops plants, and before we are able to assess 
whether any observed significant changes in gene expression or composition may impact human 
health.  These methods may already be of great value during the research and development phase 
of GMOs in order to spot potential (intended or unintended) alterations in the composition as 
result of a genetic modification process. 
Working Group 2 recommendations: 
1.  The allocation of public sector research funds to develop our understanding of food crops, 
including analyses using genomic, proteomic, and metabolomic profiling methods, is considered 
important.  We encourage the development and validation of profiling methods, as these methods 
will contribute to improving our understanding of the foods we eat and their potential 
implications for human health.  Such methods will also facilitate the development of GM crops 
with more complex traits such as nutritional enhancement and tolerance to abiotic stresses. 
2.  ENTRANSFOOD also recommends the establishment and interconnection for simultaneous 
searching of international databases on natural variation in gene expression, protein, and chemical 
composition of crops. 
Assessment of risks of gene transfer across species 
Gene transfer between organisms is common in nature and has been a driving force in evolution.  
There is no inherent risk in the transfer of DNA between organisms, since DNA is not toxic.  The 
relative risks of gene transfer of recombinant DNA from GM crops to microbes or human cells 
has to be evaluated with respect to the relative risk of a similar event occurring in nature.  The 
potential impact largely depends on two factors: first, on the function of the transferred DNA in 
the recipient cell; and second, on whether the recipient cell may have acquired the same gene 
from a source other than the GM crop. 
ENTRANSFOOD deems the risks of gene transfer from GM crops that are currently commercial 
negligible.  Transfer to microbes by transformation is a possibility, but only consequential if a 
new trait is expressed and confers selective advantage.  Uptake of GM crop-derived DNA, 
including the transgenes by human cells of the gut or the immune system, cannot be ruled out; it 
is, however, very unlikely that transgenic DNA is stably integrated in somatic cells or taken up in 
germline cells.  Even if it should be taken up, the trait conferred by the gene may not be 
expressed in human cells. 
The risk of use of antibiotic resistance markers for selection of transformed plant cells has to be 
judged on a case-by-case basis, considering their frequency of occurrence in bacterial 
populations, the extent of clinical use of the antibiotics to which resistance is conferred, and 
whether the antibiotic is of import as a last resort. 
ENTRANSFOOD has defined three groups of antibiotic resistance marker genes: those that are 
suitable for use as selectable markers in crop transformation; those whose use has to be assessed 
on a case-by-case basis for individual products, and those whose use presents an unacceptable 
risk or uncertainty to potentially undermine the therapeutic value of specific antibiotics.  
ENTRANSFOOD recommends that antibiotic resistance markers that have been assigned to 
Group I, such as the nptII gene and the hygromycin resistance gene, can be used without the risk 
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of compromising human or animal health.  GM crops developed with the nptII gene and other 
Group I markers should continue to be approved for commercial use in the EU. 
The transformation strategy and the recombinant DNA for insertion into the GM crop should be 
designed with care.  Guidelines on best practice recommend minimising recombinant DNA 
sequences transferred to GM crops in order to simplify the molecular characterisation and reduce 
uncertainty on potential genetic rearrangements and unstable gene expression.  Agrobacterium-
mediated gene delivery is considered the most controlled gene delivery system that facilitates 
obtaining GM crops with single, simple, and hence minimal inserts.  ENTRANSFOOD also 
recommends that the design of recombinant DNA transferred to GM crops should be such as to 
minimise the risks of DNA sequences that might foster independent transfer, expression of the 
DNA in microbes or viruses, and recombination in bacterial or viral genomes, where possible. 
Working Group 3 recommendations: 
1.  ENTRANSFOOD encourages further research and development on transformation methods 
and methods for the elimination or replacement of selectable markers, in particular in the public 
sector.  Public access to such methods is important.  Improvements in methods for crop 
transformation aim at simplifying the safety assessment of GM crops by reducing the introduced 
recombinant DNA in GM crops to a minimum. 
2. The risks, costs, and benefits of established and potential new transformation technologies, 
however, should be systematically compared before novel technologies are officially 
recommended for broad adoption in product development. 
Detection, labelling, traceability of GMOs, and standards for their implementation 
Regulation (EC) No 1830/2003 concerning the traceability and labelling of GMOs and the 
traceability of food and feed products produced from GMOs requires traceability of foods and 
food ingredients derived from GM crops and process-based labelling: even highly refined oils 
that do not contain detectable traces of recombinant DNA or novel protein from GMOs, and 
hence are not materially distinguishable from other oils not derived from GMOs, will need to be 
labelled. 
We consider that current thresholds for labelling requirements for foods containing or consisting 
of GM crops are very stringent and pose challenges for implementation.  Given the significant 
administrative burden from the implementation of current labelling legislation and standards on 
governments and producers, ENTRANSFOOD recommends to develop diversified sampling 
plans, more stringent plans for those cases where the safety of the food supply is at stake, and 
more lenient sampling regimes for other cases. 
Prerequisites for the implementation of the new labelling and traceability provisions include the 
establishment of systems for documenting the distribution of individual GM crops in the agro-
food chain and analytical methods for verification of this information.  Sampling and detection 
methods for verification of presence of absence of GM crops require qualitative and quantitative 
approaches.  Qualitative detection methods are required for high-throughput screening of large 
quantities of samples or distinguishing approved from non-approved GM crops.  Development of 
such methods requires reference materials and product information for all individually 
transformed GM crops that are in development or commercialised anywhere in the world. The 
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European Network of GMO Laboratories was set up for this purpose; a similar system, however, 
needs to operate globally. 
Sampling plans depend on the quality and nature of the detection method that is used and on the 
threshold set.  Appropriate sampling schemes for bulk loads where GMO-derived materials may 
be mixed in a very heterogeneous way will require the analysis of large numbers of samples per 
load.  Reliability and costs of sampling and testing depend very much on the test material in terms 
of the non-uniformity of distribution of GMO-derived material in the sample and the "food 
matrix" from which DNA or the protein have to be extracted for detection. 
At present, the lack of tools for detection of diverse GM crops released into the environment 
poses significant challenges for the food industry to comply with EU labelling legislation.  
Enforcement of the law is equally difficult.  Furthermore, EU law requires separate registration of 
seeds in which two different traits obtained by genetic modification (such as insect resistance and 
herbicide tolerance) have been combined by breeding.  Enforcement of this requirement would 
also require detection methods that can distinguish between two traits that were stacked into one 
seed by breeding and two seeds of which each contains one trait.  In the analysis of commodity 
shipments that may contain both types of seeds (single trait and stacked trait seeds), drawing such 
distinctions is impossible with current detection methods. 
The three specific objectives of legal provisions for traceability are to facilitate withdrawal of 
products should an unforeseen risk to human health or the environment be established; targeted 
monitoring of potential effects on human health or the environment, where appropriate; and 
control and verification of labelling claims.  The fundamental objective is to restore consumer 
trust through providing information and choice.  Traceability of foods and food ingredients, 
including imported foods, also requires, however, the establishment of international systems 
allowing traceability of traded foods.  It is clear that the implementation of any suitable system 
implies a substantial increase in overall costs of food production that will have to be absorbed by 
both producers and consumers.  This holds true unless a traceability system also helps to save on 
current costs, such as their use as a tool for more effective inventory- and supply chain 
management. 
The challenge to regulators will be to apply these efforts in the different GMO-related areas, to 
bundle the expertise, to expand information exchange systems outside the EU, and to come to 
optimal regulations and standards to suit all stakeholders in order to combine the guarantee of a 
safe food supply with the consumers’ right to informative labelling of food products in the market 
place. 
Working Group 4 recommendations: 
1.  Guidelines are required outlining detailed standards for the purity and type of reference 
materials and additional information on the GM crop that needs to be provided. 
2.  Closer collaboration between scientists and legislators, in particular in standard setting, is key 
to ensure agreement on standards that can be implemented and enforced. 
3.  Given the burden on administrations and producers, ENTRANSFOOD recommends 
developing diversified sampling plans, more stringent plans for those cases where the safety of 
the food supply is at stake, and more lenient sampling regimes for other cases. 
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4.  ENTRANSFOOD recommends considering whether additional testing for verification of 
claims on GM crop content should not only be carried out at critical control points in the food 
supply chain.  In some cases, paper-based or electronic traceability systems may be adequate. 
Societal aspects of introducing GM crops in the agro-food chain 
The public framing of questions on risk often differs from the framing of scientists.  For instance, 
there is a concern on potential long-term effects from adopting GM crops.  Whether society 
‘needs’ the technology is also considered important.  Risk assessment does not address these 
issues and does therefore not address public concerns.  If public confidence in the technology and 
its regulation is to be regained, it is important to explicitly incorporate public concerns into the 
risk analysis process, through developing new and influential methods of stakeholder 
involvement and consultation (including consumers).  Once public concerns and the values on 
which they are based are understood, they can be more effectively introduced into innovation 
strategies, risk assessment, and risk management practices. 
Surveys conducted in this project supported that consumer may prefer labelling of products on the 
basis of both process and product characteristics.  Research is needed to determine the most 
effective form for food labels, which take due account of cross-cultural differences in information 
preferences, where they exist. 
Working Group 5 recommendations: 
1. Research is needed to determine the most effective form for food labels, which take due 
account of cross-cultural differences in information preferences, where they exist. 
2.  Other questions for further research on societal aspects of GM foods include:  How can public 
concerns be incorporated into this process? How can effective and inclusive public participation 
in risk management and science and technology policy be developed?  What is the best way to 
involve the public in the debate about genetic modification of foods? How might the impact of 
greater public participation in policy processes be assessed? 
Lessons learnt from ENTRANSFOOD  
Deliberations on consequences from introducing biotechnology in society, beyond mere scientific 
concerns, with representatives from groups that hold diverse sets of values, are a prerequisite for 
technology adoption.  ENTRANSFOOD has provided a platform for such deliberations on food 
safety assessment, regulation, and citizen’s concerns on agricultural biotechnology from a range 
of different perspectives, including public and private sector scientists, regulators, and civil 
society organisations. 
Given the relatively short duration of the project (3 years and extended with 6 months), the 
ENTRANSFOOD project’s scope was to focus research and deliberations on the food safety of -
and societal attitudes to - agricultural biotechnology in Europe.  This scope precluded more 
detailed consideration of three broader themes central to deliberations on adoption of technology: 
the future of farming, food production, and food trade; the process of risk analysis; and diverse 
approaches to regulation and distributional effects of regulation within and across jurisdictions.  
All three themes are central to society’s deliberations on agricultural biotechnology and how its 
introduction should be governed in democracies.  Considering the global nature of the agro-food 
chain, deliberations of each of these themes would benefit from comparing situations in diverse 
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markets and jurisdictions, not just focussing on the EU.  The consideration of ethics and attitudes 
to the technology by groups with diverse sets of values pertaining to nature and technological 
progress are also fundamental to deliberations of each of these three themes.  These aspects, 
central to a more comprehensive assessment, need to be considered in future more comprehensive 
deliberations on the future of agro-food production and agricultural biotechnology. 
Other lessons can be drawn from the ENTRANSFOOD project’s structure and management.  
More interaction and more systematic approaches could have been stimulated to get to underlying 
different values shaping attitudes to technology by ENTRANSFOOD participants with diverse 
backgrounds.  Working Group’s 1, 2, 3, and 4 were populated mainly by natural scientists, 
whereas most social scientists and the permanent representative of consumer groups were 
clustered in Working Group 5.  Participants from WG5 could have contributed to the framing of 
questions and issues considered in other Working Groups.  Timely circulation of draft outputs for 
comments by members of other Working Groups with the objective to identify cross-cutting 
issues, and to frame such issues from diverse perspectives, is crucial. 
Another inherent disadvantage of the ENTRANSFOOD model was the fact that RTD projects 
were brought under the umbrella of ENTRANSFOOD after selection and approval by the 
Commission, which has limited the possibilities to integrate from the beginning to a maximum 
extent the objectives of the research projects into the overall design and objectives of 
ENTRANSFOOD.  The EU 6-th Framework Programme is designed to avoid these 
complications. 
The participation of non-members of ENTRANSFOOD in the Integrated Discussion Platform 
Meetings was very helpful, especially of the invited experts, many of which emphasised the need 
to consider the safety assessment of foods derived from GM crops in the context of food safety 
assessment in general.  The importance of aspects of introducing GM crops in the agro-food chain 
other than food safety was also highlighted. 
Notwithstanding the above mentioned limitations of the ENTRANSFOOD model, the bringing 
together of different stakeholders in food production using modern biotechnology from a wide 
range of natural and social scientific disciplines has been a unique experience and has resulted in 
the development of detailed safety assessment approaches and in new ideas concerning more 
integrated approaches for risk analysis of new food production technologies, including active 
consumer participation. 
The need for an integrated platform for deliberation on food production and biotechnology 
The ENTRANSFOOD project has highlighted the need to continue interdisciplinary deliberations 
on the introduction of new food production technologies and production practices in order to 
better understand potential impacts from adoption and diverse approaches to regulation.  Four 
types of questions should be considered more systematically, integrating a wide range of different 
perspectives: what is the objective of a new product or technology for food production, who will 
benefit from it, who might be at risk (environmentally, health-wise, economically, or culturally), 
and how can we ensure that we will learn from the experience?   
We recommend the establishment of a Permanent Evaluation and Discussion Platform that 
explores both scientific and societal issues of alternative practices in food production.  Research 
on improvement of institutional learning on how to govern risks from new technologies and food 
production practices could be part of its remit, too.  Regulators, academics, and stakeholders from 
the private sector and consumer organisations should work together to map areas where there is 
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agreement, disagreement, and the need for further research.  Such platforms could have several 
functions, such as organising events to frame questions on risk for expert deliberations, guide the 
assembly of a knowledge base for experts, review draft expert advice, and review proposed draft 
regulations and standards.  Coordinators of such an integrated deliberation platform should also 
consider on how they should interact with intergovernmental organisations working on guidelines 
and policy recommendations on agro-food production and biotechnology, such as the 
Organisation for Economic Coordination and Development (OECD), Organisations of the United 
Nations (FAO/WHO), and the European Food Safety Authority (EFSA). 
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